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ABSTRACT
Previous studies have demonstrated the facilitatory effects o f corticosteroids on the 
Pz-adrenoceptor (Pz-AR). Tolerance or subsensitivity with regular Pz-agonist use is o f 
concern in asthma therapy. As corticosteroids and Pz-agonists are often prescribed 
together, the aim o f these studies was to investigate their interaction on Pz-AR 
function.
Our initial study showed that despite taking inhaled corticosteroids, asthma patients 
developed bronchodilator and systemic Pz-AR subsensitivity following regular 
formoterol use. Administration o f systemic corticosteroid rapidly restored Pz-AR 
responsiveness. This reversibility did not appear to be related to Pz-AR 
polymorphism. However, the development o f formoterol-induced bronchodilator 
sub sensitivity was influenced by Pz-AR polymorphism, with glycine 16 homozygous 
patients developing greater desensitisation than those homozygous for arginine 16. We 
further demonstrated that inhaled corticosteroids failed to prevent the development o f 
tolerance to the bronchoprotective effects o f formoterol against methacholine and 
AMP, irrespective o f formoterol dose and dosing frequency. Pz-AR polymorphism did 
not appear to influence the development o f bronchoprotective tolerance, in contrast 
to bronchodilator tolerance. Unlike systemic corticosteroid, high-dose inhaled 
corticosteroid, in single and repeated doses, showed no significant facilitatory effect 
on lymphocyte Pz-AR parameters. In contrast, we demonstrated that low-dose 
systemic corticosteroid protected against the development o f Pz-AR subsensitivity 
induced by regular formoterol treatment.
Female sex steroid hormones also influence Pz-AR function. Indeed, abnormal Pz-AR 
regulation has been postulated as a cause o f premenstrual asthma. We found that 
normal cyclical regulation o f Pz-AR function was lost in female asthmatic patients. In 
addition, there was greater airway hyperresponsiveness to AM P during the 
premenstrual period compared to the follicular phase. O ur studies showed that 
exogenous progesterone, but not oestradiol, had facilitatory effects on lymphocyte Pz- 
AR function in normal females. In contrast, exogenous progesterone had a 
‘paradoxical’ down-regulating and desensitising effect on pz-AR function in female 
asthmatic patients. Unlike those with natural menstrual cycles, female asthmatics 
taking the oral contraceptive pill had attenuated cychcal changes in airway 
hyperresponsiveness and diurnal peak flow rates.
We therefore conclude that corticosteroids have significant facilitatory effects on Pz- 
AR function in asthma. O ur findings also suggest that there may be abnormal 
hormonal regulation o f Pz-AR in female asthma patients. Further studies examining 
the facilitatory effects o f inhaled corticosteroid on Pz-AR function in asthma are 
indicated. Research into the role o f  exogenous sex hormones on Pz-AR function in 
premenstrual asthma, pregnancy and the menopause is also necessary.
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CHAPTER 1
INTRODUCTION
1.1 PATHOGENESIS OF ASTHMA
There is at present no definition o f asthma using unequivocal criteria. The majority of 
descriptions stem from the first CIBA symposium which concluded that ‘asthma 
refers to the condition o f subjects with widespread narrowing o f the bronchial 
airways, which changes in severity over short periods o f time either spontaneously or 
under treatment, and is not due to cardiovascular disease’ (Fletcher, 1959). In addition 
to this variable airway obstruction, mucosal inflammation and hyperresponsiveness of 
the airways also have an im portant influence on asthma pathophysiology. Bronchial 
hyperresponsiveness can best be described as an exaggerated bronchoconstrictor 
response to a wide variety o f exogenous and endogenous stimuli, both specific and 
non-specific. It underlies much o f the symptomatology o f asthma, as has been 
recognised in the description o f the disease by the American Thoracic Society (1987a). 
Airway hyperresponsiveness is considered a hallmark o f asthma and its extent 
correlates with its clinical severity and the need for treatment (Juniper, 1981). Over the 
last decade, asthma has been recognised as a chronic inflammatory condition o f the 
airways with bronchial hyperresponsiveness being a manifestation o f this 
inflammation. Intense airway inflammation has been noted in patients dying o f severe 
asthma (Dunnill, 1969). With the advent o f fibreoptic bronchoscopy, inflammatory 
changes in the bronchial mucosa have been confirmed as being characteristic even of 
mild disease, suggesting that they are fundamental to the pathophysiology o f asthma 
(Djukanovic, 1990; Bradley, 1991).
1.2 Pz-AGONIST TREATMENT IN ASTHMA
Pz-adrenoceptor (Pz-AR) agonists are the core o f bronchodilator therapy in asthma. 
While the use of these agents has lessened with the emphasis on inhaled 
corticosteroids, they remain necessary for rapid symptomatic relief in asthma.
1.2.1 Mechanism of action
P-AR are subdivided into Pi, Pz and Ps-subtypes. Pi-receptors are preferentially 
activated by noradrenaline and regulated by sympathetic nerves, pz-receptors are 
preferentially regulated by circulating adrenaline. Pa-receptors or ‘atypical’ P-receptors 
are involved in lipolysis. Although both Pi and Pz-AR are present in the lungs, 
bronchodilation appears to be entirely a function o f Pz-AR (Barnes, 1995a).
Pz-AR agonists produce their effects through interaction with these specific Pz-AR 
located on the plasma membrane o f virtually all cell types. The receptor consists o f a 
protein which traverses the cell membrane seven times, forming three extracellular 
and three intracellular loops. The receptor is linked to a stimulatory guanine 
nucleotide-binding protein (Gs). Binding o f the agonist to the receptor results in a 
conformational change in the receptor leading to the activation o f the a-subunit of 
Gs. This in turn activates adenylate cyclase, which catalyses the conversion of 
adenosine triphosphate (ATP) to cyclic adenosine-3’5’-m onophosphate (cAMP). 
cAMP acts as an intracellular second messenger and is responsible for the 
physiological response, the nature o f which differs with each cell type (Nijkamp, 
1992). In airway smooth muscle, the intracellular mechanisms involved in mediating 
the relaxant effects o f Pz-agonists have been extensively investigated. The rise in
cAMP concentration activates protein kinase A (PKA) leading to phosphorylation of 
several proteins which results in smooth muscle relaxation. PKA inhibits myosin light 
chain phosphorylation and phosphoinositide hydrolysis and promotes Ca^'^'/Na'^ 
exchange. These changes cause a fall in intracellular [Ca-" ]^ and stimulate Na'^/K'^ 
ATPase. Pz-agonists also give rise to smooth muscle relaxation by opening membrane 
potassium (maxi-K) channels either by increasing cAMP or by a cAMP-independent 
route through direct activation via the a-subunit o f Gs (Barnes, 1995a).
1.2.2 Efficacy of P-agonists
Pz-agonists can be administered orally, by inhalation, or by subcutaneous or 
intravenous injection. However, the inhaled route is by far the preferred way as side 
effects are fewer for any given degree o f bronchodilation (Nelson, 1995). Inhaled Pz- 
agonists can be divided into those with a short duration o f action o f 3-6h (eg 
salbutamol, terbutaline) and those with a long duration o f action o f greater than 12h 
(eg sakneterol, formoterol). The mechanism by which the long-acting Pz-agonists 
achieve their prolonged duration o f action differs. Salmeterol has a long side-chain 
which binds to a specific site within the Pz-adrenoceptor allowing prolonged 
activation o f the receptor (Johnson, 1993). Formoterol appears to enter and then 
gradually diffuses from the plasmalemma Hpid bilayer and is available over a 
prolonged period to stimulate the Pz-adrenoceptor (Anderson, 1993). In addition to 
their bronchodilating action, Pz-agonists also demonstrate protection against a variety 
o f stimuli such as exercise (Anderson, 1979), allergen (Cockcroft, 1987) and cold, dry 
air (O’Byrne, 1982), all o f which cause bronchoconstriction in asthmatic patients This 
property o f ‘functional antagonism’ allows Pz-agonists to inhibit or reverse a 
contractile response, irrespective o f the constricting stimulus (Torphy, 1983). This is a
property o f particular importance in asthma, since several spasmogens are likely to be 
mvolved (including histamine, leukotriene D 4 , acetylcholine, bradykinin). Pz-agonists 
also have a variety of other non-bronchodilator activities. These include enhanced 
mucociliary clearance (Devalia, 1992), inhibition o f cholinergic neurotransmission 
(Rhoden, 1988), suppression o f microvascular leakage (Erjefalt, 1991) and inhibition 
o f mediator release from mast cells, basophils and other cells. In mtro, Pz-agonists 
inhibit the release o f histamine, leukotrienes and prostaglandins from human mast 
cells (Butchers, 1991). AMP is thought to cause bronchoconstriction indirectly 
through the release o f mediators from mast cells (Cushley, 1985). Inhaled terbutaline 
confers greater protection against AMP than methachohne-induced 
bronchoconstriction in asthma suggesting that Pz-agonists produce an inhibitory effect 
on mast cell mediator release (O’Connor, 1994). This difference was attributed to the 
combined effect o f terbutaline on mast cell and smooth muscle Pz-AR in protecting 
against AMP, and on smooth muscle Pz-AR only in protecting against methacholine.
1.3 p2-ADRENOCEPTOR FUNCTION IN ASTHMA
Since Szentivanyi (1968) hypothesised that there may be an inherent defect in P z -  
adrenoceptor function in asthma, there has been intensive debate about the 
contribution o f Pz-AR dysfunction to the pathophysiology o f asthma. This was 
reinforced by observations that patients with asthma, but not healthy subjects, had 
increased sensitivity to Pz-AR inhibitors (Koeter, 1982). Several early studies had 
demonstrated reduced receptor density and adenylate cyclase activity in circulating 
leukocytes o f asthmatic patients (Brooks, 1979; Kariman, 1980; Parker, 1973). It is 
difficult, however, to interpret these data because o f inadequate washout periods for 
P-agonists and other anti-asthma medication leading to confounding drug effects. It is 
well recognised that Pz-AR responsiveness is enhanced by systemic corticosteroids 
(Logsdon, 1972; Brodde 1985) and is depressed by P-agonists (Tashkin, 1982). In the 
study by Parker et al (1973), inhaled P-agonists were used by the patients but had no 
defined wash-out period. This was also the case when Brooks et al (1979) examined 
Pz-AR on leukocytes when four subjects were taking oral prednisolone during the 
study period. Two subjects studied by Kariman et al (1980), were taking prednisolone 
up to 48h prior to the study and four subjects were taking theophyllines. It soon 
became clear that these abnormalities were likely to be due to tolerance or 
subsensitivity induced by the P-agonist therapy and could be reproduced in normal 
individuals given the same therapy. Furthermore, when P-agonist therapy was 
withdrawn, Pz-AR responsiveness returned to normal (ConoUy, 1976; Galant, 1978). 
This therefore implied that the Pz-AR dysfunction reported in asthmatic patients was 
the result o f subsensitivity following exposure to P-agonists and was not due to
intrinsic Pz-AR dysfunction. Several studies have now shown that there is no 
difference in Pz-AR density or adenylate cyclase activity when comparing leukocyte 
Pz-AR from healthy controls and stable asthmatics not taking regular P-agonists 
(Connolly, 1976; Galant, 1978; Meurs, 1982; Newnham, 1993). Likewise, airway Pz- 
AR assessed by salbutamol dose-response curves (as specific airways conductance) 
showed no difference between mild asthmatics and healthy controls (Tattersfield,
1983).
1.3.1 Desensitisation and down-regulation of Pz-adrenoceptors
Reduced responsiveness occurs with most cell surface receptors when exposed 
continuously or repeatedly to an agonist. Tachyphylaxis refers to short-term 
desensitisation and tolerance after repeated exposure to an agonist. Homologous 
desensitisation refers to reduced responsiveness to P-agonists, as described above, 
while heterologous desensitisation describes desensitisation to other agonists and 
usually involves cAMP.
Homologous desensitisation has been the subject o f extensive investigation (Bames, 
1995a) and involves several steps. In the short term, there is rapid phosphorylation- 
mediated uncoupling o f the receptor from effector units. The two principle kinases 
involved are cAMP dependent protein kinase A (PKA) and P~adrenergic receptor 
kinase (P-ARIC) (Inglese, 1993). P-ARK is activated by the binding o f agonist to 
receptor. A co-factor termed P-arrestin is necessary for P-ARK inhibition o f receptor 
function (Loshe, 1990). Phosphorylation o f P-receptors by P-ARK enhances the 
abilit)^ o f P-arrestin to bind and thereby to uncouple the receptor from Gs. 
Phosphorylation o f the receptor may impair its ability to interact with Gs (biochemical
uncoupling) or it may trigger its sequestration away from Gs (physical uncoupling). 
There is rapid simultaneous sequestration or internalisation o f the receptor from the 
ceU surface which is an agonist-dependent process. This process has been 
demonstrated in frog erythrocytes (Chuang, 1980) and sm ooth muscle cells (Sher,
1984). Sequestration results in a decrease in the num ber o f surface membrane Pz-AR 
which is paralleled by an increase in cytosolic receptors. The uncoupled internalised 
receptor may return to the cell membrane once the P-agonist is removed 
(resensitisation). Following uncoupling and sequestration, down-regulation o f the Pz- 
AR occurs, usually after prolonged agonist stimulation. Down-regulation is defined as 
the loss o f total receptor binding sites with an accompanying loss in effector 
stimulation. After down-regulation, responsiveness is only restored by the synthesis of 
new receptors. Receptor uncoupling and sequestration are rapid processes which take 
place within seconds to minutes following agonist exposure, whereas down-regulation 
occurs after more prolonged stimulation (> lh). The more chronic and clinically 
relevant effects o f P-agonists may be due to changes in Pz-AR synthesis. Down- 
regulation may involve both proteolytic degradation o f the receptor moiety and 
diminished de novo synthesis o f the receptor (Bouvier, 1989). The molecular 
mechanisms underlying down-regulation are poorly understood. This process may 
involve receptor-Gs coupling and the PKA pathway. Using a hamster cultured smooth 
muscle Une, it has been shown that prolonged exposure to p-agonists or cAMP 
analogues (such as forskolin) produce down-regulation which was accompanied by 
substantial decreases in Pz-AR mRNA levels (Hadcock, 1988; Collins, 1989). Hadcock 
and Malbon (1988) observed that while agonist-promoted down-regulation o f 
receptors was rapid preceding the decline in mRNA levels, cAMP resulted in a more 
modest decrease in Pz-AR mRNA. The studies by CoUins et al (1989) indicated that
decreases in Pz-AR mRNA in response to agonist or cyclic AMP treatment, tended to 
precede the loss o f receptor numbers. In addition, the treatm ent with forskolin 
produced an equally effective reduction in Pz-AR mRNA levels, although the effect 
on receptor density was less dramatic. Since the purpose o f agonist activation o f the 
receptor is to stimulate adenylate cyclase and generate cAMP, the ability o f cAMP to 
mimic the decrease in both receptor mRNA and in part receptor number, suggests 
intimate involvement o f the PKA pathway. However, because agonists produce more 
rapid and more effective receptor down-regulation, an agonist-promoted, cAMP- 
independent mechanism may be responsible for receptor down-regulation. Down- 
regulation is achieved by inhibition o f gene transcription o f receptors or by increased 
post-transcriptional processing o f mRNA. Using actinomycin D  to inhibit 
transcription in a cultured hamster vas deferens cell line, the decline in the steady state 
level o f Pz-AR mRNA following agonist exposure was thought to be secondary to a 
reduction in Pz-AR mRNA stability (Hadcock, 1989). Molecular mechanisms of 
down-regulation have also been investigated in lung tissue after exposure to P- 
agonists. In a study with guinea pigs (Nishikawa, 1994), a seven day infusion o f 
noradrenaline produced a marked reduction in Pz-AR density in lung parenchyma 
which was associated with a similar reduction in steady state Pz-AR mRNA levels. It 
was also found that different cell types have a differing capacity to down-regulate with 
greater down-regulation in alveolar wall than in airway sm ooth muscle. This may relate 
to an increased rate o f gene transcription in airway epithelial cells compared with lung 
parenchyma.
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1.3.2 Tolerance to P-agonists in asthma
Although the molecular and cellular aspects o f P-agonist mediated Pz-AR down- 
regulation and tolerance are accepted as described above, there continues to be 
controversy about such tolerance in asthma. The more recent introduction o f long- 
acting Pz-agonists has further fuelled this debate because their prolonged receptor 
occupancy may theoretically increase the propensity for down-regulation. Before 
discussing the subject, it is im portant to appreciate the methodology required to 
demonstrate such tolerance or subsensitivity. It is necessary to distinguish between 
effects on resting bronchom otor tone (ie: bronchodilator activity) and anti- 
bronchoconstrictor properties (ie: functional antagonism) as tolerance may develop 
preferentially to one property rather than the other.
Short-acting Pz-agonists
Holgate et al (1977), in a uncontrolled study, showed that in healthy volunteers 
bronchodilator subsensitivity (measured as specific airways conductance) developed 
after 4 weeks o f inhaled salbutamol 200 pg four times a day. In healthy volunteers, 
there was rapid down-regulation o f Pz-AR density by 70% in bronchial epithelial cells 
and alveolar macrophages obtained by bronchoalveolar lavage after 24h o f inhaled 
metaproterenol (Turki, 1995a). Maximal cAMP response to isoprenaline was likewise 
reduced by 48% and 86% in epithelial cells and alveolar macrophages respectively. 
Research to date has generally shown that it has not been possible to demonstrate 
bronchodilator tolerance in asthmatic airways. There have been few dose-response 
studies with placebo control to assess bronchodilator tolerance. In a study without 
placebo control, Repsher et al (1984) demonstrated tolerance to the duration but not 
the peak bronchodilator response to a single dose o f salbutamol following regular
11
treatment with the drug. O ther studies have failed to show such tolerance following 
oral and inhaled Pz-agonists with bronchodilator responses to single and cumulative 
doses o f inhaled, intravenous and subcutaneous Pz-agonists (Larsson, 1977; Repsher, 
1981; Tashkin, 1982; Lipworth, 1989). Lipworth et al (1989) performed a crossover 
study giving placebo, low-dose inhaled salbutamol (800 pg daily) or high-dose inhaled 
salbutamol (4000 pg daily) for two weeks respectively, with two week run-in and 
wash-out periods without pz-agonists. A cumulative dose-response curve to inhaled 
salbutamol performed after each treatm ent period showed a right-hand shift in extra- 
puknonary, but not in airway Pz-AR responses, even with the higher dose. This 
apparent tissue dissociation in Pz-AR subsensitivity may reflect a high level o f Pz-AR 
gene expression or a high density o f ‘spare receptors’ in the airway, so that even a 
marked reduction in the Pz-AR density is not accompanied by a reduced response.
With regular use o f P-agonists, it is important to distinguish between tolerance to 
bronchoprotective effects and the rebound increase in airway reactivity which occurs 
after stopping therapy. It is also necessary to highlight the different stimuli used to 
provoke bronchoconstriction. Histamine and methacholine are predominantly direct 
smooth muscle stimulants, while allergen and AMP (and possibly, exercise) act 
indirectly by stimulating mast cells to release bronchospastic mediators. There may be 
differential effects o f Pz-agonists on these stimuli with a consequent difference in 
susceptibility to tolerance. O ’Connor et al (1992) assessed airway hyperresponsiveness 
to methacholine and AMP before and after one week o f treatm ent with terbutaline 
500 Pg four times daily in 12 asthmatic subjects. Their study design did not include re­
establishing the baseline PCzo values after each treatment. Terbutaline initially 
produced a 2.7 doubling dose shift o f methacholine PCzo compared with a 3.8
12
doubling dose shift o f the AMP PC 2o- This difference was attributed to the combined 
effect o f terbutahne on mast ceU and smooth muscle P2-AR in protecting against 
AMP, and on smooth muscle P2-AR only in protecting against methachohne. After 
the one week treatment period, terbutaline shifted the methacholine PC 20 by 2.2 
doubling doses (19% loss in protection). By contrast, there was a m uch greater loss of 
bronchoprotecdve effect against AMP as terbutahne only shifted the AMP PC 20 by 1.7 
doubhng doses, a reduction o f 55% from the 3.8 doubling doses. The interpretation o f 
this greater loss o f protection against inhaled AMP, a mast cell stimulus, was that P2- 
AR on mast cells might be more susceptible to tolerance than are the P2-AR on airway 
sm ooth muscle. This differential effect o f different bronchoconstrictor stimuh was 
again seen in the study by Cockcroft et al (1993). They studied the effect o f inhaled 
salbutamol 200 pg four times daily on airway hyperresponsiveness to methacholine 
and allergen. The basehne methacholine and allergen PC 20 values were re-estabhshed 
following each treatment period. Methacholine PC 20 was reduced to 2.5 doubling 
doses after two weeks treatm ent with salbutamol from an initial protection of 3.2 
doubling doses (22% loss o f protection). The protection against allergen was initially
3.7 doubling doses and it fell to 2.5 doubling doses (32% loss o f protection). 
However, the m ost striking finding was a highly significant increase in airway 
responsiveness to allergen. There was almost a doubling o f  airway responsiveness to 
allergen following two weeks o f salbutamol. Two additional studies showed that the 
late asthmatic response to allergen was almost double after a week o f regular 
salbutamol treatment compared with placebo (Cockcroft, 1995; Gauvreau, 1995). 
There does not appear to be a loss in functional antagonist effect o f salbutamol 
against exercise-induced bronchoconstriction (Inman, 1996). Studies using histamine 
as the bronchoconstrictor have been less consistent with some studies showing
tolerance while others have not (Tashkin, 1982; Van Shyack, 1990; Kraan, 1985; 
Kerrebijin, 1987; Waalkens, 1991). Vathenen et al (1988) also showed reduced 
protection o f inhaled terbutaline against histamine-induced bronchoconstriction 
following two weeks o f treatment. In addition, an increase in airway reactivity 
amounting to 1.5 doubling doses was found at 23h after stopping treatment. This 
rebound effect was also described by Larsson et al (1977) with a trend towards 
increased reactivity to allergen challenge at 48h after stopping treatm ent with oral 
terbutaline being demonstrated. W hen considering these studies, it is im portant to 
bear in mind the intrinsic variabihty o f bronchial reactivity which can amount to one 
doubhng dose. Hence, changes which are statistically significant may not be clinically 
relevant.
Long-acting p2-agonists
Early studies did not find evidence of bronchodilator tolerance to sahneterol or 
formoterol. UUman et al (1990) compared two weeks o f treatrnent with sahneterol 50 
pg twice daily or salbutamol 200 pg four times daily in 12 asthmatic patients. There 
was no placebo control and no run-in or wash-out period without Pz-agonists. A dose 
response curve to salbutamol (cumulative dose 900 pg) was constructed before and 
after each treatment period. The authors concluded that there was no evidence of 
tolerance after treatment with sahneterol. However, the basehne FEVi was 
significantly higher after than before sahneterol treatment. In addition, a ceihng was 
reached in the dose-response curve with salbutamol. This finding, together with the 
confounding effect o f different baselines, made vahd comparisons between the dose- 
response curves difficult. In a similar study (Arvidsson, 1989), formoterol 12 pg as 
twice daily dosing was compared with salbutamol 200 pg twice daily for two weeks in
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a cross-over design. Again, there was no placebo control or run-in period. As in the 
study by UUman et al (1990), baseline FEVi was significantly higher 12h after the last 
dose o f formoterol, prior to the salbutamol dose-response curve, and together with a 
ceiling being reached in the dose-response curve, comparisons between treatment are 
difficult to make. Other studies have not found evidence o f bronchodilator tolerance 
after treatm ent with sahneterol (Cheung, 1992; Pearhnan, 1992), although the findings 
were based on responses to single doses o f sahneterol and absence o f a run-in period 
prior to the study. More recent work, employing a placebo-control period, a two week 
run-in period without P2-agonists and a longer washout phase prior to the dose 
response curve has shown evidence o f tolerance to the bronchodilator effects o f 
formoterol (Newnham, 1994a; Newnham, 1995). Four weeks o f treatment with 
inhaled formoterol 24 pg twice daily, as pressurised metered dose inhalers and dry 
powder preparations, was compared with placebo, with a dose-response curve to 
formoterol constructed (cumulative dose 126 pg) at the end o f each treatm ent period. 
This tolerance was mamfested as a significant reduction in both peak bronchodilator 
response and a greater reduction at 6h after the final dose o f the DRC. It is important 
to note that in contrast to the studies by UUman et al and Arvidsson et al, there were 
no significant differences in baseline FEVi and no ceiling was reached in the dose- 
response curve. Because o f equal baselines, delta responses from baseline could be 
used in comparing the dose-response curves. Predictably, in both o f these studies by 
Newnham  et al, formoterol produced subsensitivity o f extrapulmonary P2-AR 
responses and down-regulation o f lymphocyte P2-AR density and responses, 
compared to placebo. Yates et al (1995) showed evidence o f bronchodilator 
subsensitivity foUowing two weeks’ treatment with formoterol 24 pg twice daUy, with 
a significantly reduced FEVi 36h after the last dose o f formoterol, compared with the
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first dose, but was not lower at other time periods. Using a similar design to 
Newnham et al. Grove et al (1995) compared sahneterol 50 pg twice daily with placebo 
in 17 asthmatic patients. A dose-response curve (cumulative dose 3200 pg) was 
constructed at the end o f each treatment period with a 36h washout phase. There was 
a rightward shift in the sahneterol DRC following treatment. This bronchodilator 
subsensitivity equated to a 2.5 fold and 4 fold greater dose o f salbutamol being 
required to produce a given FEVi or peak expiratory flow respectively. It is important 
to note that in these studies by Newnham et al and Grove et al, bronchodilator 
tolerance occured after regular use o f a long-acting Pz-agonist despite the fact that 
most o f the patients were receiving inhaled corticosteroids. In each o f the three 
studies, (Newnham, 1994a; Newnham, 1995; Grove, 1995), peak expiratory flow rates 
improved significantly with formoterol and sahneterol compared with placebo, which 
may lead to patients being lulled into a false sense o f security in the presence of 
bronchodilator tolerance.
Given that it is possible to demonstrate tolerance to the protective effects o f short- 
acting P 2-agonists, it is not surprising that the same phenom enon has been reported 
with long-acting P2-agonists. W hen considering tolerance to anti-bronchoconstrictor 
effects o f long-acting P2-agonists, it is important to consider whether tolerance occurs 
not only at peak effect, but also towards the end o f the action at 12h, given that these 
drugs are usually administered as a twice daily regimen. Cheung et al (1992), in a 
parallel placebo controlled trial, showed that sahneterol protection against 
methacholine challenge fell from tenfold on day 1 to only twofold protection after 
four weeks’ treatment with sahneterol 50 pg twice daily (70% loss o f protection), 
although no loss o f bronchodilator effect was noted. The methachohne challenges
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were performed Ih  after receiving a dose o f sahneterol, having withheld treatment for 
36h previously. In this study, there was no rebound hyperresponsiveness after the 
eight week treatment was discontinued. The loss o f bronchoprotective effect of 
sahneterol was also demonstrated in asthmatic children (Verbeme, 1996). Another 
study (Bhagat, 1995), studied the time course o f the development o f tolerance to the 
bronchoprotective effect o f sahneterol against methacholine. Methachohne PC 20 was 
measured Ih  after the first, third, fifth and seventh doses o f twice daily 50 pg 
sahneterol in double-blind, placebo cross-over design. M ethacholine PC 20 was also 
measured 10 minutes after 200 pg salbutamol 24h after stopping sahneterol. By the 
third dose of sahneterol, the bronchoprotective effect was reduced from 3.3 to 2.4 
doubling doses and continued to fall to a protection o f only 1.5 doubling doses after 
the seventh dose. The PC 20 after salbutamol on day 5 was also reduced from a 3.7 
doubhng dose protection after placebo to a 1.9 doubhng dose shift after the seventh 
dose o f sahneterol. These studies may be criticised for selecting patients with very 
müd asthma, not on inhaled corticosteroids, in whom  long-acting P-agonists would 
not have been indicated. Booth et al (1993) studied a group o f mild to moderate 
asthma patients in whom  19 out o f 26 were taking inhaled corticosteroids. In a parallel 
group study, patients received eight weeks’ treatment, with either sahneterol 50 pg 
twice daily or placebo, with methacholine challenge perform ed at 12h after the first 
dose and at four and eight weeks o f treatment. N o significant difference was detected 
in the protection afforded by sahneterol, when comparing the first dose (0.9 doubhng 
doses difference from baseline) with subsequent repeat dosing at four weeks (1.2 
doubhng doses) or eight weeks (0.6 doubhng doses). However, the patients were 
allowed free access to inhaled P-agonists before and during the study as rescue 
medication, so any tolerance may have been present at the beginning o f the study.
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Therefore the negative results were likely to be caused by the pre-trial and continued 
use o f rescue inhaled P-agonists. The same investigators have since repeated a study 
using the same design as Cheung et al, by performing the methachohne challenge Ih  
after inhalation o f sahneterol following a 36h washout period (Booth et al, 1996). In 
this study, aU patients received inhaled corticosteroid. It was found that the 
bronchoprotection against methacholine feU from 3.3 doubling doses after the first 
dose to 2 doubling doses after four and eight weeks’ treatment. Regular dosing with 
formoterol 24 pg twice daily in steroid-naive asthmatic patients also resulted in a 
significant loss o f protection against methacholine at 12h after the first dose (1.9 
doubhng dose protection) compared with two weeks’ treatment (0.5 doubling dose 
protection) (Yates, 1995). This amounted to a 74% loss o f  bronchoprotection. There 
was no rebound increase in airway hyper-reactivity on stopping treatment. There is 
also evidence to show that tolerance develops to the protective effect o f sahneterol 
against exercise-induced bronchoconstriction in a study comparing sahneterol 50 pg 
twice daily with placebo given for two weeks, with an exercise challenge performed at 
6h and 12h after the first dose and after four weeks’ treatm ent (Ramage, 1994). 
Sahneterol protected against exercise-induced bronchoconstriction by 66% and 40% 
at 6h and 12h respectively compared with placebo after the first dose. After four 
weeks’ treatment, the last dose produced only a 27% and 18% reduction in exercise- 
induced bronchoconstriction at 6h and 12h respectively which was not significantly 
different from placebo (55-60% loss o f bronchoprotection). It is worth noting that the 
patients had mild asthma and only three out o f 12 patients were taking corticosteroids.
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Several of the studies described have shown that inhaled corticosteroids do not appear 
to prevent the development o f anti-bronchoconstrictor tolerance. Kalra et al (1996) 
showed that there is a rapid onset o f tolerance to the bronchoprotective effect of 
sahneterol in subjects using inhaled corticosteroids 500 to 1500 pg daily. Tolerance to 
the bronchoprotective effect against methacholine was significant after the first two 
days (at 24h) and was similar after seven doses. In addition, subjects showed less 
protection against challenge following administration o f salbutamol 24h after the last 
dose o f sahneterol, compared with placebo. This was further evaluated by Yates et al 
(1996) in a crossover study with twelve asthmatic patients who received inhaled 
budesonide (800pg twice daily) or placebo for two weeks. Sahneterol 50pg twice daily 
was then added for one week. The protection afforded by a single dose o f salbutamol 
against methacholine challenge was evaluated after two weeks’ treatm ent (without 
sahneterol) and after three weeks (with sahneterol), 12h after the last dose. There was 
a significant attenuation in the protection by salbutamol after treatment with 
sahneterol by 1.1 doubhng doses in those receiving budesonide and by 1.4 doubling 
doses in those receiving placebo, with no significant difference in protection between 
the budesonide and placebo periods. Inhaled corticosteroids also do not appear to 
protect against the loss o f functional antagonist effects o f short-acting P-agonists. 
High dose budesonide (1600 pg per day) was compared with high dose budesonide 
plus salbutamol in a blinded cross-over trial (Cockcroft, 1995). An equivalent 
tolerance to bronchoprotection was found, with the initial protection falhng from 2.9 
doubling doses to 2.25 doubling doses (22% loss o f protection), with no significant 
difference between placebo and salbutamol. Inhaled budesonide did no t prevent the 
parallel increase in airway responsiveness to allergen when salbutamol and budesonide 
were administered concurrently.
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In summary, regular use o f long-acting P-agonists appears to result in bronchodilator 
subsensitivity although this does not seem to be the case with short acting P-agonists 
in patients with asthma. Tolerance to functional antagonism however, appears to be 
more readily demonstrable than bronchodilator subsensitivity. Significant tolerance 
can be seen at very low doses and can develop very rapidly, and occurs with all agents 
and to all stimuli. Corticosteroids do not seem to prevent development o f such 
tolerance. The mast cell stimuli (AMP and allergen) appear to be m ore prone to 
tolerance than are the direct stimuh (methacholine and histamine). In addition, regular 
use o f inhaled P-agonists increases baseline airway responsiveness to allergen (early 
and late) such that the post-salbutamol allergen PC 20 after two weeks o f salbutamol 
was almost two doubhng doses lower than after placebo (Cockcroft, 1993). How this 
tolerance relates to the increased morbidity and mortahty associated with the regular 
use o f P-agonists is at present uncertain. However, as inhaled P-agonists are often 
used for theh functional antagonist effect, it would seem likely that the significant loss 
o f protection against allergen and exercise, seen particularly with long-acting P- 
agonists might have important clinical relevance.
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1.4 P2-ADRENOCEPTOR POLYMORPHISMS IN ASTHMA
Although asthma is now regarded as a chronic inflammatory disorder o f the airways, 
Szentivanyi’s (1968) original hypothesis that the disease may be due to dysfunctional 
P2-AR has again become topical. The previous discussion on P2-AR tolerance and 
down-regulation as a result o f chronic P-agonist effects assumes that the mechanisms 
underlying these effects are the same throughout the population. Since the cloning of 
the P2-AR on the long arm o f chromosome 5 (Kobilka, 1987), a num ber o f common 
variants (or polymorphisms) o f the receptor have been identified which could alter the 
behaviour o f the receptor (Reishaus, 1993). Reishaus et al compared genomic 
DN A from peripheral blood lymphocytes in 51 asthma patients and 56 normal 
volunteers, usmg the original cloned ‘wild type’ D N A  as reference. Nine point 
mutations were found in the entire cohort. O f these, five were degenerate in that they 
did not result in a change in amino acid sequence. Four other point mutations resulted 
in amino acid substitutions. Before discussing these, it is im portant to describe the 
‘wüd type’ of the receptor which was originally sequenced by Kobilka et al (1987). It 
consists o f arginine (Arg) at locus 16, glutamate (Glu) at locus 27, valine (Val) at locus 
34 and threonine (Thr) at locus 164. The four point mutations identified by Reishaus 
resulted in substitution o f glycine (Gly) for Arg at locus 16, glutamine (Gin) for Glu at 
locus 27, methionine (Met) for Val at locus 34 and isoleucine (He) for Thr at locus 
164. The frequency o f the polymorphisms at loci 16 and 27 was no different between 
the asthmatic and normal groups (the polymorphisms at loci 34 and 164 were too 
infrequent for analysis), indicating that polymorphisms o f the p 2-AR were not a 
primar}^ cause o f asthma. Further work investigating the functional significance o f the 
polymorphisms was performed using site-directed mutagenesis and transfecting
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Chinese hamster fibroblast cell lines (which do not normally express P-adrenergic 
receptors but contain G-proteins, adenyl cyclase and other regulatory proteins 
necessary for receptor-prom oted signal transduction) to express the different forms o f 
the receptor (Green, 1993). It was found that the Met 34 polymorphism displayed 
normal agonist binding and functional coupling profiles, while the He 164 form 
displayed four times less affinity for certain agonists (Green, 1993). Loci 16 and 27 
polymorphisms had normal agonist and antagonist binding and coupling to adenylate 
cyclase (Green, 1994). However, after exposure to agonist, the Gly 16 polymorphism 
underwent enhanced down-regulation (41%) compared to the Arg 16 receptor (26%). 
In contrast, the Glu 27 receptor appeared to be refractory to down-regulation, 
displaying no significant change in receptor expression after prolonged agonist 
exposure. However, ceUs with the Gly 16 and Glu 27 polymorphisms had enhanced 
down-regulation, similar to those with Gly 16 polymorphism, indicating that effects o f 
Gly 16 are dominant over those due to Glu 27. Similar findings also resulted from 
examination o f these receptor polymorphisms on primary bronchial smooth muscle 
cell cultures (Green, 1995a).
Two clinical studies have suggested that the Gly 16 polymorphism may be associated 
with markers o f more severe asthma. Holdroyd et al (1995) found Gly 16 to be 
associated with bronchial hyperresponsiveness in a group o f D utch asthmatic famihes. 
In addition, asthma patients experiencing nocturnal symptoms were more likely to 
have the Gly 16 polymorphism than those without nocturnal falls in peak flow rate 
(Turki, 1995b). The Gly 16 allele frequency was 80% in the nocturnal group compared 
to 52% in the non-nocturnal group. This finding could be explained by day-time P- 
agonist use by patients with Gly 16 polymorphism, enhancing P2-AR down-regulation 
and increasmg susceptibility to nocturnal asthma. This hypothesis is supported by the
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observation that in patients with nocturnal asthma, leukocyte P2-AR expression 
decreases at 0400h compared to 1600h (Szefler, 1991). More recently, it was shown 
that wheezy children with the Gly 16 receptor were less likely to have a significant 
bronchodilator response to a single 180 pg dose o f salbutamol compared to those 
with Arg 16 (Martinez, 1997). N o association was found between polymorphisms at 
locus 27 and response to salbutamol. The two groups used similar anti-asthma 
medication and thus had no difference in predisposition to P2-AR down-regulation 
prior to the study. W hen 65 mild to moderately severe asthmatics were assessed using 
methacholine challenge, those with the Glu 27 polymorphism had airways which were 
four times less reactive than those with the Gin 27 form (Hall, 1995). These workers 
also found a significant association between the Gin 27 form o f the receptor and 
elevated IgE levels in 60 asthmatic patients (Dewar, 1997). This could be accounted 
for by linkage disequihbrium between the P2-AR gene and the gene for control o f IgE 
production (that is, the two are not independently distributed in the general 
population) which is also located on the long arm o f chromosome 5 (Postma, 1995). 
There was no association between Gin 27 and asthma or atopy. Recently, however, 
the same group has demonstrated an association between Gin 27 and reported asthma 
symptoms in 410 children (Hopes, 1998). The Gin 27 allele conferred an independent 
increased risk o f reported asthma with an odds ratio o f 2.18. Conversely, the Glu 27 
homozygotes had a lower risk (odds ratio 0.46).
The evidence to date would indicate that polymorphisms at loci 16 and 27 may be 
relevant to the asthma phenotype. However, this is further comphcated by the 
observation that the two loci are in linkage disequihbrium (Dewar, 1998). Although it 
is highly unlikely that P2-AR polymorphism is a cause o f asthma, it might partly
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account for an individual’s propensity to develop asthma, when exposed to 
appropriate environmental stimuli. In particular, it may influence a patient’s response 
to inhaled (3-agonist treatment with regard to developing P2-AR down-regulation and 
tolerance.
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1.5 REGULATION OF P2-ADRENOCEPTOR FUNCTION BY STEROID 
HORMONES
1.5.1 Corticosteroids
Corticosteroids are the most effective therapy available for patients with asthma, 
forming the cornerstone o f anti-inflammatory treatment (Barnes, 1995b). The 
undisputed clinical efficacy o f inhaled and oral corticosteroids in suppressing this 
airway inflammation has been substantiated by intensive research and will not be 
discussed further.
Corticosteroids have been known to have facihtatory effects on the P2-AR (Davies, 
1984). Chronic administration o f P-agonists leads to P2-AR down-regulation and 
subsensitivity as discussed above. As both corticosteroids and P-agonists are often 
prescribed together in asthma, it is therefore o f particular interest to examine the 
interaction between ‘up-regulating’ corticosteroids and ‘down-regulating’ P-agonists 
on P2-AR function and responsiveness.
There are two major areas o f action of corticosteroids on the P2-AR: receptor number 
and coupling to adenylate cyclase. In a number o f early studies, hydrocortisone was 
found to increase isoprenaline-stimulated cAMP accumulation (Lee, 1977; Logsdon, 
1972; Marone, 1980). Davies and Lefkowitz (1980) found that when corticosteroids 
were administered, adenylate cyclase activity increased by 93% in neutrophils. This 
effect has also been seen in mast cells (Tolone, 1979). The steroid-induced changes in 
adenylate cyclase activity are associated with increased receptor binding sites. 
Corticosteroids have been shown to increase P2-AR density in a num ber o f different
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tissues, including rat lung (Mano, 1979), cultured hum an lung cells (Fraser, 1980), 
cultured human astrocytoma cells (Foster, 1980) and rabbit foetal lung tissue (Cheng, 
1980). Oral administration o f cortisone in humans results in a 39% increase in 
neutrophil P2-AR density (Davies, 1980). Mano et al (1979) found that adrenalectomy 
in rats induced a 30% fall in the number o f P2-AR and this change was reversed by the 
exogenous administration o f hydrocortisone. In addition, oral cortisone administered 
to healthy volunteers increased the P2-AR proportion in the high affinity state (ie - 
increased efficiency in coupling to adenylate cyclase) from 54% to 80% o f receptors. 
This was also repeated in human neutrophils exposed to hydrocortisone in vitro 
(Davies, 1980). It can therefore be concluded that corticosteroids regulate P2-AR 
function by increasing receptor num ber and the formation o f the high-affinity coupled 
form o f the receptor.
More recent works have shown that corticosteroids increase the transcription o f the 
p 2-AR gene amongst others (Barnes, 1992). The hum an P2-AR gene has several 
glucocorticoid-response element consensus sequences (GREs) in its 5’ noncoding, 
coding and 3’ noncoding regions (Emorine,1987). The GREs in the 5’ noncoding 
region are obhgatory for corticosteroid responsiveness (Malbon, 1988). 
Corticosteroids increase the steady-state level o f P2-AR mRNA in cultured hamster 
vas deferens muscle cells without any increase in mRNA stability, indicating that 
corticosteroids may elevate P2-AR density by increasing the rate o f gene transcription 
(Collins, 1988). This is confirmed by an increased transcription rate in these cells 
recovered by nuclear run-on assay, which directly measures gene transcription 
(Hadcock, 1989). Preceding that o f the P2-AR, the rate o f mRNA increase was rapid 
(within Ih) and then declined to a steady-state level, twice normal. Similarly,
26
corticosteroids have also been shown to increase the P2-AR gene transcription in 
hum an lung tissue (Mak, 1995a). Following incubation with dexamethasone, an 
increase in P2-AR mRNA could be detected after only 15 min, whilst P2-AR density 
rose by 1.6 fold within 17-24h. Again, P2-AR mRNA stability was unchanged by 
dexamethasone and a doubling in the rate o f P2-AR mRNA transcription led to a 
greater steady-state level o f mRNA, confirmed by a nuclear run-on assay.
Although the effects o f corticosteroids on P2-AR in normal tissues have been 
discussed, it is perhaps more relevant to review the effects o f corticosteroids on 
desensitised tissues and in particular to understand the interaction o f corticosteroids 
and P-agonists on P2-AR function. Early studies have examined the facihtatory action 
o f corticosteroids on airway P2-AR function. As discussed previously, Holgate et al 
(1977) induced bronchodilator sub sensitivity in healthy volunteers with inhaled 
salbutamol 200 pg four times daily for four weeks. Following an intravenous injection 
o f 200 mg hydrocortisone, bronchodilator response to salbutamol was completely 
restored by 6h. There was no change in bronchodilator responsiveness in those 
subjects who had not been receiving regular salbutamol following the steroid. In an 
earher study (EUul-MicaUef, 1975), ten asthmatic patients who were declared resistant 
to bronchodilator therapy were studied. It was found that the bronchodilator response 
to a single 200 pg dose o f inhaled isoprenaline was significantly greater after an 
intravenous injection o f 40 mg prednisolone compared to placebo injection. This 
improvement was maintained 8h after injection. Subsequent studies investigated the 
effect o f corticosteroids on peripheral leukocytes. In healthy volunteers and mildly 
asthmatic patients receiving regular terbutahne, there was, as expected, down- 
regulation of P2-AR on lymphocytes (Hui, 1982; Brodde, 1985; Tashkin, 1982).
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Following a single intravenous injection o f corticosteroid, receptor numbers were 
restored to normal levels by 8-1 Oh. Hui et al observed that corticosteroid had no effect 
on P2-AR density in subjects not exposed to P-agonists, nor was there any effect after 
in vitro incubation with corticosteroid. Interestingly, Brodde et al (1985) showed 
concomitant administration o f ketotifen and oral terbutaline completely prevented the 
P-agonist induced decrease in P2-AR density and responsiveness, although this effect 
was not studied using corticosteroid. Brodde et al (1988) further studied asthmatic 
patients who had been desensitised due to regular P-agonist therapy. Although 
lymphocyte P2-AR density increased in 16h following a single dose o f intravenous 
hydrocortisone (lOOmg), this was not accompanied by any improvement in 
bronchodilator responsiveness to an inhaled p-agonist. An in vitro study (Davies, 1983) 
examined neutrophils from healthy volunteers which were incubated with isoprenaline 
and hydrocortisone simultaneously. There was attenuation in the fall in cAMP 
responsiveness to catecholamine and the high-affinity state o f the receptors was 
maintained compared with the group treated only with isoprenaline. However, 
hydrocortisone did not prevent the fall in P2-AR density. A nother study also 
demonstrated that hydrocortisone could reverse prior agonist-induced down- 
regulation (Samuelson, 1984). Mak et al (1995b) showed that dexamethasone in rat 
lung prevented the down-regulation o f P2-AR following a prolonged infusion o f 
isoprenaline. This appears to be due to an increase in gene transcription, which 
counteracts the decrease in transcription due to chronic P-agonist exposure.
In summary, it would seem that simultaneous in vivo exposure o f P2-AR to P-agonist 
and corticosteroid results in attenuation of the desensitisation process by altering the 
impaired coupling o f the receptors, while consecutive in vivo exposure o f P2-AR to P-
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agonist then corticosteroid reverses the down-regulation. This latter process appears 
to be due to increased P2-AR mRNA transcription.
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1-5.2 Female sex steroid hormones
Despite progesterone and oestradiol being steroid hormones and therefore hkely to 
have facihtatory effects on P2-AR function, there has been relatively httle research on 
this subject. In animal studies, oestrogen was found to increase 0 (,2-AR numbers 
(Hoffman, 1981), while progesterone reduced (X2-AR numbers, but had no effect on 
P2-AR in rabbit myometrium (Roberts, 1981). Wagner et al (1979) found that chronic 
exposure o f oophorectomised rats to oestrogen reduced P2-AR and cAMP 
responsiveness in the cerebral cortex. They also showed that P-AR and cAMP 
responsiveness to catecholamines in rat brain were reduced in those female rats with 
normal oestrous cycles compared with oophorectomised females or males (Wagner 
and Davis, 1980). It is not yet clear as to how this apphes to P-AR in other tissues. 
The effects o f sex steroids were examined in rabbit lung tissue (Moawad, 1982). P-AR 
numbers increased in vivo with the administration o f oestrogen, but returned to control 
values with the subsequent addition o f progesterone. This influence o f sex steroids 
was further demonstrated by changes suggesting the dynamic regulation o f ovarian P- 
AR numbers during the oestrous cycle o f the rat (Jordan, 1981). The P-AR numbers 
fell by 50% during the oestrogen phase, compared to the progesterone phase.
Female sex steroid hormones have been shown to potentiate the vasorelaxant and 
bronchorelaxant effects o f corticosteroids. Kalsner (1969) demonstrated a greater 
contractile effect o f catecholamines on rabbit aortic strips when incubated with 
oestradiol, progesterone and deoxycorticosterone. This potentiating effect was greater 
for adrenaline than for noradrenaline. However, there was no facihtatory effect seen 
with sympathomimetic amines lacking the catechol nucleus (eg - phenylephrine) and 
the steroid potentiating effects were abohshed by the addition o f catechol-O-methyl
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transferase (the major mechanism for inactivation o f catecholamines). It was therefore 
concluded that these steroids potentiated the action o f catecholamines by inhibiting 
their inactivation. A similar mechanism o f action was also proposed for the 
potentiation by sex steroids and cortisol on the bronchorelaxant action o f isoprenaline 
on pig bronchus (Foster, 1983).
Hum an studies show that female subjects exhibit greater systemic P2-AR responses to 
inhaled and intravenous P-agonists when compared to males (Johansson, 1988; 
Rahman, 1992) and that this enhanced response was independent o f body weight 
(Johansson, 1988). Rahman et al observed that compared to males, females had 
significantly greater hypokalaemic, chronotropic and electrocardiographic (reduction 
in T-wave amplitude and prolongation o f QTc interval) changes. This research again 
suggests that sex steroid hormones may have a facihtatory effect on P2-AR function, 
although four out o f ten subjects were taking the combined oral contraceptive piU and 
the subjects were studied during different phases o f their menstrual cycle. To further 
investigate these findings, W heeldon et al (1994) measured in vitro parameters o f 
lymphocyte P2-AR function in nine non-asthmatic females during the folhcular (day 2- 
4) and luteal (day 21-23) phases o f the menstrual cycle. Compared to male controls, in 
whom  there were no horm one changes, female P2-AR density and cAMP response to 
isoprenaline were significantly greater during the luteal phase and were m irrored by an 
increase in serum progesterone and oestradiol. However, when extra-pulmonary P2- 
AR responses to weight-adjusted intravenous infusion o f salbutamol were studied, 
females had significantly greater in vivo responsiveness to salbutamol compared to 
males during the folhcular phase o f the menstrual cycle (Newnham, 1994b). This 
enhanced effect was again independent o f weight, suggesting a heightened sensitivity
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of extra-pulmonary P2-AR. This may initially appear surprising, as W heeldon et a /h ad  
shown greater P2-AR density and responsiveness during the luteal phase. Newnham 
concluded that P2-AR in different tissues may exhibit dissociated sensitivity to the 
facihtatory effects o f oestradiol and progesterone. Up-regulation o f the P2-AR in 
target tissues by the ovarian sex hormones may therefore take longer than would be 
expected from in vitro data and in effect, result in a time lag for in vivo P2-AR 
responses.
Research suggesting that a proportion o f female asthmatic patients suffer a 
premenstrual exacerbation o f their condition lends weight to the putative role o f 
female sex steroid hormones in the regulation o f P2-AR. Premenstrual asthma was 
probably first described by Frank (1931) in his original pubhcation on premenstrual 
tension. This was foUowed by a study o f 36 females with asthma who had 
perimenstrual worsening o f asthma symptoms (Claude, 1938). Dawson (1969) further 
strengthened the evidence for a link between asthma and the menstrual cycle by 
observing a higher incidence o f asthma in post-pubertal compared with pre-pubertal 
females. A t the age o f 10, the ratio o f asthma in girls : boys was found to be 1:3, 
whereas at 14 years, the ratio became 1:1. More dramatically, Barkman (1981) reported 
asthmatic deaths occuring premenstrually in two sisters aged 13 and 14 years. Each 
had been menstruating for 12 m onths and in both instances, death occured on the day 
preceding the onset o f menses. Skobeloff et al (1992) found that 75% o f patients 
admitted to hospital for exacerbations o f asthma were female and that these patients 
required longer hospital stays than age-matched males. A recent survey by the same 
workers o f female attendances to the Emergency Departm ent for exacerbation o f 
asthma, found that the majority (46%) occured during the perimenstrual period.
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(Skobeloff, 1996). Lenoir (1987) described three cases o f severe acute asthma 
associated with menstruation which required ventilation in the intensive therapy unit. 
Improvement o f asthma in each patient coincided with cessation o f menstruation. 
Case reports document the decline in asthmatic symptoms following the withdrawal 
o f a combined oral contraceptive in premenopausal wom en (Horan, 1968) and 
horm one replacement therapy in a post-menopausal female (Collins and Peiris, 1993). 
Two studies used hormonal manipulation in an attem pt to treat premenstrual asthma. 
Beynon et al (1988) described three patients with severe premenstrual asthma, resistant 
to conventional anti-asthma medication including high-dose corticosteroid. The 
addition o f intramuscular progesterone (100 mg daily in two cases and 600 mg twice 
weekly in one) eliminated the premenopausal dips in peak flow and allowed a 
significant reduction in the maintenance dose o f prednisolone. Another patient with 
severe premenstrual asthma was successfully treated using gonadotrophin releasing 
horm one analogue with improvement in her spirometry and reduction in the use o f 
systemic corticosteroids and P-agonist, resulting in fewer hospital admissions 
(Blumenfeld, 1994). Although there was litde doubt that female sex steroid hormones 
played a role in premenstrual asthma, much of the data had been based on 
circumstantial evidence and anecdotal reports. Several studies attempted to investigate 
the subject more thoroughly. Rees (1963) asked 81 female premenopausal asthmatic 
patients to chart the subjective measures o f frequency and severity o f asthma attacks. 
He found that 27 patients (33%) had a ‘clear tendency’ for exacerbations to occur 
seven to ten days prior to menstruation. There was, however, no objective data 
regarding the severity o f asthma and its relation to menstruation and he concluded 
that psychological factors were responsible. Three retrospective questionnaire-based 
studies were performed (Hanley, 1981; Gibbs, 1984; Ehasson, 1986). These estimated 
premenstrual asthma to be present in 33-40% o f female asthmatic patients. These
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studies could have been subject to recall bias, with the use o f leading questionnaires 
resulting in false positive reporting. Gibbs et al and Hanley also asked their 
symptomatic patients to keep daily peak flow diaries. Although statistically 
significantly lower peak flow rates occured premenstrually, the amplitude o f these 
changes (16% in Hanley’s, 5.3% in G ibb’s cohort respectively) was small enough to be 
o f doubtful clinical significance. W einmann et al (1987) studied nine asthmatic females 
during two consecutive menstrual cycles. N one o f his subjects had symptoms of 
premenstrual asthma and despite appropriate changes in serum progesterone and 
oestradiol, there were no changes in spirometry and airway responsiveness to 
histamine (expressed as PCis). A more detailed prospective study was carried out in 11 
female asthmatics and 29 controls over three to four consecutive menstrual cycles 
(Pauh, 1989). Although there were increased asthma symptoms during the luteal 
period compared to the folhcular, there were no significant changes in spirometry or 
airway hyperresponsiveness to methacholine. The authors noted that six out o f 11 
patients who were previously unaware o f premenstrual asthma recorded worsening o f 
asthma symptoms and had reduced peak expiratory flow rates seven days preceding 
menstruation, although again the amphtude o f these peak flow changes was small. 
Juniper et al (1987) examined 17 female asthmatics, ten with natural menstrual cycles 
and seven receiving the combined oral contraceptive pill. N o changes could be 
detected in spirometry and airway hyperresponsiveness to methacholine between the 
folhcular and luteal phases in either group.
In summary, female sex steroid hormones, hke corticosteroids have a facihtatory role 
in P2-AR function, in terms of regulating receptor num ber and its coupling to 
adenylate cyclase. Being a steroid hormone, hke the corticosteroids, it might regulate 
the transcription o f several genes including the P2-AR gene, although this is
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speculative at present. How the sex steroid hormones interact with P2-AR in 
premenstrual asthma is unclear, although we postulate that there may be abnormal 
hormonal regulation o f P2-AR in female asthmatics.
CHAPTER 2
GENERAL METHODS AND MEASUREMENTS
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2.1 SUBJECTS
Patients with asthma were recruited from the out-patient dim e at King’s Cross 
Hospital, Dundee and by advertisement. Healthy subjects were recruited from staff 
and students at NineweUs Hospital and Medical School, Dundee. All subjects gave 
written informed consent prior to enrolment to a study. AU had a fuU physical 
examination and normal haematological and biochemical profile prior to inclusion 
into any study. AU asthma patients were non-smokers and aU had asthma according to 
American Thoracic Society criteria (American Thoracic Society, 1987a). N one had had 
an exacerbation o f asthma that required the use o f oral corticosteroids or antibiotics in 
the preceding three months prior to a study. AU healthy volunteers were not on any 
regular medication.
2.2 SPIROMETRY
The forced expiratory volume in one second (FEVi) and the forced mid expiratory 
flow rate (FEF25-75) are the m ost used parameters to detect airflow limitation in 
asthma. Spirometry was performed to criteria o f the American Thoracic Society 
(1987b) using a Vitalograph Compact spirometer (Vitalograph Ltd, Buckingham, UK) 
with a pneumotachograph head and pressure transducer, and on-line computer- 
assisted determination o f FEVi and FEF25-75. Forced expiratory manoeuvres were 
performed from total lung capacity to residual volume. The best test FEVi value was 
taken from three consistent measurements (a coefficient o f variation o f less than 3% 
was considered acceptable).
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The peak expiratory flow rate is a very useful and simple way for the patient with 
asthma to monitor disease control. This is done using a portable W right peak flow 
m eter (Airmed, London, UK) which the patient uses in the morning and evening, 
prior to taking any inhaled medication, recording the best o f three consecutive 
manoeuvres.
2.3 BRONCHIAL PROVOCATION TESTS
Bronchial provocation tests have an established place in the investigation o f asthma 
and have provided insight into the pathophysiology and pharmacology o f asthma. 
Bronchoconstrictor stimuli can be either direct-acting or indirect-acting. The 
methacholine inhalation test has been described since the 1940’s and is an example o f 
a direct-acting bronchoconstrictor whereby it induces bronchoconstriction by acting 
directiy on bronchial smooth muscle to cause contraction. Adenosine m onophosphate 
challenge, on the other hand is more recently described (Cushley, 1983) and is an 
example o f an indirect acting bronchoconstrictor as it is thought to induce 
bronchoconstriction by stimulating mast cells to release histamine which in turn acts 
on bronchial smooth muscle cells to contract (Cushley, 1985). Results are expressed as 
either the provocation concentration or dose required to produce a 20% fall in FEY i, 
the PC 20 or PD 20 respectively. Both o f these bronchial provocation tests have been 
employed in the subsequent studies.
2.3.1 Adenosine monophosphate challenge
Bronchial challenge was performed using a Nebicheck nebuliser controller (PK 
Morgan Ltd) with a System 22 Acorn nebuliser (Medic-Aid Ltd) with a driving
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pressure o f 20 psi (138 kPa). The nebuliser was activated for 1.2 seconds from the 
initiation o f inspiration. Fresh solutions o f adenosine 5’-monophosphate (AMP; 
Sigma, Poole, UK) were made up in normal saline on each study day in a range o f 
concentrations from 0.04 m g/m l to 400mg/ml. A mouthpiece was used with the 
nebuhser and the nose clipped during the procedure. The m outhpiece was placed 
between the teeth o f the subject who exhaled to slighdy below functional residual 
capacity and then inhaled slowly over one to two seconds toward total lung capacity, 
where the breath was held for three seconds before taking the next breath. Subjects 
inhaled five breaths o f normal saline control solution followed by sequential doubling 
concentrations o f AMP given at three minute intervals. FEVi was measured one 
minute after each administration o f saline and AMP. The test was terminated when a 
20% fall in FEVi from the post-saline value was attained. A log-dose response curve 
was constructed and PC 20 was calculated by linear interpolation. If  the FEVi did not 
show a 20% fall after the maximum concentration had been given, a censored PC 20 
value o f 800 m g/m l (double o f the maximum concentration) was assigned for that test 
for the purpose o f statistical analysis (Chinn, 1991).
2.3.2 Methacholine challenge
In Chapter 5, a collaborative study with the Respiratory Unit at Newcasde General 
Flospital was carried out. This used a bronchoprovocation challenge previously 
validated by that Unit (Beach 1993; ConnoU 1988) so that identical equipment and 
protocols were used in both centres. In this test, methacholine was administered in 
double cumulative doses from 3.125-6400|ig using a m icroprocessor controlled 
dosimeter, and given at 5 minute intervals until a 20% fall in FEVi was recorded. The 
aerosol was released electronically using a pressure sensor in lOjll aliquots over 
approximately 2 seconds as the subject begins to inhale from functional residual
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capacity. The patient continued to inhale for 5 seconds until an electronically 
controlled bleep indicated the inspiratory manoeuvre was completed. Five such 
ahquots were inhaled in immediate succession comprising a single dose. Each dose 
was adrninistered immediately on completing the FEVi measurement, the start o f 
spirom etnc manoeuvres governing the time sequence o f the whole test. Spirometry 
involved 6 immediately consecutive forced expiratory manoeuvres and the mean of 
the 3 best FEVi readings is calculated at that time point. In order to avoid discomfort 
o f completing the forced vital capacity manoeuvre, each forced expiration is 
discontinued after 1 second. All the nebuHsers were calibrated individually prior to 
first use. The calculation o f P D 20 was by computer assisted log linear interpolation 
from the dose-response ’curve. If  a 20% fall in FEVi was not observed after the last 
dose, log linear extrapolation was applied. If  the extrapolated P D 20 value was larger 
than twice the last dose, then the P D 20 was censored as twice the value o f the last dose 
for the purpose of analysis. I f  a 20% fall in FEVi was obtained after the first dose, the 
P D 20 value was calculated using linear interpolation between baseline and the first 
dose. If  the interpolated dose was smaller than half o f the first given dose, the P D 20 
value was censored as half o f the first dose value.
2.4 LYMPHOCYTE P2-ADRENOCEPTOR PARAMETERS
Lymphocyte P2-adrenoceptor parameters including receptor density (Bmax), binding 
dissociation constant (Kd) and maximal cyclical A M P response to isoprenaline (Errm) 
were evaluated. Forty ml whole blood was collected into tubes containing ethylene 
diamine tetraacetic acid, diluted to 50ml with phosphate buffered saline (PBS) and 
then two equal portions were centrifuged with 15ml Lymphoprep (Nycomed Pharma
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AS, Oslo, Norway). The lymphocyte layer was removed and, after two further washes 
and centrifugation, the lymphocyte pellet was removed and resuspended in 5ml PBS 
prior to lymphocyte counting, with 5 x 10  ^ cells being required for cyclic AMP 
stimulation by isoprenaline. Lymphocyte Bmax and Kd were determined with 
iodocyanopindolol (ICYP, N E N -D uPont (UK) Ltd, Stevenage, UK) at eight 
concentrations between 5 and 160 pmol/1. CGP 12177 (Ciba-Geigy, Basle, 
Switzerland) was added to half the tubes to prevent ICYP binding to the receptor 
sites, thus allowing non-specific binding to be evaluated. After washing with assay 
buffer, the bound and unbound suspensions were aspirated onto filter paper using a 
Brandel Cell Harvester (Semat Technical [UK] Ltd, St Albans, UK). The resultant 
counts were determined with a gamma camera (LKB WaUac, Wallac OY Pharmacia, 
Turku, Finland) and specific binding was calculated from total binding minus non­
specific binding. Receptor density was calculated from extrapolation from the specific 
and non-specific binding curves plotted for each concentration o f ICYP. The inter­
assay coefficients o f variation for analytical imprecision were 10.3% for Bmax and 5.9% 
for Kd. A radioimmunoassay technique (Incstar, Stillwater, USA) was used to evaluate 
cyclic AMP levels (Emax) following suspension in PBS containing theophylline (lOOpg) 
and bovine serum albumin. It was stimulated with isoprenaline (IG'^^M) during 
incubation at 37° C, before terminating the reaction by heating to 95° C. After 
centrifugation the supernatant was removed and cyclic AMP measured. The intra­
assay and inter-assay coefficients o f variation for analytical imprecision were 2.7% and 
10.2% respectively.
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2.5 P2-ADRENOCEPTOR POLYMORPHISM
A num ber o f comm on variants (polymorphisms) o f the P2-adrenoceptor have recently 
been described which alter the behaviour o f the receptor following exposure to 
agonist. Four polymorphisms have been identified which result in single amino-acid 
substitutions in the receptor protein sequence; two o f which have been studied in this 
thesis, codon 16 and 27. Analysis o f P2-adrenoceptor genotype in this thesis was 
carried out at the D epartm ent o f Medicine, University Hospital o f Nottingham. P2- 
adrenoceptor genotype was assessed by allelle-specific oligonucleotide hybridisation 
with methods adapted from those designed to study mutations in the ai-anti-trypsin 
gene and its prom oter region. 5 ml whole blood was taken from each subject and 
genomic DNA extracted with the Nucleon system (Scot Lab). A 234 base pair 
fragment spanning the mutation o f interest was generated by PCR from the 5’ end o f 
the P 2-adrenoceptor gene. The primers used were: upstream,
CCCAGCCAGTGCGCTTACCT, and downstream, CCGTCTGCAGCTCGAAC. 
One pL PCR product was applied to duplicate Hybond N  plus filters on a dot-blot 
apparatus. To assess genotype, each filter was hybridised as appropriate with excess 
‘cold’ (unlabeUed) followed by ‘hot’ (^^P-labeUed) probes homologous with either the 
wild-type (Arginine 16, Glutamine 27) or Glycine 16 and Glutamate 27 forms o f the 
receptor. The duplicate filter was treated identically but with the probes in reverse 
order. A random  selection o f PCR fragments was also directly sequenced to confirm 
the specificity o f genotype identification by allelle-specific oligonucleotide 
hybridisation.
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2.6 HORMONE ASSAYS
Blood samples for hormone assays were centrifuged at 4° C and serum extracted and 
stored at -20° C till analysed in batches at the end o f each study in duphcate. Serum 
oestradiol (Sorin Biomedica, Saluggia, Italy) and progesterone (Incstar, Stillwater, 
USA) were measured by radioimmunoassay. The intra-assay coefficients o f variation 
for analytical imprecision were 2.9% and 6.3% respectively. Serum cortisol was also 
measured by radioimmunoassay (Sorin Biomedica, Saluggia, Italy). The intra-assay and 
inter-assay coefficients o f variation for analytical imprecision were 9.4% and 6.65% 
respectively.
2.7 SERUM POTASSIUM
Serum potassium was measured by flame photometry (IL943 analyser. 
Instrumentation Laboratory Ltd, W arrington, UK) with analysis being performed in 
batches at the end o f each study and samples being assayed in duplicate. The 
coefficients o f variation for analytical imprecision within and between assays were 
0.93% and 0.79% respectively. The normal reference range for our laboratory is 3.5 to 
5.0 m mol'h
2.8 HEART RATE
Heart rate was calculated from the R-R interval o f the electrocardiogram. The 
electrocardiogram was recorded on a standard lead II using a Hewlett-Packard (Palo
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Alto, California, USA) m onitor and printer with paper speed set at 50 m m /s and 0.5 
m V /cm  gain. The R-R interval was calculated from the mean o f five consecutive 
complexes.
2.9 FINGER TREMOR
Finger trem or was recorded by a previously validated m ethod (Lipworth, 1989) using 
an accelerometer transducer (Entran Ltd, Ealing, UK). This was taped to the distal 
phalanx o f the middle finger. Postural tremor was measured with the fingers extended 
and the wrist in neutral position for 20 second periods. Five recordings were 
measured, and the results were stored on computer disc for subsequent spectral 
analysis o f total tremor power o f more than 2 FIz (units o f mg^/sec) using computer- 
assisted autocovariance. The mean of three lowest consistent readings was analysed.
2.10 STATISTICAL ANALYSIS
Data for finger tremor, receptor density Bmax and PC 20 and P D 20 were transformed 
with logarithm to base 10 prior to analysis as these variables were not normally 
distributed. For dose-response curves, all parameters were analysed as delta responses 
from baseline. For all parameters comparisons were made by multifactorial analysis o f 
variance (MANOVA) using subjects, treatments, visits and period as factors for 
analysis. W hen significant overall differences between treatments were found to occur 
with MAN OVA, multiple-range testing was applied to identify where these 
differences occurred. A value o f p<0.05 (two-tailed) was considered as being
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significant, and 95% confidence intervals (95% Cl) for mean treatm ent differences 
were calculated where significant. Data were analysed with a Statgraphics Statistical 
software package (STSC Software Publishing Group, Rockville, USA).
2.11 DRUGS
Formoterol (Foradil®) pressurised metered dose inhaler, 12 pg per actuation.
Formoterol (Turbuhaler®) multi-dose dry powder inhaler and matching placebo, 
prepared by Astra Pharmaceuticals.
Terbutaline (Bricanyl®) multi-dose dry powder inhaler.
Ipratropium bromide (Atrovent Forte®) pressurised metered dose inhaler, 40 pg per 
actuation.
Prednisolone 25mg and 5mg tablets, with matching placebo tablets prepared by the 
Pharmacy Department, NineweUs Hospital.
Hydrocortisone lOOmg ampoules for intravenous injection.
Fluticasone propionate (Flixotide®), pressurised metered dose inhaler, 250 pg per 
actuation with matching placebo inhaler prepared by the Pharmacy Department.
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Salbutamol (Ventodisk®), dry powder inhaler, 400 pg per dose.
Salbutamol (Ventolin®) pressurised metered-dose inhaler, 100 pg per actuation.
Medroxyprogesterone (Provera®) lOmg tablets.
Ethinyloestradiol (non-proprietary) 50 pg tablets.
2.12 ETHICAL APPROVAL
In aU clinical studies, all subjects gave written informed consent prior to being 
evaluated. AU studies had been approved by the Tayside Committee on Medical 
Research Ethics.
CHAPTER 3
SYSTEMIC CORTICOSTEROID RAPIDLY REVERSES 
BRONCHODILATOR SUBSENSITIVITY 
INDUCED BY FORMOTEROL 
IN ASTHMATIC PATIENTS
(American Journal of Respiratory and Critical Care Medicine 1997;
156: 28-35)
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3.1 INTRODUCTION
There have been several studies demonstrating that bronchodilator subsensitivity 
develops after regular treatment with the long-acting P2-agonist, formoterol in asthma 
patients (Newnham 1994a; Yates 1995; Newnham 1995). This has also been 
demonstrated with sakneterol (Grove, 1995). The mechanism for this subsensitivity 
appears to be due to P2-adrenoceptor (P2-AR) down-regulation and desensitisation 
from prolonged P2-agonist exposure. Most o f the patients involved in the above 
studies were receiving inhaled corticosteroid, indicating that perhaps inhaled 
corticosteroids do not protect against the development o f P2-AR subsensitivity. There 
is some evidence to suggest that systemic corticosteroid may exhibit a facilitatory role 
in terms o f reversing previously down-regulated P2-AR in normals and asthmatics 
(Hui, 1982; Brodde, 1985; Brodde, 1988). However, it is unclear as to the time-course 
for such effects in vivo. Also, it is unclear as to whether up-regulation o f P2-AR in vitro 
correlates with reversal o f in vivo responses.
In this initial study, we have investigated the acute facilitatory effects o f systemic 
corticosteroid on in vitro and in vivo P2-AR function in asthmatic patients treated with 
regular inhaled formoterol, that is in the presence o f established P2-AR subsensitivity.
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3.2 METHODS 
Patients
Twelve asthmatic patients (four female and eight male), with a mean age o f 44 years 
(range: 20 - 63 yr) were recruited and completed the study. All gave written informed 
consent before being randomised according to a double blind, placebo controlled, 
cross-over protocol approved by the Tayside medical ethics committee. A full physical 
examination, 1 2 -lead electrocardiogram, and measures o f biochemical and 
haematological parameters were normal prior to inclusion o f the patients. AU had 
asthma according to the criteria o f the American Thoracic Society (1987a), and aU 
were non-smokers. A t the initial screening visit, subjects were required to have an 
FEV j of 40-80% o f predicted normal with at least 15% reversibility o f FEV j with 
inhaled formoterol 24pg. The mean (SEM) FEV j in Utres and percent predicted was 
2.14 (0.15) and 6 6  (3)% predicted, range 1.34 to 2.97 L (% predicted range 47-75%). 
AU patients were receiving inhaled corticosteroid (either budesonide or 
beclomethasone dipropionate; one patient received fluticasone propionate), median 
dose 1000 Pg/day, range 400 - 1600 pg/day. AU had been inhaling short-acting ^ 2 “ 
agonists as required prior to recruitment in doses o f <800 pg/day. Five subjects were 
inhaling salmeterol 100 pg/day. In addition, 4 subjects were taking slow-release oral 
theophylline preparations. N one had received oral corticosteroid for at least 3 months, 
and none had had a recent exacerbation o f asthma in the m onth preceding the study. 
Before entry into the study, aU subjects were supervised in the use o f a metered-dose 
inhaler (MDI) using a Vitalograph aerosol inhalation m onitor (Vitalograph Ltd, 
Buckingham, UK)
Protocol
After the initial screening visit, the subjects had a two week washout period without 
any P2 -agonists during which they used ipratropium bromide at 40pg per actuation 
(Atrovent Forte, Boehringer IngeUieim, BrackneU, UK) as a substitute for rescue
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requirements. After two weeks, subjects attended for a randomisation visit, and FE V j 
was measured yielding a mean (SEM) value 2.20 (0.15)L or 67(3)% predicted. Subjects 
were then randomised to receive concurrent treatments in crossover fashion with 
either inhaled placebo or inhaled formoterol 24pg twice-daily (12pg per actuation; 
Foradil, Ciba-Geigy AG, Basel, Switzerland) both via a m etered dose inhaler, for four 
weeks, whilst maintaining their inhaled steroid and other anti-asthma therapy at a 
constant dose (Figure 3.1). Six subjects received formoterol as first treatment and six 
received placebo first. During the treatment period, an ipratropium bromide inhaler 
was also available for rescue purposes in order to ensure that P2 ”^g°^sts  were not 
used during the placebo period. The study treatm ent was taken twice daily, between 
7:00 A.M. and 9:00 A.M. and again between 7:00 P.M. and 9:00 P.M. The subjects 
were also asked to keep morning and evening peak expiratory flow readings, made 
with a W right peak flow meter (Airmed, London, UK), in a diary.
Subjects attended the laboratory after three weeks and four weeks o f treatm ent at 8:00 
A.M., having withheld their study medication for 24 hours, ipratropium bromide for at 
least 8  hours and oral theophylline for 48 hours. A t each visit, an intravenous cannula 
was inserted and kept patent by bolus injections o f heparinised saline. A cannula dead 
space o f 2ml was withdrawn prior to blood sampling. A dose-response curve (DRC) 
to inhaled formoterol was constructed one hour after ingestion o f placebo tablets and 
intravenous placebo injection at the three week visit, and one hour after oral 
prednisolone 50mg and intravenous hydrocortisone 200mg at the four week visit. The 
rationale for the adrninistration o f corticosteroid was to mimic what would be 
normally given in an acute asthma attack ie. an initial bolus o f hydrocortisone and a 
first dose o f oral prednisolone to provide cover over the next 24 hours. The 
administration o f placebo at week three and systemic corticosteroid at week four was 
done so as to avoid any possibility o f carry-over from one dose-response curve to 
another.
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The DRC was constructed with inhaled formoterol, given via a metered-dose inhaler, 
using doses o f 12 pg, 24 pg, 24 pg and 48 pg - that is, a cumulative dose o f 108 pg 
after the last dose, with the doses separated by 40 minutes. Measurements o f F E V \, 
FEF25-75, serum potassium (K), heart rate (HR), and postural finger trem or (Tr) were 
undertaken over a 1 0 -minute period at baseline (before placebo/steroid tablets and 
injection), one hour after placebo/steroid tablets and injection (that is, the start o f the 
DRC) and 30 minutes after each dose, and repeated at 1, 2, 4 and 6  hours after the last 
dose. 40 ml o f blood for lymphocyte P2 -AR parameters (Bj^^x» ^.j^ax &od K j) was 
withdrawn at one and three hours post-adininistrafion o f placebo/steroid. The next 
day, twenty-four hours after administration o f placebo/steroid, subjects attended the 
laboratory for lymphocyte P2 ~^I^ parameters, and measurement o f FE V j and FEF25_ 
7 5  before and 30 minutes after 12pg formoterol. The purpose o f the latter 
measurement was to observe whether the effects o f the steroid were still present after 
24 hours in terms o f modulating in vitro and in vivo P2 -AR function, although a fuU 
DRC was not performed.
1 0  ml whole blood was also taken for pz-AR polymorphism and stored in 
ethylenediamine tetraacetic acid at -20°C. Unfortunately, one sample was lost and we 
have analysed P2-AR polymorphism in 11 o f 12 subjects.
Measurements
FEVi and FEF25-75 - see Chapter 2, Spirometry. 
Semm potassium - see Chapter 2.
Heart rate - see Chapter 2.
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Finger trem or - see Chapter 2.
Lymphocyte P2-adrenoceptor parameters - see Chapter 2. 
Identification o f P2-adrenoceptor polymorphisms - see Chapter 2.
Statistical analysis
AU variables were analysed as delta responses from the baseline 1 hour after injection 
o f placebo or hydrocortisone. Comparisons for the DRC were made as area-under- 
curve (AUC) in order to obviate multiple comparisons at several time points. For aU 
parameters, comparisons were made by multifactorial analysis o f  variance 
(MANOVA) using subjects, treatments, visits and period as factors for analysis. W hen 
significant overaU differences between treatments were found to occur with 
M ANOVA, D uncan’s multiple-range testing was applied to identify where these 
differences occurred. A value o f p<0.05 (two-tailed) was considered as being 
significant, and 95% confidence intervals (95% Cl) for mean differences were 
calculated where significant.
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3.3 RESULTS
Baseline values for airway and systemic parameters were not significandy different 
after treatm ent with either placebo or formoterol, either before or after administration 
o f placebo/steroid tablets and injection (Table 3.1).
Bronchodilator and systemic DRC
The bronchodilator and systemic dose-response curves (as area-under-curve, AUC) 
after regular treatment with placebo and formoterol, with and without systemic steroid 
are summarised in Table 3.2, and shown graphically in Figures 3.2, 3.3 and 3.4.
The DRCs (as change from baseline) after pretreatment with either placebo or 
form oterol showed dose-dependent increases in delta FEVi and delta FE F 25-75 and a 
plateau in response was not attained within the dose range, 40 minutes after the last 
dose (ie. at t=2h 40min) (Figure 3.2). There was a rightward shift in the DRC for both 
delta FEVi and delta FEF 25-75 after treatment with formoterol compared with placebo: 
p=0.01 for dFEVi and dFE F 2s-75. Following administration o f systemic corticosteroid 
(S), there was significant reversal o f bronchodilator tachyphylaxis for dFEVi (p=0.03) 
and dFE F 25-75 (p=0.005). There was no significant difference in response between 
formoterol plus steroid (FM+S) and placebo plus steroid (PL+S).
O n the following day (ie. 24 hours after injection o f placebo or steroid), the baseline 
FEV 1 and FEF25-75 were lower following pretreatment with formoterol compared with 
placebo: p=0.02 for FEVi and p=0.004 for FEF25-75 (Figure 3.3). Form oterol 12pg 
was then administered and the 30 minute post-bronchodilator values for FEVi and 
FEF25-75 were not significantly different.
There were dose-dependent increases in finger trem or (Tr) and heart rate (HR), and 
decrease in serum potassium (K) (Figure 3.4). There were significant rightward shifts
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in delta T r and H R after treatm ent with formoterol compared with placebo: p < 0.001 
for HR and p=0.04 for Tr. There was no significant rightward shift in delta K  
(p=0.13). After the administration o f systemic corticosteroid, tachyphylaxis in HR 
response was reversed (p<0.001). There was no significant reversal in DRC in delta Tr 
response following FM with steroid compared with FM alone (p=0.20). There was 
augmentation o f the delta HR response with placebo plus steroid compared with 
placebo alone (p<0.001).
Lymphocyte P 2 " adrenoceptor parameters
There were no significant differences in log (fm ol/10^ cells) between any o f the
treatments one hour after injection o f placebo or steroid (Figure 3.5). However, at 3 
hours after injection, there was a significant increase in log Bj^^x comparing 
formoterol with steroid with formoterol alone (p=0.01). There was also a significant 
increase with systemic steroid after placebo pretreatment (p<0.001). After 24 hours, 
the effect o f corticosteroid had diminished, and log B ^ ^ ^  had fallen to levels below 
baseline. The trend for tdme-profile changes in (pm ol/10^ cells) mirrored those
o f log in that there was a significant increase 3 hours post-corticosteroid
administration in the placebo pre-treated group (Emax at Ih  vs Emax at 3h ; p=0.003). 
Values at 3 hours were: (PL+S vs PL) 4.62 vs 3.74, but these were not significantly 
different. For dissociation constant K j , the time-profile changes were different to 
those o f Bj^ax one and three hours post-administration o f
corticosteroid, there were no significant differences in K j. However, by 24 hours 
there was a significant (p<0.05) decrease in in subjects treated with formoterol or 
placebo, except in those given corticosteroid.
PEER diary cards
Mean peak expiratory flow rates (L/min) in the morning were higher with formoterol 
than with placebo which was sustained for 4 weeks o f treatment: (PL vs FM), for
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week 1: (p=0.05); week 2: (p=0.008); week 3: (p=0.008) and week 4: (p—0.005). 
Likewise, evening PEFR was higher with formoterol than with placebo throughout 
the 4 weeks o f treatment. (Figure 3.6)
p2-adrenoceptor polymorphism
Eleven subjects were analysed for P2-AR polymorphism at codon 16 and 27. Seven 
subjects were homozygous Gly 16, three were heterozygous Arg 16/G ly 16 and one 
was homozygous Arg 16; three were homozygous Glu 27, six were heterozygous Gin 
27 /G lu  27 and two were homozygous Gin 27. The individual responses for AUC 
FEVi and AUC FEF 25-75 in terms o f P2-AR polymorphism at codon 16 and 27 are 
shown in Figures 3.7 and 3.8 respectively. The data were not analysed in terms o f 
differing subsensitivity because o f insufficient numbers o f subjects with different 
polymorphisms. Hence, only a qualitative assessment can be made o f these results. 
After the development o f bronchodilator subsensitivity following treatm ent with 
formoterol, the adrninistration o f systemic corticosteroid produced reversal in the 
majority o f subjects irrespective o f P2-AR polymorphism.
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Baseline(pre-
injection)
Baseline(l hour 
post-injection)
PL PL+S FM FM+S 'P'
value
FEVj (1) 2.18 2 .1 1 2 .0 0 2 .0 1 0 . 1 0
(2.07-2.30) (1.99-2.22) (1.89-2.12) (1.90-2.13)
FEF2 5 . 7 5 1.41 1.25 1.27 1.37 0.53
a/s) (1.23-1.60) (1.06-1.44) (1.09-1.46) (1.19-1.56)
K (mmol/1) 3.91 3.86 3.84 3.97 0.69
(3.75-4.08) (3.69-4.02) (3.68-4.01) (3.80-4.14)
Tr aog units) 2.27 2.48 2.47 2.42 0.69
(1.97-2.57) (2.20-2.76) (2.19-2.75) (2.16-2.68)
HR 75 71 75 77 0 . 1 2
(beats/min) (71-78) (67-74) (72-79) (73-80)
FEV| 0 2.26 2.16 2.08 2.07 0.07
(2.15-2.38) (2.05-2.27) (1.96-2.19) (1.95-2.18)
FEF2 5 . 7 5 1.56 1.47 1.36 1.41 0.24
a/s) (1.41-1.71) (1.32-1.62) (1.21-1.51) (1.26-1.56)
K (mmol/I) 3.84 3.96 3.94 3.98 0.50
(3.70-3.98) (3.82-4.10) (3.80-4.08) (3.84-4.12)
Tr aog units) 2.08 2.05 2.15 2.32 0.09
(1.92-2.23) (1.89-2.22) (2.00-2.31) (2.17-2.47)
HR 6 8 6 6 69 67 0.69
(beats/min) (65-70) (64-69) (66-71) (65-70)
T ab le  3.1 Mean (95% Cl) baseline values measured before and one hour after 
administration o f systemic corticosteroid (S), after regular treatm ent with placebo (PL) 
and formoterol (FM), before construction o f the dose-response curve.
'p' value refers to overall comparisons between treatments by MANOVA.
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PL PL+S FM FM+S
AUC FEVi 
(L.h)
4.22*
(3.39-5.05)
4.26*
(3.74-4.78)
2.51
(1.68-3.34)
3.57*
(3.06-4.09)
AUC FE F 25-75 
(LxlO^)
19.94 * 
(15.34-24.55)
20.05 * 
(17.47-22.63)
11.30
(6.72-15.92)
18.47*
(15.89-21.04)
A U C K
(mmol.h/L)
2.92
(3.94-1.89)
3.55*
(4.57-2.52)
2.03
(3.11-0.96)
2.10
(3.18-1.03)
AUC Trem or 
(log units.h)
5.49*
(4.33-6.65)
6.00*
(3.52-8.49)
3.39
(1.85-4.92)
4.31
(3.08-5.54)
AUC HR 
(beats)
5200*
(3600-6900)
11400*+
(9780-13080)
2700
(1320-4140)
9600 *+ 
(8200-11000)
T ab le  3.2 Mean (95% CI) airway and systemic dose-response curves (as area-under- 
curve, AUC) after treatment with placebo (PL) and formoterol (FM), with and without 
steroid (S). * denotes p<0.05 compared with FM, + denotes p<0.05 compared with 
PL
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Run-in Formoterol 24|ig bd/placebo Placebo/form oterol 24pg bd 
(2 weeks) (4 weeks) (4 weeks)
t t t T
Placebo Steroid Placebo Steroid
DRC DRC DRC DRC
P2-AR P2-AR P2-AR P2-AR
(week 3) (week 4) (week 3) (week 4)
F igure  3.1 Overview o f study design.
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Figure 3.2 Dose-response curves and time-profile after last dose for FEVi and FEF 25- 
75 after regular treatment with placebo (PL) and formoterol (FM) with or without 
acute adrninistration of systemic corticosteroid (S). Values are shown as mean (SEM) 
change from baseline. * p<0.05 versus formoterol for AUC.
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Figure 3.5 Lymphocyte P2-adrenoceptor parameters; Bmax, Emax and Kd with or 
without steroid (S) at 1,3 and 24h after adrninistration, following regular treatment 
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Figure 3.6 Mean (SEM) peak expiratory flow diary recordings (12h after each dose) in 
the morning and evening during 4 wk of treatment with placebo (PL) and formoterol 
(FM). *p<0.05 FM versus PL.
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Figure  3.7 Individual responses for AUC FEVi and AUC FE F 25-75 after treatment 
with placebo (PL) and formoterol (FM), compared with reversibility following steroid 
(FM+S), according to P2-adrenoceptor polymorphism at codonl6.
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F igure  3.8 Individual responses for AUC FEVi and AUC FEF25-75 after treatment 
with placebo (PL) and formoterol (FM), compared with reversibility following steroid 
(FM+S), according to p 2-adrenoceptor polymorphism at codon 27.
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3.4 DISCUSSION
O ur results in this study have demonstrated that subsensitivity o f bronchodilator and 
systemic responses occurs after treatm ent with regular inhaled formoterol
compared with placebo. These results are consistent with previous studies with long- 
acting P2 ”^gonists with dry powder (Newnham, 1994a) and aerosol (Newnham, 1995) 
preparations o f formoterol and sahneterol (Grove, 1995). In contrast, bronchodilator 
subsensitivity does not appear to occur with short-acting P2 "^g°*^sts in placebo- 
controlled studies (Lipworth, 1989;Lipworth, 1990), although Turki et al (1995a) have 
reported down-regulation o f lung cell ^ 2 " ^ ^  after 24 hours with metaproterenol.
It is important to note that baseline values for FEVi and FEF25-75 were virtually 
identical between treatments for both pre and post injection o f placebo or steroid, 
making it unlikely for differences between treatments to be due to baseline effects. 
There was no period effect between visits which excludes the possibility that the 
difference between formoterol alone and formoterol with steroid was a sequence 
phenomenon.
The use of formoterol in the present study in constructing dose-response curves has 
clinical relevance, in that formoterol is fast acting and it is conceivable that patients 
who are on regular therapy might also use it repeatedly for rescue purposes, as might 
occur during an acute attack o f asthma.
As in previous studies (Newnham, 1994a;Newnham, 1995;Grove, 1995), morning and 
evening expiratory flow rates from diary cards at 12 hours after dosing were 
significandy greater with formoterol compared to placebo and this was sustained 
during the four week treatment period. This clearly illustrates the importance o f 
constructing proper dose-response curves and ensuring at least 24 hours washout 
prior to DRC, in order to detect sub sensitivity. It is, however, conceivable that
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improved peak flow rates may luU patients into a false sense o f security and delay 
seeking medical attention. It is also possible that regular long-acting P2 ’^go^st 
therapy whilst improving symptoms and PEFR might result in the masking o f 
deteriorating inflammation, as might occur leading up to an acute asthmatic attack. In 
this study, it is also relevant to note that bronchodilator sub sensitivity has been 
demonstrated despite the fact that all the subjects were receiving regular inhaled 
corticosteroid, suggesting that inhaled corticosteroids do not protect against such 
tolerance.
O ur results also showed rapid reversal o f bronchodilator subsensitivity within one 
hour o f injection o f hydrocortisone. This finding is similar to that o f a previous report 
(EUul-MicaUef, 1975). In an open placebo-controlled study, intravenous prednisolone 
restored the bronchodilator response to a single 200 pg dose o f isoprenaline given 60 
minutes after injection in 10 patients who had previously been shown to be non- 
responsive. Also, Holgate et al, in normal subjects, showed reversal o f salbutamol 
DRC (sGaw) 16 hours after hydrocortisone (Holgate, 1977).
There is conflicting evidence as to whether lymphocyte P2"-^^ can be used as a 
surrogate for following changes in airway smooth-muscle ^2 ”^ ^  (Hauck, 1990; 
Hayes, 1996). In our subjects, systemic corticosteroid up-regulated lymphocyte ^2" 
AR, in keeping with reversal o f bronchodilator subsensitivity. This is in keeping with 
previous studies with lymphocytes, where up-regulation has been shown to occur in 
normal (Hui, 1982; Brodde, 1985) and asthmatic (Brodde, 1988) subjects with 
systemically administered corticosteroid. The mechanism o f this effect by 
corticosteroids may involve an increase in the rate o f synthesis o f receptors by a 
process o f increased ^ 2 "^ ^  gene transcription (Mak, 1995a), or a reversal or 
inhibition o f internalisation o f receptors from the cell surface (Davies, 1984). 
Corticosteroids are also thought to prom ote the formation o f the coupled, high- 
affinity state o f the receptor, which in turn increases receptor function (Davies, 1980).
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Systemic corticosteroid also up-regulated lymphocyte which had not previously
been down-regulated ie after placebo pretreatment. Mean values for log Bmax after 
placebo were similar to previously reported control values from normal volunteers 
(0.29 vs 0.28 fmol/10^ cells) (Chapter 7). This up-regulation o f lymphocyte P2 -AR by 
corticosteroid was mirrored by its effect on heart rate where steroid administration 
augmented the heart rate response after placebo pretreatment. Indeed, even after 
formoterol, the presence o f steroid increased the heart rate response compared to 
placebo alone. This therefore suggests that systemic corticosteroid is capable o f 
supernormaHsing P2 -AR density. This, along with the lack o f protection against P2 - 
AR down-regulation and subsensitivity by inhaled corticosteroid would therefore 
suggest that a facilitatory effect o f corticosteroid is only conferred by the systemic 
route.
We studied a group o f asthmatics who were heterogenous in terms o f P2-AR 
polymorphism. In particular, it is known that homozygous Gly 16 and homozygous 
Glu 27 polymorphism confers susceptibility and protection respectively to the 
development o f down-regulation to P2 "^g°^^sts (Green, 1995b). The results in this 
study show that in general, systemic corticosteroid produced reversal o f 
bronchodilator subsensitivity independent o f P2-AR polymorphism. This is clinically 
relevant because homozygous Gly 16 subjects are m ost susceptible to desensitisation 
but appear to be responsive to the facilitatory effects o f systemic corticosteroid. O ur 
patients had stable, moderately-severe asthma and it is conceivable that even a small 
degree o f subsensitivity would assume greater clinical importance in more severe 
asthmatics in the setting o f an acute attack.
There were also some interesting findings which occured 24 hours after administration 
o f corticosteroid. The baseline level o f FEV^ at 24 hours was lower after pretreatment 
with formoterol compared with placebo, irrespective o f administration o f steroid.
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However, this is unlikely to reflect persistent subsensitivity since the 30 minute 
response to formoterol 12 pg was preserved. This does not appear to relate to 
lymphocyte density and isoprenaline cAMP response which were both
diminished at 24 hours, irrespective o f prior steroid administration. This fall in 
lymphocyte P2 -AR density and cAMP responsiveness between 3 hours and 24 hours 
may represent the legacy o f the repeated formoterol doses from the DRC. 
Lymphocyte receptor affinity as measured by the dissociation constant, K^j, showed a 
different pattern in that corticosteroid prevented a fall in K j  which occured 
irrespective o f formoterol or placebo pretreatment, inferring an effect o f the previous 
formoterol DRC.
W hat might be the clinical relevance o f our study? In acute asthma, where patients 
may be desensitised as a consequence o f regular long-acting P2 -agonist therapy, it 
demonstrates the importance o f the early administration o f systemic corticosteroid in 
order to restore normal airway P2 -AR responsiveness. This suggests that systemic 
corticosteroid has a dual action in acute asthma in terms o f an early effect on P2 -AR 
response and a later effect on the inflammatory response.
Although the mean results showed significant bronchodilator subsensitivity, there 
were considerable inter-individual variation (Figures 3.7 and 3.8). It would be 
interesting therefore to investigate if these individual differences could be influenced 
by P2-AR polymorphism.
CHAPTER 4
ASSOCIATION BETW EEN P2-ADRENOCEPTOR  
POLYMORPHISM AN D  SUSCEPTIBILITY TO  
BRONCHODILATOR DESENSITISATION IN  
MODERATELY SEVERE STABLE ASTHMATICS
(Lancet 1997; 350: 995-999)
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4.1 INTRODUCTION
In the previous study, it was shown that bronchodilator subsensitivity developed after 
regular inhaled formoterol in asthma patients. Although significant mean differences 
between treatments were demonstrated, there were quite marked inter-individual 
differences in the development o f bronchodilator subsensitivity. We know from in 
vitro studies that genetic polymorphisms o f the Pz-adrenoceptor (Pz-AR) might 
influence the development o f Pz-AR subsensitivity (Green, 1995b). The presence of 
glycine at codon 16 o f the receptor predisposes to down-regulation following agonist 
exposure to a greater extent than the arginine 16 form o f the receptor. likewise, the 
presence o f glutamate at codon 27 is thought to confer protection against such down- 
regulation compared to the glutamine 27 form.
In this study, we have performed a retrospective analysis o f three similar randomised, 
placebo-controlled, double-blind, cross-over studies (Newnham, 1994a; Newnham 
1995; Chapter 3) involving asthma patients receiving regular inhaled formoterol, 
including the previous study, to evaluate the relationship o f Pz-AR polymorphism to 
the development o f bronchodilator subsensitivity.
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4.2 METHODS 
Patients
The three reference studies were done between 1992 and 1996. 35 patients were 
originally recruited to all three studies, which comprised 29 individuals. We were able 
to recall 22 (76%) o f the 29 patients to the department to have a blood sample taken 
for genotype analysis. O f the remaining seven patients, one declined to return and six 
had moved from the area and could not be contacted. O f the 22 recalled patients, four 
participated in two studies, and one in three studies; these five patients had all 
participated in one particular study (Newnham, 1995), the data from which were thus 
included in analysis. A breakdown o f the proportion o f  patients included from each o f 
the three studies was five o f seven (Newnham, 1994a), 11 o f 16 (Newnham, 1995) and 
six o f 12 (Chapter 3).
AU participants had moderately severe asthma with a F E V | between 50-80% 
predicted with 15% reversibility to and 20 participants were receiving
inhaled corticosteroid median dose lOOOpg/day (range 200-2000pg/day). They were 
divided into groups depending on their polymorphism at codon 16: homozygous Arg 
16 (n=4), heterozygous Arg 16/Gly 16 (n=8) and homozygous Gly 16 (n=10); and at 
codon 27: homozygous Gin 27 (n=5), heterozygous Gin 2 7 /Glu 27 (n = ll)  and 
homozygous Glu 27 (n=6). ^ 2 " ^ ^  genotype was determined using previously 
described methodology (HaU, 1995). The characteristics o f these patients are shown in 
Table 4.1. Baseline pulmonary function, as percentages o f normal predicted FE V j and 
FEF25-75 are not significantly different between the groups. Approval was obtained 
from the Tayside committee on medical research ethics, and aU patients gave 
informed, written consent.
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Protocol for studies
All three studies (Newnham 1994a; Newnham 1995; Chapter 3) had a similar 
protocol. In brief, subjects were randomised to receive either inhaled placebo or 
inhaled formoterol 24 pg twice daily for four weeks in double-blind, cross-over 
fashion. All inhaled corticosteroids were continued unchanged throughout the study. 
They were required to withhold all other P 2 -agonists and were supplied with 
ipratropium bromide for rescue purposes during the run-in period and during each 
treatment. Bronchodilator dose-response curves (DRC) to inhaled formoterol (6-108 
pg as cumulative doses) were then constructed at the end o f each treatm ent period. 
FE V j and FEF25_75 were measured 30 minutes after each dose and for up to 6 hours 
after the last dose. Mean (SD) baseline values for F E V | and FEF25_75 (prior to DRC) 
were not significandy different for all 22 patients: 2.23 L  (0.14) after placebo vs 2.30 L 
(0.14) after formoterol for F E V j, and 1.57 L /s  (0.23) after placebo vs 1.70 L /s  (0.23) 
after formoterol for FEF 2 5 _7 5 -
Identification o f P2 -adrenoceptor polymorphisms - see Chapter 2.
Statistical Analysis
Bronchodilator responses were measured after treatment with placebo or formoterol 
from the DRC, and defined as changes from baseline to the maximum and 6-h 
responses. The bronchodilator-desensidsation percentage was calculated with the 
following formula:
% subsensitivity = delta response (placebo! - delta response (formoterol) x 100
delta response (placebo)
The percentage desensitisation for maximum and 6-h responses was calculated for 
both FEVi and FE F 25-75. For example, if the delta-FEVi response from the DRC after
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placebo is a 1.00 L rise, and the delta-FEVi response from the DRC after formoterol 
is a 0.20 L rise, then the desensitisation percentage from the equation will be 80%. 
However, if the DRC after formoterol showed a fall rather than a rise from baseline, 
then the equation would produce a value for desensitisation exceeding 100%. For 
example, if the delta response from DRC after placebo is a 0.80 L rise, and the delta 
response from DRC after formoterol is a 0.20 L fall, then the desensitisation 
percentage will be 125%. Comparisons between groups were then made by two-way 
analysis o f variance. A probability value o f p<0,05 (two-tailed) was considered as 
being o f significance and 95% confidence intervals (95% Cl) for mean differences 
were calculated where significant.
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4.3 RESULTS
Individual and mean group bronchodilator responses are depicted in Figures 4.1 to 
4.4. The mean values for percentage desensitisation for homozygous polymorphisms 
at codon 16 and 27 are summarised in Table 4.2. For codon 16 polymorphisms, 
maximum FEVi and FEF25-75 responses showed a significantly greater degree of 
bronchodilator desensitisation with homozygous Gly 16 than with homozygous Arg 
16. This result was m irrored by significandy greater desensitisation with homozygous 
Gly 16 than with homozygous Arg 16 for 6-h FEVi and FEF25-75 responses. Mean 
values for the heterozygote form (Arg 16/G ly 16) were intermediate between 
homozygous Arg 16 and Gly 16, except for the maximum FEVi response, in which 
we found significandy greater desensitisation with Arg 16/G ly 16 than with Arg 16 
(46% and -8%, respectively; 95% Cl 10-98, p<0.05).
For codon 27 polymorphism, there were significant differences in FEF25-75 but not 
FEVi responses, with homozygous Glu 27 showing greater desensitisation than 
homozygous Gin 27 for maximum and 6-h FEF25-75 responses. All patients who were 
homozygous for Glu 27 were also homozygous for Gly 16.
We found no evidence o f genotype-related subsensitivity for bronchodilator response 
from the DRC after prior treatm ent with placebo, in terms o f mean (SEM) maximum 
delta F E V | response (as % of predicted): Arg 16 19% (±3), Arg 16/G ly 16 25% (±5) 
and Gly 16 29% (±5).
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G enotype Sex
(M /F )
Age
(yeais)
FEV i 
(% pred .)
F E F 25-75 
(% p red .)
In h a led
ste ro id
(p g /d a y )
C odon  16
Arg 1 6 /Arg 16 4 /0 38(3) 64 (15) 39 (10) 700 (1000)
(n=4)
Arg 16/G ly 16 4 /4 31 (17) 69 (15) 46 (14) 1000 (1600)
(n=8)
Gly 16/G ly 16 5 /5 44 (11) 57 (17) 30 (13) 1250 (800)
(n=10)
C odon  27
Gin 27 /G ln  27 5 /0 40 (14) 63 (13) 38(9) 1000 (600)
(n=5)
Gin 27/G lu  27 5 /6 36 (16) 66 (14) 42 (15) 1000 (1200)
(n = ll)
Glu 27 /G lu  27 3 /3 40 (10) 58 (22) 29 (16) 1150 (800)
(n=6)
T a b le  4.1 Patients' characteristics according to genotype at codon 16 and 27, Values 
are shown as means (SD) and median (interquartile range) for inhaled steroid dose. 
FEVi and FEF25-75 values are shown as % predicted (% pred.).
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C odon  16 A rg l6 /A tg l6 Gly 16/ Gly 16 ‘p ’ value 95% C l
Max FEVi -8% 46% p<0.05 15%-92%
Max FE F 25-75 -32% 74% p<0.05 49%-164%
6h FEVi 30% 81% p<0.05 2%-105%
6h FEF 25-75 21% 104% p<0.05 38%-130%
C odon  27 G ln27/G ln27 G lu27/G lu27
Max FEVi 2% 35% p=0.08 -6%-73%
Max FE F 25-75 -7% 68% p=0.05 2%-147%
6h FEVi 46% 76% p=0.24 -24%-83%
6h FEF 25-75 43% 93% p<0.05 5%-94%
T ab le  4.2 Degree o f desensitisation for maximum (max) and 6h bronchodilator 
responses after treatment with formoterol for Pz-adrenoceptor homozygous 
polymorphisms at codon 16 and codon 27. (Mean values for % desensitisation shown 
for each polymorphism alone with 95% Cl for difference).
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4.4 DISCUSSION
O ur results suggest that P2-AR polymorphism may be associated with altered P2-AR 
expression in asthmatic patients, in terms o f susceptibility to bronchodilator 
desensitisation after chronic exposure to a long-acting P2-agonist. Those asthmatic 
patients who were homozygous Gly 16 developed significantly greater bronchodilator 
subsensitivity than those who were homozygous Arg 16; whereas heterozygote 
patients developed desensitisation to a degree intermediate between the two kinds o f 
homozygote patients. These results are consistent with in vitro studies that have shown 
the Gly 16 form of the receptor to be more prone to down-regulate than the Arg 16 
form (Green, 1994). We expected the Glu 27 homozygous form to protect against 
bronchodilator subsensitivity, as it did in in vitro studies (Green, 1994). However, we 
found that the Glu 27 group developed greater desensitisation than the Gin 27 group. 
This can be explained by the observation that aU six subjects with homozygous Glu 27 
were also homozygous Gly 16, which suggests that the effects o f Gly 16 are dominant 
over those o f Glu 27; this has been borne out in in vitro studies (Green, 1994). There is 
substantial linkage disequilibrium in the white population between these two 
polymorphisms as expected (Dewar, 1998).
We believe this is the first time the development o f bronchodilator desensitisation to 
a long-acting hi asthmatic patients has been associated with P2 -AR
polymorphism. All but two o f our patients were receiving inhaled corticosteroid, 
which does not seem to protect against bronchodilator or bronchoprotective 
desensitisation with regular long-acting Pz-agonist therapy (Grove, 1995; Kahra, 1996). 
O ur results confirm some o f Green and colleagues’ (1995b) earlier predictions on the 
physiological implications o f P2 -AR polymorphism. The fact that bronchodilator 
responsiveness after pretreatment with placebo was not related to Pz-AR genotype 
suggests that those patients with the Gly 16 polymorphism were not already 
desensitised before they received the chronic formoterol therapy.
82
We recognise and accept the limitations o f a study with small numbers o f participants. 
O ur recalled sample represented 76% o f all individual patients originally enrolled in 
the three reference studies. Criticism may be levelled, in particular at the small number 
o f patients with homozygous Arg 16, even though this is believed to be the ‘wild-type’ 
o f the receptor. The proportion o f homozygous Arg 16 patients and other 
polymorphisms in this study is similar to that previously described (Reishaus,1993). 
The magnitude o f the differences in our restricted sample suggest that their effects 
may be clinically - as well as statistically - relevant. Such effects are a basis on which to 
do a larger prospective study on groups o f asthmatic patients with known P2“^ ^  
polymorphisms.
W hat are the chnical implications o f our results? We recom mend caution in the 
extrapolation o f our findings to patients with more severe asthma, although even a 
small degree o f desensitisation may be relevant in such cases. O ur results may also 
have important consequences on research. Clinical studies o f P2 -AR function in 
normal and asthmatic people may have to be done in at-risk groups with known P2 - 
AR polymorphism implicit in the study design - that is, with cohorts o f homozygous 
Gly 16 patients. For the study o f bronchodilator desensitisation due to long-acting P 
2 -agonists in asthmatic patients, smaller groups o f people homozygous for Gly 16 
would be needed to give an accurate picture o f the 'worst-case' scenario, since these 
patients are m ost likely to develop such desensitisation.
There has also been some concern about the safety o f the regular use o f long-acting p 
2 -agonists, and it would have been interesting to know whether there was an excess o f 
Gly 16 homozygotes in reports o f those asthma deaths associated with the use o f 
sahneterol (Clark, 1993; Castle, 1992; Finklestein, 1994), The Gly 16 P2 -AR 
polymorphism may have predisposed patients with brittle asthma to develop 
bronchodilator desensitisation; hence the reduced efficacy o f P2 -agonists during 
worsening asthma. Another possible mechanism might be the loss, with chronic use.
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of the bronchoprotective properties o f P2 ”^ g°^sts. Previous studies have shown a 
development o f tolerance to the bronchoprotective effects o f  long-acting P2 ^g°^sts 
(Cheung, 1992; Ramage, 1994; Booth, 1996; Yates, 1996). However, we presume that 
groups who were heterogenous in terms o f P2"AR polymorphism would have been 
evaluated in their studies, although P2 -AR were not genotyped. We know already that 
the Gly 16 polymorphism is associated with increased bronchial hyperreactivity 
(Holroyd, 1995) and that the Glu 27 polymorphism is associated with lower 
hyperreactivity (Hall, 1995), though neither polymorphism seems to a risk factor per se 
for the development o f asthma in the adult population. To investigate the possible 
association between P2 -AR polymorphism and the development o f  tolerance to the 
bronchoprotective properties o f Pz-agonists would thus be worthwhile.
The recently revised British Thoracic Society guidelines recommended the earlier use 
of regular long-acting Pz-agonists in Step 3, in addition to low dose inhaled 
corticosteroid (200-800 pg/day) (British Thoracic Society, 1997). O ur preliminary data 
suggest there may be a subset o f individuals in whom  bronchodilator desensitisation 
occurs when long-acting Pz-agonists are used on a regular basis. A larger prospective 
study is required to investigate this further.
CHAPTER 5
EFFECTS OF TREATMENT WITH 
FORMOTEROL ON BRONCHOPROTECTION 
AGAINST METHACHOLINE
(American Journal of Medicine 1998; 104: 431-438)
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5.1 INTRODUCTION
P 2 -agonists exhibit protection against bronchoconstrictor stimuli such as 
methacholine, in addition to their bronchodilating properties. In the previous 
chapters, we have shown that the regular use o f a long-acting Pz-agonist, formoterol 
resulted in bronchodilator subsensitivity. It is also known that with regular P2 -agonist 
treatment, subsensitivity develops to the functional antagonism against 
bronchoconstrictor stimuli (Cockcroft, 1996). The current role o f regular twice-daily 
long acting P2 -agonists is for patients whose asthma is not adequately controlled on 
inhaled corticosteroid therapy (British Thoracic Society, 1997). However, recent 
studies have shown that inhaled corticosteroids do not protect against the 
development o f bronchoprotective tolerance induced by long-acting Pz-agonists 
(Kalra, 1996; Yates, 1996). W ith regard to tachyphylaxis with regular long-acting P2_ 
agonist therapy there remain some unresolved issues which have been addressed in 
the present study. Firstly, is the degree o f tachyphylaxis determined by the total daily 
dose o f long acting P2 -agonist? Secondly, does the dosing frequency influence the 
development o f subsensitivity, in terms o f having a possible period o f  unoccupied 
airway P2 -adrenoceptors (Pz-AR) during a 24 hour dosing interval in association with 
once daily administration? Finally, how do long and short acting p 2 _agonists compare 
in their relative propensity for inducing bronchoprotective subsensitivity? We have 
attempted to resolve these questions in this study.
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5.2 METHODS 
Patients
The inclusion criteria for the study were as follows: (a) 16-65 years o f age, (b) a 
diagnosis o f asthma with minimum duration o f 6 m onths according to American 
Thoracic Society criteria (American Thoracic Society, 1987a), (c) an FE V j equal to or 
greater than 60% o f predicted normal value, (d) a methacholine P D 2 0  value equal to 
or less than lOOOpg, and at least with a four-fold increase in P D 2 0  one hour after 
inhaling 24pg of formoterol from a Turbuhaler (Astra Draco, Sweden), (e) prior 
treatment with inhaled corticosteroids at a constant dosage level for at least 4 weeks 
prior to initial screening at visit 1 (up to 2000 pg/day o f budesonide, beclomethasone 
dipropionate or fluticasone propionate).
Patients were excluded according to the following criteria: (a) treatment with oral 
corticosteroids within 4 weeks o f visit 1, (b) a history o f allergy during the relevant 
pollen seasons, (c) a lower respiratory tract infection within 4 weeks o f visit 1, (d) 
cigarette smoking in the past year.
Study Design
This two-centre study was carried out at the Departm ent o f Clinical Pharmacology, 
NineweUs Hospital (Centre 1) and the Departm ent o f Respiratory Medicine, 
Newcastle General Hospital (Centre 2) using an identical protocol and equipment. 
The overall study design is summarised in the flow chart in Figure 5.1. In brief, 
eligibility for inclusion and enrolment was assessed at visit 1 on two successive days, 
with an unprotected challenge on day 1 and a protected challenge 1 hour after 24 pg 
o f formoterol on day 2. This was followed by visit 2 with a baseline unprotected 
methacholine challenge performed 7-12 days after visit 1. Randomisation at visit 3 was 
performed 2-7 days after visit 2, 1 hour after the first dose o f the study medication.
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The duration between visits 1-3 was required to be no greater than 14 days. Visit 4 
was performed after 7-9 days of study treatment, with a challenge done 1 hour after 
inhalation o f the study medication. Visit 5 was performed after 14-16 days o f study 
medication, with a challenge done 1 hour after the last dose o f each treatment. The 
final visit (visit 6) was performed after a further 2-4 days o f treatment, with a challenge 
performed 1 hour after inhalation with a reference 6 |lg dose o f formoterol (having 
stopped study medication 24 hours earlier). During the initial run-in period between 
visit 1 and visit 3 all P2 "^go^^st therapy was withdrawn and substituted with 
ipratropium bromide M DI 2 puffs (as Atrovent forte, Boehringer Ingelheim, 
Bracknell, UK) which was used for rescue purposes. The same rescue medication with 
ipratropium was also available to use as required during each o f the 2 week treatment 
periods. The patients were instructed to withhold rescue medication for at least 12 
hours prior to any given methacholine provocation test.
Patients were randomised to receive one o f the following five treatments: 
(a) Formoterol fumurate (via Turbuhaler 6 pg per actuation metered dose, 4.5 pg per 
actuation delivered dose) 6 pg twice daily given morning and evening plus placebo 
Turbuhaler given midday and bedtime; (b) Formoterol fumurate (via Turbuhaler 12pg 
per actuation metered dose, 9 pg per actuation delivered dose) given 24 pg twice daily 
morning and evening, plus placebo Turbuhaler given midday and bedtime; (c) 
Formoterol fumurate (via Turbuhaler 12 pg per actuation metered dose, 9 pg per 
actuation delivered dose) 12 pg once daily in the morning plus placebo Turbuhaler at 
midday, evening and at bedtime; (d) Terbutaline sulphate (via Turbuhaler 500 pg per 
actuation metered dose) 500 pg four times daily given morning, midday, evening and 
bedtime ; (e) Placebo via Turbuhaler qid given morning, midday, evening and bedtime.
Patients were instructed to take the study medication at the same time in the morning 
(between 6 and 8 am), at midday (between 12 and 2 pm) in the evening (between 6
and 8 pm), and at bedtime at least 3 hours after the evening dose. All study medication 
was withheld for at least 12 hours prior to the methacholine provocation tests at 
chronic dosing (at visits 4 and 5). At visit 6 study medication was withheld for at least 
24 hours prior to the methacholine provocation test.
Patients received written and verbal instructions on correct inhalation technique at 
each visit. At visit 1 patients were instructed in the correct use o f Turbuhaler and 
pM DI to ensure good compliance using the Turbuhaler usage trainer (Astra Draco, 
Sweden) and the pM DI usage trainer (Vitalograph, Buckingham, UK). At this stage 
patients were also shown how to use a peak expiratory flow (PEF) meter properly and 
were required to measure the best o f three morning and evening recordings in a diary 
card. As a measure o f compliance the remaining doses in the study inhalers were 
checked during each treatment period and the number o f doses taken were estimated. 
If less than 75% o f the study medication was taken in the treatm ent period, the dose 
was considered to be non-evaluable. The patient was also asked to recall the time for 
study drug intake four times a day in a diary card.
The only other asthma medications except for the study treatm ent and rescue 
medication, which was allowed during the run-in and randomised treatm ent periods 
were: inhaled corticosteroids, sodium cromoglycate and nedocromil sodium, with the 
dose o f these to be kept constant. All other treatments were withdrawn prior to visit 1 
including: short and long-acting P2 -agonists, theophylline, antihistamines and oral 
corticosteroids.
Measurements:
Methacholine Challenge - see Chapter 2 
FEV 1 - see Chapter 2, Spirometry
Dormicülary peak expiratory flow - see Chapter 2, Spirometry
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Statistical Analysis
Based on previous studies with a similar design it was calculated that the between 
subject standard deviation as change from baseline was 1.3-doubling doses of 
methacholine. Thus, with 12 patients in each group it would be possible to detect a 
1.5-doubling dose (2.8-fold) difference in P D 2 0  with 80% power, assuming a 
significance level o f  5% and a two-sided test. AU values for log PD 2 0  were calculated 
as change from the initial unprotected baseUne (i.e. visit 2).
The five treatments were compared in order to determine the foUowing: (a) to 
compare the protection afforded by each o f the active treatments compared with 
placebo, and to see whether there was a difference between first dose, 1 week and 2 
weeks, (b) to assess whether there was a dose dependent difference between the low 
and high dose twice daily formoterol treatments (i.e. formoterol 6 pg bid versus 
form oterol 24 pg bid), (c) to assess whether there was a difference between the regular 
bid and od regimes o f formoterol administration, and (d) to assess whether there was 
a difference between regular treatm ent with short-acting and long-acting P2 -^gonists 
(i.e. terbutahne vs formoterol).
The different time points were analysed as foUows: (a) to assess whether there was any 
decrease in protective effect from the first dose to the last dose (after 14 days 
treatment), (b) to see if there was any additional decrease in protection between 7 and 
14 days treatment, (c) to assess the residual protective effect o f  study treatm ent after 
14 days, (d) to evaluate whether the protective effect o f a single 6 pg dose o f 
form oterol is affected by prior treatm ent with regular formoterol or terbutaline.
W ithin patient ratios for P D 2 0  values at each time point and the unprotected baseline 
at visit 2 were calculated. For example, a P D 20 protection ratio o f 4-fold indicates that
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a 4 times higher dose o f methacholine is required after a given treatm ent as compared 
to baseline, in order to ehcit a 20% fall in FEVi. This would equate to a two doubling 
dose shift in the methacholine dose-response curve. These ratios were then compared 
using a multipHcative analysis o f variance model with patient, centre and treatment as 
factors; and baseline P D 2 0  a covariate for the analysis. 95% confidence intervals 
were calculated for comparisons with placebo.
Pre-challenge values for FEV^ (1 hour after study medication) were also analysed in 
the same way as PD 2 0  using multiphcative analysis o f variance models to compare 
treatm ent effects. Data for morning and evening PEF values from diary cards were 
analysed by calculating the average value for the last 7 days during the second 
treatm ent week as compared w ith the last 7 days o f the run-in. The change from run- 
in to treatm ent was compared using an additive analysis o f variance model with 
patient, centre and treatment as factors, and the run-in average as a covariate.
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5.3 RESULTS 
Patient demography
A total o f 72 patients were randomised into the study o f which 67 completed the fuU 
protocol. The demographic basehne data are summarised in Table 5.1 according to 
each o f the 5 treatm ent groups. Mean demographic data at screening (visit 1) for the 
72 randomised patients were: age 38 years, F E V | 87% o f predicted, geometric mean 
methacholine P D 2 0  was 37 pg with geometric mean 30-fold protection after 
formoterol 24 pg. The geometric mean baseline unprotected P D 2 0  after the initial 
run-in, before randomisation (at visit 2) was 60 pg.
Methacholine challenge
The data for the methacholine protection with each o f the treatm ent groups are 
shown in Figure 5.2 and Table 5.2. This illustrates the effects o f  methacholine 
challenge when unprotected at baseline, after the first dose o f  treatment, after 
repeated dosing at 7 days and 14 days, and finally after 15-17 days o f treatment 
following a reference formoterol dose o f 6 pg. Compared with placebo the first dose 
o f active treatm ent produced significant protection. For the first dose o f  formoterol 
the degree o f protection exhibited a dose-related pattern and the protection afforded 
by the first-dose o f terbutahne was lower in comparison with the three formoterol 
treatments. For formoterol 24 pg twice daily this amounted to a 3.0-fold difference 
(95% Cl 1.4-6.6).
After 14 days o f repeated dosing, aU three formoterol treatments exhibited a 
significant loss o f protection as compared with the first-dose effect (as geometric 
mean and 95% Cl for percentage loss between first and last dose vs placebo); 
formoterol 24 pg twice daily: a 87% loss (95% Cl 69 - 94), 12 pg once daily: a 76% 
loss (95% Cl 41 - 90), 6 pg twice daily: a 71% loss (95% Cl 29 - 88). There was no
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significant difference in the degree o f protection loss between any o f the formoterol 
treatm ent regimes. Regular terbutahne showed a smaller degree o f protection loss 
between first-dose and 14 days and this was not significantly different compared with 
placebo: a 47% loss (95% Cl -28 -78). The degree o f protection loss between first- 
dose and 14 days was significantly less with terbutaline as compared to formoterol 24 
pg twice daily, amounting to a 75% difference (95% Cl 40 - 89).
For formoterol 6 pg and 24 pg twice daily, there were no further significant change in 
P D 2 0  after the first week o f treatment, in contrast to 12 pg once daily where there 
was an additional decrease in protection compared to placebo, between day 7 and day 
14: a 60% difference (95% C l 23-79). The protection exhibited by terbutaline reached 
a plateau after the first week.
In comparison with placebo after 14 days, there was no significant difference for any 
o f the active treatments and there were no differences between the three formoterol 
treatments, or between formoterol and terbutahne.
The degree o f protection conferred by formoterol 6 pg administered following 16 
days o f each active treatment (having stopped study medication 24 hours earher), 
showed no significant difference as compared with after placebo treatment, although 
there was a trend towards lower responses after treatment with formoterol 12 pg once 
daily and formoterol 24 pg twice daily (as a percentage o f placebo response and 95% 
Cl): formoterol 24 pg twice daily: 59% (95% Cl 24-143), 12 pg once daily: 53% (95% 
Cl 21-130), 6 pg twice daily: 88% (95% Cl 36-218) and terbutahne: 29% (95% Cl 51- 
325).
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Pre-challenge FEVj
Values for FE V j one hour after inhalation (i.e. bronchodUator response prior to the 
methacholine challenge) after 14 days treatment were significantiy greater than 
placebo with all three formoterol regimens but not with terbutaline (as percentage 
ratio vs placebo and 95% Cl); formoterol 24 pg twice daily 109% (95% Cl 113-116%), 
12 pg once daily 111% (95% C l 105 - 118%), 6 pg twice daily 109% (95% Cl 102- 
115%) and terbutahne 105% (95% Cl 99 - 112%) (Figure 5.3). There were no 
significant differences between the active treatments and there was no sign o f a 
decrease in FE V \ response during the 2 week treatm ent period.
Peak expiratory flow
The diary card PE F  data were calculated as the change from the last 7 days o f run-in 
to the last 7 days o f each treatment (Figure 5.4). Compared with placebo only 
formoterol 24 pg twice daily exhibited a significant difference for both morning PEF 
(as mean difference and 95% Cl) 49L/m in (95% Cl 25-72) and for evening PEF 40 
L /m in  (95% Cl 15 - 66). Corresponding values for formoterol 12 pg once daily vs 
placebo were: morning PE F -4L/m in (95% Cl -29-20), evening PE F 12L/m in (95% 
Cl -14-38); and for 6 pg twice daily vs placebo were: morning PE F 16L/m in (95% Cl 
-9-40), evening PEF 34L/m in (95% Cl 7-60). There was also a significant difference 
in morning PEF when comparing formoterol 24 pg twice daily vs 6 pg twice daily: 
33L/m in (95% Cl 9 - 57), and comparing formoterol 24 pg twice daily vs terbutahne 
for morning PEF: 47L/m in (95% Cl 22-71) and evening PEF: 27 L /m in  (95% Cl 1- 
53). There was no sign o f a diminution in morning or evening PEF values over the 2 
week treatm ent period with formoterol 24 pg twice daily.
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F24pg bid F12pg od F6pg bid T500pg qid PL
Patient numbers 15 15 14 14 14
Mean age (yr) 33.3 35.5 39.4 41.7 38.1
Men/Women 7/8 8/7 10/4 7/7 6/8
Centre 1/Centre 2 7/8 7/8 6/8 6/8 6/8
Mean dose inhaled steroid
(pg/day)
580 740 700 600 496
Mean FEVj (L) 3.20 3.08 3.09 2.88 2.70
Mean FEVj (% predicted) 90 87 85 88 86
Geom mean PD 2 0  (pg) 30 29 44 61 30
Fold protection post 
formoterol 24pg
38 24 29 36 25
T ab le  5.1 Summary o f demographic basehne data (visit 1)
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T re a tm e n t M ean 95% C l
Formoterol 24pg bid:
First dose 10.2 4.6-22.5
14 days 1.4 G.6-3.4
Formoterol 12pg od:
First dose 6.4 2.9-14.1
14 days 1.5 G.6-3.8
Formoterol 6pg bid:
First dose 5.5 2.5-12.3
14 days 1.6 0.6-4.0
Terbutaline 500pg qid:
First dose 3.4 1.5-7.8
14 days 1.9 0.8-4.9
T ab le  5.2 Methacholine protection ratios. Values shown are geometric means fold 
protection ratio and 95% confidence interval, versus placebo. (Confidence intervals 
excluding unity denote a significant difference from placebo)
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STUDY FLOW CHART
Randomised parallel treatments (2 weeks)
Run-in
Form oterol 24pg bid + placebo
Form oterol 6pg bid + placebo
Form oterol 12pg od + placebo
Terbutaline SOOpg qid
Placebo qid
X X X X X X
Visit No: 1 2 3 4 5 6
Cumulative 1 /2 7 14 21 28 30
days:
Methacholine Pre/post Baseline 1" dose of 1 week o f 2 weeks o f Post F
challenge: F24pg (unprotected) study study study
(screening) treatment treatment treatment
Figure 5.1 Flow chart overview for study protocol. All protected challenges were 
performed Ih  after inhalation o f study drug. Prior to challenge at visits 4 and 5, study 
medication was withheld for at least 12h, and for at least 24h at visit 6. Prechallenge 
FEVi was recorded at each visit.
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Figure 5.2 Effects o f each o f five treatments on methacholine challenge, performed 
at baseline (unprotected), Ih  after the first dose, 1 wk and 2 wks, and after stopping 
treatment for 24h with a single 6 pg dose o f formoterol (interrupted line). The 
protection ratio is calculated as the geometric mean for the fold-difference for each 
treatment versus unprotected baseline.
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F igure  5.3 Mean values for pre-challenge FEVi as percentage predicted. Values were 
measured at Ih  after inhalation o f study for the first dose (visit 3), 1 wk (visit 4) and 2 
wk (visit 5) o f treatment. Baseline value (visit 2) was measured at the same time o f day 
but after no study medication.
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Figure 5.4 Effects o f each o f five treatments on morning and evening dormicillary 
peak expiratory flow (PEF) measurements. Values are shown for the run-in and 
treatment.
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5.4 DISCUSSION 
Summary of findings
There are three new findings which have emerged out o f the results o f the present 
study regarding the development o f tachyphylaxis with long-acting P2 "^g<^^sts. 
Firstly, we found that the degree o f protection after 14 days was not dependent upon 
the total daily dose o f formoterol, when comparing 6 pg twice daily and 24 pg twice 
daily. Secondly, the degree o f tachyphylaxis occurred to a comparable degree with 
once daily and twice daily administration o f formoterol. Thirdly, the residual degree of 
protection exhibited by regular formoterol was comparable to that observed with 
regular terbutaline. The degree o f protection loss with regular formoterol appeared to 
reach a plateau level after one week o f treatm ent when administered with a twice daily 
regime, in contrast to a once daily regime where there was a further loss o f protection 
between 1 and 2 weeks o f treatment.
The development o f tachyphylaxis to the bronchoprotective effects o f formoterol or 
terbutaline occurred despite concomitant administration o f inhaled corticosteroid 
therapy. Despite the presence o f bronchoprotective subsensitivity, diurnal control was 
better with twice daily formoterol compared to terbutahne four times daily, in terms o f 
effects on morning and evening peak expiratory flow. The bronchodilator efficacy 
with aU three formoterol treatments showed no evidence o f subsensitivity in terms o f 
maintained FE V j response 1 hour after inhalation (pre-challenge) as measured over 
the 2 week treatment period.
Interpretation of results
In evaluating the degree o f tachyphylaxis, it is also im portant to look at the magnitude 
o f protection exhibited by the first dose o f each treatm ent regime. In this respect there 
appeared to be a dose-related protection exhibited by formoterol when comparing the
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first dose effects o f 6 |Tg, 12 pg and 24 pg. Furthermore, the first dose protection 
exhibited by all three formoterol treatment regimens was greater than with terbutaline 
500 Pg, although this was only significant in comparison with formoterol 24 pg. As a 
consequence o f these differences in first dose protection, the absolute loss of 
protection between single and chronic dosing was greatest for formoterol 24 pg twice 
daily and was least for terbutaline 500 pg four times daily, with there being a 
significant difference in the protection loss between these two regimes from the first 
dose to 14 days. Nonetheless, in terms o f the absolute fold protection ratio for PD 2 0  
as compared with the initial unprotected baseline, there was a similar degree o f 
residual antagonism with all four active treatments. In other words, the remaining 
degree o f absolute protection seemed to be independent o f the level o f first dose 
protection.
It was particularly interesting to find that loss o f protection after 14 days occurred to a 
similar degree in terms o f comparing the same total daily dose o f formoterol given 
once or twice daily (i.e. 12 pg once daily vs 6 pg twice daily). However, w ith the once 
daily regime but not the twice daily regime there was a further significant loss of 
protection between 7 days and 14 days o f treatment. These findings with once daily 
administration o f formoterol suggests that there m ust presumably be persistent 
occupancy o f airway P2 -AR even with a 24 hour dosing interval. In this respect we 
have previously shown no evidence o f persistent bronchodilator activity for FEV^ 
and FEF 2 5 _ 7 5  at 24 hrs after stopping steady-state dosing with formoterol 24 pg 
twice daily (Newnham, 1995). The diurnal time profile after administration o f a single 
12 pg dose o f formoterol (metered dose inhaler) has shown no significant difference 
from placebo at 24 hours for bronchodilator (FE V |) or bronchoprotective 
(methacholine) activity (Rabe, 1993). This is supported by the present study where 
there was no evidence o f any significant residual bronchodilator activity at 24 hours
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after administration o f formoterol 12 pg once daily at steady-state, as assessed by 
effects on morning peak expiratory flow.
The finding o f tachyphylaxis with a once daily dosing regime for form oterol therefore 
implies that only a small degree o f residual receptor occupancy is required towards the 
end o f a 24 hour dosing interval, and that this cannot be detected in terms o f 
bronchodilator activity. This would be consistent with the previous finding o f 
persistent down-regulation o f lymphocyte ^ 2 " ^ ^  24 hours after stopping steady-state 
dosing with formoterol 24 pg twice daily, in the absence o f detectable bronchodilator 
activity at the same time point (Newnham, 1995).
We chose to use terbutaline in a dose o f 500 pg four times daily as this was the usual 
recom mended dose for use on a regular basis. Although the residual degree o f 
protection conferred by terbutaline 500 pg four times daily was comparable to that o f 
formoterol 24 pg twice daily, the peak expiratory flow data clearly showed that diurnal 
control was superior with regular formoterol in terms o f a significantly higher mean 
value for both morning and evening measurements, amounting to a mean treatment 
difference o f 47L /m in and 27L /m in for morning and evening values respectively. 
This difference in morning and evening peak flow rates is not surprising given that the 
duration o f action for formoterol is for up to 12 h as compared with the duration o f 
terbutaline o f up to 6 h. Furthermore these improvements in peak flow showed no 
sign o f diminution over the 2 week treatment period. The bronchodilator response 
one hour after inhalation o f active treatment (ie prior to methacholine challenge) 
showed that there was no evidence o f any subsensitivity in terms o f attenuation o f the 
FEV j response with therapeutic doses o f formoterol over the 2 week study period as 
compared with the first dose effects. It is well recognised that tachyphylaxis to 
bronchoprotective effects o f P2 -agonists occurs more readily than for bronchodilator 
effects (Lipworth, 1997). O ur findings are in contrast to those o f Pauwels et al (1997)
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who showed a marked fall o ff in morning peak expiratory flow during the first two 
weeks o f formoterol treatment, which occurred despite concomitant therapy with low 
or high dose inhaled corticosteroid.
Limitations of the study
The main limitation o f this study is in terms o f its power with a relatively small 
sample size in each treatm ent group. The study was powered at the 80% level such 
that it may have been possible to have missed a mean treatm ent difference in P D 2 0  o f 
less than 1.5 doubling doses (i.e. a 2.8-fold difference in protection). However, it 
should be appreciated that a one doubling dose difference in methacholine PD 2 0  is 
within the limits o f biological variability for the method. O n inspecting the within- 
subject 95% confidence intervals for mean treatm ent differences after 14 days, it is 
evident that this amounts to approximately 2 doubling doses o f methacholine. 
Another possible criticism o f our methodology was the use o f methacholine which 
acts directly on cholinergic receptors on bronchial smooth muscle, whereas in real life 
m ost bronchoconstrictor stimuh such as allergen, exercise or cold air act indirectly via 
inflammatory mediator release or neuronal stimulation. It would therefore be 
im portant to evaluate whether this loss o f protection occurs with indirect-acting 
bronchoconstrictors such as AMP.
Clinical relevance of results
O ur study was performed in patients with stable asthma o f mild to m oderate severity, 
all o f w hom  were receiving concomitant therapy with inhaled corticosteroids. We felt 
it im portant to have the latter as an inclusion criteria because the present U K  asthma 
management guidelines advocate the use o f regular long-acting (32-agonists only for 
patients who are already receiving inhaled corticosteroids (British Thoracic Society, 
1997). O ur results should be taken in the context o f the study o f Pauwels et al (1997),
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where formoterol showed additive effects to inhaled corticosteroid on asthma control 
over a 12 m onth period. In their study, the predom inant effect on the rate o f severe 
exacerbations occurred as a consequence o f using a higher dose o f inhaled 
corticosteroid rather than the addition o f formoterol. The finding o f tachyphylaxis to 
methacholine bronchoprotection with formoterol in our study is no t surprising given 
that previous studies with sahneterol have also showed tachyphylaxis in patients taking 
inhaled corticosteroids (Booth, 1996; Grove, 1995; Kaka, 1996; Yates, 1996). It may 
not be possible to extrapolate our results to what happens in patients with more 
severe asthma, where tachyphylaxis may have more serious consequences, in that a 
given bronchoconstrictor response would occur from a lower starting baseline F E V | 
value.
O ur results indicate that after two weeks there was a residual level o f protection from 
baseline with all three formoterol regimes ranging from 1.6-fold to 2.3-fold. However, 
in view o f the subsensitivity which occurs with chronic dosing, patients should be 
made aware that regular treatm ent with formoterol may not confer fuU protection 
against a given bronchoconstrictor stimulus, and additional rescue
medication may therefore be needed in order to overcome an acute 
bronchoprovocation stimulus. W ith this in mind, studies with regular sahneterol have 
shown that cross-tolerance occurs in terms o f producing subsensitivity to protection 
afforded by rescue therapy with salbutamol (Yates, 1996). Thus, it is likely that 
additional rescue therapy with short-acting would have to be given in
higher doses in order to overcome this subsensitivity. Since form oterol unlike 
sahneterol, has a rapid onset action, it would therefore be possible to use additional 
doses o f formoterol in this way in the event o f being exposed to a bronchoconstrictor 
stimulus, although it is not currendy hcensed for this indication.
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W hat is the rationale for using regular long-acting P2 “^ go^^sts as suggested by the 
current asthma management guidelines? Studies with twice daily sahneterol and 
formoterol have shown that long-acting (32-agonists and inhaled corticosteroids have 
additive actions in terms o f their long-term effects in improving asthma control and 
reducing exacerbation rates (Greening, 1994; W oolcock, 1996; Pauwels, 1997). 
However, there are many patients in whom  adequate asthma control can be achieved 
with an optimised dose o f inhaled corticosteroid as monotherapy, who only require 
occasional P2 -agonists for rescue purposes for breakthrough episodes o f 
bronchoconstriction. The question therefore arises in such patients as to whether a 
short or long-acting P2 "^go®^sts should be used on an as required basis for rescue 
therapy. Formoterol could in theory be used in this way because o f its fast onset o f 
action, although the results o f our study would suggest that subsensitivity to 
protection occurs if it is taken at least once daily in a dose o f 12 pg.
In the present study we also looked at whether the protection afforded by the single 6 
Pg dose o f formoterol was influenced by prior treatm ent for two weeks with regular 
formoterol, having had a 24 h washout prior to the methacholine challenge. Our 
results suggest that after pretreatm ent with formoterol 24 pg twice daily for two 
weeks, there was persistent subsensitivity to the subsequent protection afforded by 
formoterol 6 pg, with a mean response which was 41% lower compared to placebo 
pretreatment, although this was not significant. Interestingly, prior treatm ent with 
formoterol 12 pg once daily also produced a similar degree o f persistent subsensitivity, 
with the response to formoterol 6pg being 47% lower compared to placebo 
pretreatment.
It would be interesting to know for the purposes o f rescue therapy, whether the ^2~ 
AR down-regulation and associated subsensitivity could be overcome by using a
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higher dose o f formoterol, and whether it would be possible to achieve the same level 
o f protection as with the first dose. In other words is there simply a parallel rightward 
shift in the formoterol dose-response curve for bronchoprotection, or is there an 
associated reduction in the maximal response which cannot be overcome by using a 
higher dose? Previous data from studies in asthmatic patients with lymphocyte 
have shown that 24 hours after stopping regular treatment with formoterol 24 pg 
twice daily, a reduction in receptor binding density is accompanied by an attenuated 
maximal cAMP response to isoprenaline stimulation (Newnham, 1995). This therefore 
suggests that it may not be possible to achieve a normal maximal airway response by 
using higher doses o f rescue P2 "^g°^st therapy.
It is known from in vitro studies that corticosteroids exhibit a facüitatory effect on (3 
2 ~AR in terms o f preventing or reversing agonist induced down-regulation and 
associated desensitisation (Mak, 1995b; Samuelson, 1984). In Chapter 3, we have 
demonstrated in asthmatic patients, that airway ^ 2 " ^ ^  bronchodilator subsensitivity 
induced by regular formoterol 24 pg twice daily is rapidly reversed after administration 
o f a bolus o f systemic corticosteroid. In our study, the subsensitivity to 
bronchoprotection occurred despite concomitant inhaled corticosteroid therapy. It 
would therefore be interesting to know whether this subsensitivity could be overcome 
by giving a bolus o f high-dose inhaled corticosteroid as an alternative to using 
systemic corticosteroid administration.
CHAPTER 6
SUBSENSITIVITY TO BRONCHOPROTECTION 
AGAINST ADENOSINE MONOPHOSPHATE 
CHALLENGE FOLLOWING 
REGULAR ONCE DAILY FORMOTEROL
(European Respiratory Journal, in press)
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6.1 INTRODUCTION
In the previous chapter, we demonstrated that subsensitivity developed to the 
bronchoprotective effects o f inhaled formoterol against methacholine; and that this 
tolerance was not dependent upon the total daily dose o f formoterol nor on its dosing 
frequency (ie once versus twice daily). Inhaled corticosteroids did no t appear to 
prevent against the development o f subsensitivity. In this present study, we have 
compared the effects o f once-daily versus twice-daily inhaled formoterol on 
bronchoprotection, but to render the study clinically relevant, we have used adenosine 
monophosphate (AMP) as the bronchoconstrictor stimulus, because it is an indirectly 
acting agent, which causes inflammatory mediator release from m ast cells. This is 
likely to reflect other indirectly acting stimuli which occur in real life, such as allergen, 
cold air or exercise challenge. There are two other im portant differences from the 
previous study in Chapter 5. Firstly, the protocol was to perform  the AM P challenge 
test twelve hours after the drug was administered, because the airways would be at 
their most vulnerable to the bronchoconstrictor stimuli at the time before the next 
dose is due. Secondly, we compared the dose o f 24 pg form oterol once-daily against 
24 pg twice-daily (in Chapter 5, we compared 12 pg once-daily versus 24 pg twice- 
dady).
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e.2 METHODS 
Subjects
Ten asthmatic subjects (5 male and 5 female), mean (SEM) age 30.8 (4.3), aU taking 
hhaled corticosteroids median (range) dose 400 (200-2000) pg/day, all were using 
iahaled P2-agonists on as required basis for symptomatic relief (<4 puffs per day) were 
lEcruited to take part in the study. AU had stable asthma according to the American 
Thoracic Society criteria (American Thoracic Society, 1987a) for at least three m onths 
prior to taking part in the study and no one had had oral steroids during this time. 
Baseline spirometry showed mean (SEM) FEVi 2.95 (0.23) L, 82 (4.5) % predicted 
and mean (SEM) FEF25-75 2.51 (0.30) L /s , 57.8 (5.9) % predicted. AU the randomised 
patients had unknown genotype prior to entry into the study. Patients were 
subsequendy typed for P2-adrenoceptor polymorphisms in order to assess whether 
there was a preponderance o f a particular polymorphism which may have biased our 
sample. AU gave written informed consent before being randomised in the double­
blind, double-dummy crossover study, which was approved by the Tayside committee 
on medical research ethics. A fuU physical examination, haematological and 
biochemical parameters were normal prior to inclusion in the study.
Study Design
Subjects were randomised to receive one week treatm ent with either a) inhaled 
formoterol 24 pg twice daUy, or b) inhaled placebo twice daUy, or c) inhaled placebo 
(morning) and inhaled formoterol 24 pg (evening). Formoterol was deUvered by dry 
powder capsules, 12 pg per capsule (ForadU: Geigy Pharmaceuticals, Florsham, UK). 
The doses were chosen to be within the manufacturer’s recommended total daUy dose
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range o f 24-48 pg. Placebo was delivered using identically prepared capsules 
containing lactose. The medication was taken between 8:00 P.M. and 9:00 P.M. for the 
evening dose and between 8:00 A.M. and 9:00 A.M. for the m orning dose. The first 
and last doses were taken in the evening before each respective visit. There was a one 
week run-in period before randomisation and a minimum o f a week washout between 
each o f the randomised treatments. From  the start o f the run-in period till the end o f 
the study, all P2-agonist therapy was stopped and was substituted with inhaled 
ipratropium  bromide (Atrovent Forte; Boehringer Ingelheim, Bracknell, UK) for 
symptomatic rescue relief.
Subjects attended the laboratory for the first visit between 8:00 A.M. and 9:00 A.M. 
after taking the first dose on the previous evening and withholding the second dose, 
which was taken in the morning after the AMP challenge. The second visit was a week 
later, after seven days o f each treatment, again twelve hours after the last evening 
dose, when the second AMP challenge was done. This was followed by the washout 
period before the next treatment cycle.
M easu rem en ts
FEVi - see Chapter 2, Spirometry
Airway reactivity to adenosine m onophosphate - see Chapter 2, Bronchial 
Provocation Tests
P2-adrenoceptor polymorphism - see Chapter 2 
S tatistical A nalysis
The study was powered at 80% to detect difference in AM P PC 20 o f 1.5 doubling 
doses (within subject SD = 1.3 doubling doses). The data for PC 20 were log
Ill
tan s  formed prior to analysis. The change in log PC 20 protection was calculated as the 
geometric mean (and SEM) fold difference, comparisons between the three treatments 
and for comparison o f first versus, the last dose. The comparisons were made by 
nultifactorial analysis o f variance (MANOVA) using subjects, treatments and visits as 
fictors for analysis, followed by Bonferroni multiple range testing. A probabihty value 
of p<0.05 (two-taüed) was considered as being significant and 95% confidence 
htervals (95% Cl) for mean differences were also calculated. The genotype data was 
not subjected to statistical analysis because o f small num ber o f  subjects within a given 
genotype for each locus.
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6.3 RESULTS
Spirometry, genotype and demographic data on the patients at recruitment are shown 
in Table 6.1. All the subjects completed the study and no adverse effects were 
reported.
Pre-challenge FEVi
The FEVi 12 hours after the first dose, prior to the AMP challenge during the active 
Hmbs o f the trial, showed a small improvement as compared to placebo (PL: 2.85 L, F 
24 |Tg bid : 3.22 L, F 24 pg od : 3.12 L) although this was not statistically significant 
(PL vs. F 24 pg bid : p=0.06). This effect was diminished after the last dose o f regular 
treatm ent (PL : 2.88 L, F 24 pg bid : 3.00 L, F 24 pg od : 2.97 L). (Figure 6.1)
Airway reactivity to AMP
After the first dose there was significant difference in protection against AMP 
challenge between both active treatments and placebo: for form oterol 24 pg bid : a 
6.7-fold difference (95% Cl 2.5 to 18.0) p=0.002, and for formoterol 24 pg od : a 5.2- 
fold difference (95% Cl 2.0 to 13.1) p=0.003, as compared to placebo. (Figure 6.2). 
There was no difference between the two active treatments, after the first dose. After 
the last dose there were no significant differences between active treatments and 
placebo : for formoterol 24 pg bid : a 1.7-fold difference (95% Cl 0.9 to 3.3) and for 
formoterol 24 pg od : 1.7-fold difference (95% Cl 0.6 to 5.0).
W ithin each treatment regimen there was a significant loss o f protection between first 
and last dose protection: for formoterol 24 pg bid (geom. mean) PC 20 FEV I for first
113
versus last dose; 475 m g/m l vs. 129 m g/m l p=0.006, a 3.7-fold difference (95% Cl 
1.6 to 8.3); and with formoterol 24 od : 367 m g/m l vs. 127 m g/m l p=  0.005, a 2.9- 
fold difference (95% Cl 1.5 to 5.6). There was no significant difference between the 
first and last doses for placebo: 71 m g/m l vs. 75 m g/m l.
Individual responses for the loss o f protection between first and last dose are depicted 
in Figure 6.3 according to genotype for P2-adrenoceptor at locus 16 and 27. AH o f the 
three subjects who were homozygous for Glu 27 were also homozygous for Gly 16. 
The data showed considerable inter-individual variation in the degree o f protection 
loss for both once and twice daily formoterol. There appeared to be no particular 
relationship between genotype and degree o f subsensitivity with either once or twice 
daily dosing.
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Subject Age Sex Genotype Genotype FEVi FEVi FE F 25-75 FEF 25-75
(yrs) Codon 16 Codon 27 (L) % pred (L/s) % pred
1 34 F Gly-Gly Glu-Glu 2.38 82 2.33 62
2 29 M Gly-Gly Gln-Gln 2.84 74 2.31 49
3 21 F Gly-Arg Glu-Gln 2.59 93 3.15 79
4 60 M Gly-Arg Glu-Gin 2.02 63 1.29 37
5 49 M Gly-Arg Glu-Gln 2.65 63 1.14 27
6 20 M Gly-Gly Glu-Glu 3.85 79 2.59 49
7 28 F Gly-Arg Glu-Gln 3.50 105 2.58 63
8 25 F Gly-Gly Glu-Glu 2.85 95 3.09 75
9 20 M Gly-Arg Gln-Gln 4.35 92 4.5 86
10 22 F Arg-Arg Gln-Gln 2.47 74 2.1 51
Mean 30.8 2.95 82 2.51 57.8
SEM 4.3 0.23 4.5 0.30 5.9
T ab le  6.1 Spirometry, genotype and demographic data at recruitment
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Figure 6.1 FEVi (L) before AMP challenge for each o f the three treatments, after first 
and last dose. Results are expressed as mean (SEM),
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Figure 6.2 AMP PC 20 (mg/ml) for each o f the three treatments, after first and last 
dose. Results are shown as mean (SEM). (* indicates p<0.01 between first and last 
dose; + indicates p<0.005 between active treatments and placebo) AMP PC 20 is 
plotted on a log2 scale in order to show doubling doses.
117
in
in
O
0)
in
O
tn
(O
O in
Q) >+-»
O 
Q.
Q)
(/>
O
Û
(/)
32 n 
16 - 
8 -  
4 
2 
1
o  G l y 1 6 / G l y 1 6  ( n = 4 )  
□  G l y 1 6 / A r g 1 6  ( n = 5 )  
A  A r g 1 6 / A r g 1 6  ( n = 1 )
F24 od
 1
F24 bid
0>
in 3 2  -1in
in
0
0
Û
+-•
in
16  -
c <00
*4^
_ J 8  -
0 in
0> >
■*-»
0 Q) 4  -
L _ CO
Û . 0
"O 0 2 -
0
UL
4 - '
in
1 -Li.
o  G l u 2 7 / G l u 2 7  ( n = 3 )  
□  G l u 2 7 / G l n 2 7  ( n = 4 )  
A  G l n 2 7 / G l n 2 7  ( n = 3 )
F24  od F24  bid
F igure  6.3 Individual data plotted to show the protection loss in AM P PC 20 between 
first and last dose for once daily (F24 od) and twice daily (F24 bid) treatm ent with 
formoterol. Fold protection loss is plotted on log2 scale in order to show doubling 
doses. The results are depicted to show the individual’s genotype for codon 16 and 27 
o f  the P2-adrenoceptor. Data points for each individual with F24 od and F24 bid are 
joined by a solid line.
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6.4 DISCUSSION
O ur results showed that regular once daily treatm ent with form oterol leads to the 
developm ent o f subsensitivity to its bronchoprotective effect, which is comparable to 
the subsensitivity produced by twice daily therapy. This occurred despite the use o f 
concom itant inhaled corticosteroid therapy. This is consistent with the findings in 
Chapter 5. The finding of tachyphylaxis with a once daily dosing regimen suggests that 
there m ust presumably have been a persistent degree o f occupancy o f airway P2-AR 
throughout the 24 hour dosing interval. We have previously shown that there is no 
detectable bronchodilator activity at 24 hours after stopping regular treatm ent with 
form oterol dry powder 24 pg bid (Newnham, 1995). This in turn suggests that 
measuring effects on basal bronchom otor tone cannot be used as a sensitive surrogate 
for detecting persistent occupancy o f airway P2-AR.
T he doses o f formoterol which we used were chosen to be within the m anufacturer’s 
recom m ended dose range o f 24-48 pg per day. Although there have been no previous 
studies looking specifically at protection loss with once daily long-acting P2-agonists 
therapy, previous studies with formoterol (Yates, 1995) and with sahneterol (Grove,
1995) had similarities in their design to the present study in their evaluating the 
bronchoprotective effect 12 hours after dosing. In the study o f  Yates et al with 
methachoHne challenge on steroid naïve patients, there was a 2.7 fold protection loss 
between first and last dose o f 24 pg bid o f formoterol dry powder given for two 
weeks. Values for first and last dose protection compared with placebo were 4.4 fold 
and 1.5 fold respectively. Grove et al reported only on the last dose protection against 
histamine in steroid treated asthmatics, after 50 pg bid o f sahneterol dry powder for 4
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weeks, which showed a 1.5 fold residual protection compared with placebo. These 
data are similar to the results o f the present study with AMP in terms o f the degree of 
residual protection after the last dose, which was a 1.7 fold difference with both once 
and twice daily regimens. Taken together this suggests that the residual degree of 
protection is similar with either direct (methachoHne and histamine) or indirect (AMP) 
challenge at 12 hours after dosing, with both sahneterol and formoterol given on a 
regular basis.
In a recent study, there was close agreement between the level o f protection by 
terbutaline against AMP and histamine challenge, although only a single 500 pg dose 
o f terbutaline was evaluated (Egbagbe, 1997). O ’Connor et al (1992) showed that 
treatm ent with regular inhaled terbutaline produced a greater degree o f  subsensitivity 
for AMP than methachoHne challenge. In their study there was a 4.2-fold loss o f 
protection against AMP challenge after regular terbutaline, as compared to a 3.7-fold 
loss with twice daily formoterol in the present study.
O ther studies (Cheung, 1992; Booth, 1996) have not shown any loss o f bronchodilator 
effect after regular treatm ent with sahneterol 50 pg bid. In our study there was a trend 
towards a dirninished pre-challenge FEVi value between the first and last dose, which 
is similar to findings reported by Yates et al (1995) with formoterol 24pg bid for two 
weeks. This could be due to a decrease in the duration o f  therapeutic bronchodilator 
effect o f formoterol with regular treatment, as the FEVi was measured after one hour 
m the studies of Cheung and Booth, whilst in Yates’s and our own study the FEVi 
was measured twelve hours after dosing. It is also im portant to m ention that in the 
studies o f Cheung et al and Booth et al there was a 36 hour washout after chronic 
dosing which might conceivably have restored P2-AR function and hence
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bronchodilator response. It should be pointed out that our study was powered to 
detect bronchoprotection subsensitivity rather than bronchodilator subsensitivity and 
hence it is not possible to draw any firm conclusions on pre-challenge FEVi values 
with the present sample size. Furthermore a proper P2-agonist dose-response-curve is 
necessary in order to detect bronchodilator subsensitivity as demonstrated in Chapter 
3. Studies with greater power are therefore required to investigate whether 
bronchodilator subsensitivity develops in the presence o f regular once daily 
form oterol treatment.
We performed retrospective genotype analysis o f P2-AR polymorphism in order to 
evaluate whether there was a preponderance o f a particular polymorphism which may 
have biased our sample. From  inspection o f the individual data it was clear that the 
subsensitivity which developed with once or twice daily dosing regimens was 
independent o f genotype at locus 16 and 27. In other words the finding o f 
subsensitivity with once daily formoterol cannot be explained by a particular 
preponderance o f a polymorphism in our sample, such as homozygous Gly 16 (Hall,
1996). Since bronchoprotection subsensitivity occurs m ore readily than 
bronchodilator subsensitivity, this may explain why there was no apparent relationship 
between the homozygous Gly 16 genotype and the degree o f protection loss, even in 
association with formoterol 24 pg twice daily. Larger prospective studies are underway 
to further investigate whether there is any association between P2-AR polymorphism 
and bronchoprotective subsensitivity.
In conclusion, regular treatment with inhaled formoterol induces subsensitivity to its 
bronchoprotective effect against AMP challenge, which is no t influenced by the 
dosing frequency or by concomitant use o f inhaled corticosteroids. O ur research
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disproves the hypothesis that the use o f a 24 hour dosing interval may obviate the 
development o f subsensitivity. This suggests that even with a once daily dosing 
regimen, there must presumably be inadequate recovery o f P2-adrenoceptor down- 
reguladon, due to prolonged receptor occupancy over a 24 hour period. It would 
therefore seem rational to suggest that long-acting P2-agonists could be used in the 
same way as short-acting P2-agonists, on an as required basis on top o f optimised 
inhaled steroid therapy, up to a maximum recommended daily dosage. In this respect, 
formoterol has an advantage over sahneterol in that it has a fast onset o f action and 
could therefore afford rapid relief o f bronchospasm. For those patients with severe 
asthma who requite regular formoterol, physicians should be aware that 
bronchoprotective subsensitivity occurs even with once daily administration, and 
hence higher doses o f rescue P2-agonists might be required to obviate the effects o f an 
acute bronchoconstrictor challenge.
CHAPTER 7
EFFECTS OF SINGLE DOSES OF INHALED 
FLUTICASONE PROPIONATE AND  
ORAL PREDNISOLONE ON LYMPHOCYTE 
P2-ADRENOCEPTOR FUNCTION IN  
ASTHMATIC PATIENTS
(Chest 1996; 109: 343-347)
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7.1 INTRODUCTION
Inhaled corticosteroids are the most effective and widely used form o f preventative 
anti-inflammatory treatm ent for use in bronchial asthma, and have been incorporated 
into national guidelines for this purpose (British Thoracic Society, 1997). In addition 
to potent anti-inflammatory properties, corticosteroids are known to play an 
important role in the regulation o f P2-adrenoceptors (P2-AR). In Chapter 3, inhaled 
corticosteroids did not prevent the development o f bronchodilator subsensitivity in 
patients with asthma when exposed to regular inhaled formoterol. likewise, in 
Chapters 5 and 6, inhaled corticosteroids did not prevent the development o f 
tolerance to the bronchoprotective effect o f formoterol against methacholine and 
AMP respectively. O n the other hand, in Chapter 3 we have shown that systemic 
corticosteroids rapidly reversed formoterol-induced bronchodilator subsensitivity. 
Hence, it would appear that inhaled corticosteroids did not have facilitatory effects on 
the P2-AR, in contrast to systemic corticosteroids. In this study, we have investigated 
the facilitatory effects o f single doses o f an inhaled corticosteroid compared with that 
o f a systemic corticosteroid, which is known to possess significant facihtatory effects 
at the P2-AR (Hui, 1982; Brodde, 1985). In this respect, we chose to evaluate the 
effects o f fluticasone propionate, a novel corticosteroid with enhanced glucocorticoid 
potency.
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7.2 METHODS 
Patients
10 (4 female) asthmatic patients were studied, with a mean (SEM) age o f 28.6 (2.0) 
years, F E V | o f 3.4 L (0.3), 79.9% (8.7) predicted and FEF25_75 3.0 L (0.4), 66.5% 
(9.7) predicted. Haematological and biochemical parameters were normal prior to 
inclusion. All gave written, informed consent before being randomised in a double­
blind, placebo-controlled cross-over study approved by Tayside Medical Ethics 
Committee. All apart from one were non-smokers and aU subjects had asthma 
according to the criteria o f the American Thoracic Society (1987a). A t the initial 
screening visit, subjects were required to have FE V j> 70%  predicted and were 
inhaling less than or equal to 400ug corticosteroid per day. O f  the 10 subjects, 9 were 
inhaling corticosteroid (beclomethasone dipropionate) in doses o f 100 pg (one 
patient), 200 pg (three patients), 300 pg (one patient) and 400 pg (four patients). AU 
patients were inhaling P2-agonists as required, at a dose o f < 200 pg salbutamol per 
day. In addition, one patient was taking beclomethasone nasal spray (100 pg daily). 
N one had received oral corticosteroids within the preceding three m onths and none 
had had a recent exacerbation o f asthma in the preceding three months.
For comparison as controls, we have also included data on lymphocyte p 2- 
adrenoceptor parameters for normal volunteers (n=59) and also asthmatic subjects 
(n=39), the latter having been off any P2-agonist therapy for at least 4 weeks.
Protocol
Subjects attended the initial screening visit for measurement o f  FE V j using a 
Vitalograph Compact spirometer (Vitalograph Ltd,Buckingham, UK), having withheld 
inhaled bronchodilators for 8 hours and inhaled corticosteroid for 24 hours. Their 
inhaler technique was assessed using an aerosol inhalation m onitor and instructions in
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the correct usage were given. Subjects were then randomised to receive, via a 
pressurised metered dose inhaler, placebo, fluticasone propionate 1000 pg, fluticasone 
propionate 2000 pg (Flixotide®, Allen & Hanburys, Uxbridge, UK) or oral 
prednisolone 50 mg. Predmsolone was given as open medication within the 
randomisation sequence and inhaled treatments were given double-blinded. 
Fluticasone was delivered as 250 pg per actuation.
They had 4 study days separated by at least 3 days. Subjects were told to omit their 
morning dose o f inhaled corticosteroid on the study day. At 10:00 PM on the evening 
prior to a study visit, subjects were instructed to take the appropriate dose from their 
study inhaler. They were instructed to use their bronchodilator inhaler 15 minutes 
before the study drug, and to take no further bronchodilator therapy overnight. In 
addition, they were instructed to m outh rinse after taking the inhaled steroid. They 
then attended the laborator)^ the following morning at 08:00 PM having fasted 
overnight, and withheld bronchodilators. After 30 minutes supine rest, 50 ml blood 
was taken from an antecubital vein for analysis o f parameters o f lymphocyte P2- 
adrenoceptor function and for serum cortisol.
Measurements
Lymphocyte P2-adrenoceptor parameters - see Chapter 2 
Serum cortisol - see Chapter 2, Horm one Assays
Statistical analysis
Data for Bmax were transformed using logarithm to base 10, as it is not normally 
distributed. For all parameters, comparisons between treatments were made by
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multifactorial analysis o f variance (MANOVA), followed by Duncan's multiple range 
testing to identify where differences were significant. A probability value o f p < 0.05 
(two-tailed) was considered as being o f significance. Values shown in the text as 
means for each treatm ent and pooled standard errors. 95% confidence intervals for 
the differences between treatments are shown for statistically significant differences.
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7.3 RESULTS
Lymphocyte Pz-adrenoceptor parameters
Parameters o f receptor density (B m ax ) and maximal cAMP responses to isoprenaline 
(E m a x )  showed a significant (p<0.05) increase after oral prednisolone, but not after 
inhaled fluticasone, with the mean (SEM) values f o r  l o g B m a x  ( f m o l / 1 O^ceUs) being: 
placebo 0.27 (0.03), fluticasone 1000 pg 0.30 (0.03), fluticasone 2000 pg 0.32 (0.03) 
and prednisolone 0.48 (0.03) [95% Cl prednisolone vs placebo: 0.075 to 0.341]. 
(Figure 7.1). The results for Emax (pmol/lO^ceUs) mirrored those for Bmax: placebo 
4.00 (0.83), fluticasone 1000 pg 4.68 (0.83), fluticasone 2000 pg 4.26 (0.88) and 
prednisolone 7.46 (0.88) [95% Cl prednisolone vs placebo: -0.01 to 6.91]. Dissociation 
constant (Kd: pmol/1) was not significantly altered by any treatment: placebo 13.44 
(1.87), fluticasone 1000 pg 13.45 (1.48), fluticasone 2000 pg 14.04 (1.73) and 
prednisolone 16.75 (1.87).
Values o f logBmax for normal volunteers (n=59) and for asthmatics o ff P2-agonist 
therapy (n=39) were 0.28 (0.02) and 0.30 (0.02) respectively.
Serum cortisol
There was significant (p<0.05) suppression o f serum cortisol (nmol/1) following 
treatm ent with inhaled fluticasone propionate (2000 pg) and oral prednisolone 
compared with placebo: placebo 307.9 (26.75), fluticasone 1000 pg 323.2 (26.75), 
fluticasone 2000 pg 130.1 (26.75) [95% Cl fluticasone 2000 pg vs placebo: 69.76 to 
285.8] and prednisolone 51.8 (28.66) [95% Cl prednisolone vs placebo: 144.11 to 
368.01] (Figure 7.1).
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F igure  7.1 Values are shown for lymphocyte (32-adrenoceptor density (log Bmax), 
cAMP response (E m a x ) ,  and serum cortisol after treatment with single doses o f inhaled 
placebo (PL), inhaled fluticasone 1000 pg (FI000), inhaled fluticasone 2000 pg 
(F2000) and oral prednisolone 50 mg (PRED). (* p<0.05 versus PL) Values are mean 
( S E M ) .
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7.4 DISCUSSION
The results o f this study indicate that high dose inhaled fluticasone, in a dose 
sufficient to suppress serum cortisol, did not have any significant facilitatory effects on 
lymphocyte P2-AR parameters. This is in contrast to oral prednisolone which up- 
regulated P2-AR density and increased cAMP responses. This would suggest a 
dissociation in systemic sensitivity between the effects o f inhaled corticosteroid on 
adrenal suppression and lymphocyte P2-AR regulation.
Inhaled fluticasone was chosen in this study as it is a novel inhaled corticosteroid with 
a high degree o f glucocorticoid potency. Using the Mckenzie skin vasoconstrictor 
assay in humans, fluticasone showed approximately twice the topical anti­
inflammatory activity in comparison to beclomethasone dipropionate (Phillips, 1990). 
The high intrinsic activity is probably due in part to the higher affinity o f fluticasone 
to the glucocorticoid receptor (Hogger, 1994). Also, the oral bioavailability of 
fluticasone is virtually zero due to almost complete first-pass hepatic metabolism 
(Harding, 1990), and together with using m outh rinsing (Selroos, 1991; Pedersen, 
1993) absorption o f fluticasone from the gastrointestinal tract will be negligible. 
Hence, in the present study, any systemically bioactive drug would have been due to 
absorption via the lung-vascular bed, which would obviate first-pass hepatic 
metabolism (Lipworth, 1995). The finding o f significant systemic bioactivity with a 
single 2000 pg dose of fluticasone is not surprising, and consistent with recent data 
from other single and chronic dosing studies in normal and asthmatic subjects 
(Grahnen, 1994; Grove 1994; Boe, 1994).
The other finding o f note is the lack o f facüitatory effects o f inhaled fluticasone on 
lymphocyte P2-AR function, in clear contrast to the effect o f a single dose of 
prednisolone. Systemic corticosteroids, as weU as having potent anti-inflammatory 
effects, have important regulatory functions affecting the P2-AR. This mechanism may
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underlie some o f their beneficial effect in the treatment o f asthma. Corticosteroids 
increase the num ber o f P2-AR and enhance the coupling o f the receptor to the 
adenylate cyclase system (Davies, 1984). Oral prednisolone has been shown to rapidly 
restore previously down-regulated receptors after exposure to chronic P2-agonist 
treatment in normals and asthmatics (Hui, 1982; Brodde, 1985; Brodde, 1988). In 
Chapter 3, we also demonstrated the facilitatory effect o f systemic corticosteroids in 
reversing bronchodilator subsensitivity induced by formoterol. It is therefore 
im portant to investigate if these facilitatory effects applied to inhaled corticosteroid as 
well. It is worth noting that the value for logBmax observed in the present group of 
asthmatic patients is similar to values obtained from normal volunteers and from 
asthmatic subjects off P2-agonist therapy. This is in keeping with only minimal down- 
regulation in the present group o f patients, as one would expect from their prior 
exposure to P2-agonists. The lack o f effect o f fluticasone may be due to the low level 
o f  P2-agonist consumed by the patients studied. This would not, however, explain why 
prednisolone had a positive effect and perhaps might infer that prednisolone ‘super­
normalised’ P2-AR density, at least when compared with normal controls.
Another possibility is that the time-course o f pharmacodynamic effects o f fluticasone 
on lymphocyte P2-AR might be different to that on adrenocortical receptors. Our 
study compared single doses o f fluticasone and it is conceivable that repeated doses 
might have up-regulated lymphocyte P2-AR. However, the long pharmacokinetic 
elimination half-life o f fluticasone would be against this latter hypothesis.
In a study by Molema et al (1988), up-regulation o f airway P2-AR does not appear to 
occur with inhaled beclomethasone dipropionate in doses up to 2000 |ig per day given 
for four weeks in that there was no left-shift in the bronchodilator dose-response 
curves to inhaled salbutamol. However, in-vitro lymphocyte P2-AR parameters were 
not evaluated in that study. The findings o f Molema et at probably reflect the absence 
o f bronchodilator tolerance even in patients exposed to high doses o f inhaled
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salbutamol (Lipworth, 1989). In two studies by Newnham  et al (Newnham, 1994a; 
Newnham, 1995) tachyphylaxis to bronchodilator and systemic P2-AR responses after 
treatment with formoterol mirrored down-regulation o f in vitro lymphocyte P2-AR 
parameters, including a significant reduction in receptor density and cAMP response. 
Virtually all o f the patients in these two studies were taking inhaled corticosteroids and 
it is interesting that the latter did not prevent P2-AR down-regulation. Likewise, we 
have demonstrated in Chapter 3, the development o f bronchodilator subsensitivity in 
asthma patients on regular inhaled formoterol despite aU patients receiving inhaled 
corticosteroids.
There is now accumulating evidence that regular inhaled Pz-agonist treatm ent may 
have adverse effects on disease control in asthmatic patients (Sears, 1990; Van 
Schayck, 1990; Van Schayck, 1991). The question arises as to whether inhaled 
corticosteroid might protect against any potentially harmful effects o f concomitant 
regular inhaled P2-agonist. O ur study shows that lymphocyte P2-AR up-regulation 
does not occur, but this might not conceivably reflect effects on airway P2-AR or 
indeed effects on airway reactivity. There are studies (Paggiaro, 1991; Waalkens, 1991; 
Kerstjens, 1992) that have compared the combination o f inhaled corticosteroid plus 
P2-agonist with P2-agonist alone. Such studies have shown that combined therapy 
with inhaled corticosteroid plus Pz-agonist confers protection against bronchial 
hyperresponsiveness as well as against early and late allergen responses.
In summary, this study has shown that inhaled fluticasone propionate, given in a 
single dose o f 2000 pg which suppressed adrenal function, had no significant 
facilitatory effects on lymphocyte Pz-AR parameters in patients with asthma.
CHAPTERS
EFFECTS OF REPEATED DOSES OF FLUTICASONE 
PROPIONATE AND ORAL PREDNISOLONE 
ON LYMPHOCYTE ^-ADRENOCEPTOR FUNCTION 
IN ASTHMATIC PATIENTS
(British Journal of Clinical Pharmacology 1997; 44: 565-568)
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8.1 INTRODUCTION
Although the anti-inflammatory actions o f inhaled corticosteroid are weU known 
(Laitinen, 1992; Djukanovic, 1992; Jeffrey, 1992), the facilitatory effects on ^2" 
adrenoceptor (P2 -AR) function is less clear. Systemic corticosteroids have been shown 
to reverse P2 -AR down-regulation in normal subjects (Hui,1982; Brodde, 1985) and 
asthmatics (Brodde, 1988) who have been exposed to P2 -agonists. Inhaled 
corticosteroids, however, do not appear to protect against the development o f P2 -AR 
subsensitivity. In Chapter 3, inhaled corticosteroid did not prevent the development of 
formoterol-induced bronchodilator subsensitivity; while in Chapters 4 and 5, inhaled 
corticosteroids did not protect against the development o f tolerance to the 
bronchoprotective effect o f P2 -agonist against methacholine and AMP respectively. In 
Chapter 7, we had demonstrated that single inhaled doses o f fluticasone propionate 
(1000 Pg and 2000 pg) did not have any significant facilitatory effects on lymphocyte 
P2 -AR in asthmatic patients, in contrast to oral prednisolone, which produced up- 
regulation. This begs the question as to whether this lack o f  effect with single doses o f 
fluticasone may be due to pharmacokinetic properties and hence its time-profile for 
up-regulation. To address possible differences between single dose and steady-state 
time-profUes, we have performed a further study to see whether up-regulation might 
occur at steady-state with repeated dosing o f fluticasone propionate.
134
8.2 METHODS 
Patients
Ten asthmatic subjects (5 female), mean age 29 years (range 19-52) were recruited and 
completed this study. All gave written informed consent before being randomised into 
a double-blind, placebo controlled, cross-over study which was approved by the 
Tayside Committee on Medical Research Ethics. A full physical examination, 
hiematological and biochemical profile were normal prior to inclusion into the study. 
AU had asthma according to the criteria o f the American Thoracic Society (1987a) and 
all were non-smokers. Mean (SEM) FEV j in litres and %  predicted were 3.09(0.09) L 
and 89(5)% predicted, range 2.70 to 3.54 (% predicted range 65-108%). Nine subjects 
were inhaling corticosteroid (either budesonide or beclomethasone dipropionate) in a 
median dose o f 400pg/day, range 200 to 800pg/day. AU were inhaling a short-acting 
P2-agonist as required in doses o f <400pg/day. N one had received oral corticosteroid 
fcr at least 3 m onths, and none had had a recent exacerbation o f  asthma in the past 
month.
Protocol
All usual inhaled corticosteroids were discontinued four days prior to the study and 
for the duration o f the study. Subjects were randomised to receive either inhaled 
phcebo, inhaled fluticasone 1000 pg/day (given as 500 pg twice daUy; Flixotide®, 
ARen Sc Hanburys, Uxbridge, UK), inhaled fluticasone 2000 pg/day  (given as lOOOpg 
twice daUy) and oral prednisolone 50mg. AU inhaled medication was deUvered by a 
pressurised metered-dose inhaler, which was taken at 08:00 AM and 10:00 PM with 
mouth rinsing after each dose. The study medication was taken for four days with a 
four-day washout between each treatment. Subjects attended the laboratory at 08:00 
AM, with the last dose o f study drug taken at 10:00 PM the previous night. Patients 
were instructed in the use of a metered-dose inhaler with the help o f an aerosol 
inhalation m onitor (Vitalograph Ltd, Buckingham, UK).
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Oral prednisolone was given as open-medication but within the randomisation 
scheme. 50mg of oral prednisolone was taken at 10:00 PM and the subjects attended 
the laboratory at 08:00 AM the following day. At each visit, an intravenous cannula 
was inserted into an antecubital vein. After 15 minutes supine rest, 50ml o f blood was 
withdrawn for plasma cortisol and lymphocyte ^ 2 " ^ ^  parameters (Bj^ax» ^m ax
K d ) .
Measurements
Lymphocyte P2 "^(^Gnoceptor parameters - see Chapter 2 
Plasma Cortisol - see Chapter 2
Statistical analysis
Data for B^^^ax were log-transformed prior to analysis as it is not normally distributed. 
For all parameters, comparison between treatments was by multifactorial analysis of 
variance (MANOVA) with subjects and treatments as within factors for analysis. A 
probability value o f p<0.05 (two-tailed) was considered as being o f significance and 
95% confidence intervals (95% Cl) for mean treatment differences were calculated 
where significant. The milligram equivalence ratio for fluticasone versus prednisolone 
was estimated by log-linear interpolation.
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8.3 RESULTS
Lymphocyte P2 -AR parameters
P2 -AR density (Bj^ax’ hno l/10^ cells) was significantly increased after oral 
prednisolone but not after inhaled fluticasone. The geometric mean values for B^^^x 
being as follows: placebo (PL) 1.51, fluticasone 1000 pg/day (Fiooo) 1.20, fluticasone 
2000 P g/day (F2000) 1.20 and prednisolone (PRED) 2.14 (a 1.4 fold difference PRED  
vs PL; 95% Cl 1.05 to 1.95; p<0.001) (Figure 8.1). There was no significant difference 
in Kd following any o f the treatments. (Table 8.1). E ^ ^ ^  showed a similar trend to 
effects observed with B ^ ^ ^  but was not significandy different.
Plasma Cortisol
There was significant (p<0.001) suppression o f plasma cortisol (nmol/1) following 
F2000 and PRED compared with placebo: PL 393.8, Fiooo 302.1, F2000 205.0 (95% Cl 
F2000 vs PL: 58.1 to 319.4) and PR ED  87.0 (95% Cl PR ED  vs PL: 176.2 to 437.5). 
There was suppression o f plasma cortisol following Fiooo (Figure 8.1) which was not 
significant. The estimated milligram equivalence ratio for adrenal suppression was 
calculated at 1:11 for fluticasone vs prednisolone.
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P L FIOOO F2000 P R E D
Kd 16.3 12.2 14.8 13.2
(p m o l/L ) (11.7-20.9) (7.3-17.1) (10.2-19.4) (8.6-17.8)
Emax 4.85 4.64 4.39 5.91
(pmol/lQG
cells)
(3.72-5.97) (3.52-5.77) (3.26-5.51) (4.78-7.03)
T ab le  8.1 Receptor dissociation constant (Kd) and maximal cyclic AMP response to 
isoprenaline (Emax) after treatm ent with inhaled placebo (PL), inhaled fluticasone 1000 
fig/day (FI 000), inhaled fluticasone 2000 p,g/day (F2000), each given for 4 days, and 
after a single dose o f oral prednisolone 50 mg (PRED). Values are mean and 95% CL
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Figure  8.1 Values are shown for lymphocyte |32-adrenoceptor binding density (log 
Bmax) and plasma cortisol after treatment with inhaled placebo (PL), inhaled 
fluticasone 1000 pg/day (FIOOO), inhaled fluticasone 2000 pg/day (F2000), each given 
for 4 days, and after a single dose o f oral prednisolone 50 mg (PRED). Values are 
mean (SEM). (* denotes p<0.05 versus PL)
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8.4 DISCUSSION
The results o f this study shows that repeated dosing with high dose inhaled fluticasone 
did not have any facilitatory effects on lymphocyte despite having significandy
suppressed early morning plasma cortisol with an estimated milligram equivalence 
ratio o f 1:11 versus prednisolone. This result is in contrast to a single dose o f oral 
prednisolone although suppressing plasma cortisol, significantly up-regulated 
density. This study confirms our previous finding that single doses o f inhaled 
fluticasone did not up-regulate p2‘^ ^  (Chapter 7). Both o f these studies suggest a 
dissociation in sensitivity between effects o f inhaled corticosteroid on adrenal 
suppression and lymphocyte P 2 '^ ^  regulation. O ur patients had relatively mild 
disease and had been exposed to small amounts o f P2 "^g°^sts, mostiy on an as 
required basis. Thus, it is conceivable that their ^2"^^- were not down-regulated prior 
to the study, and hence the lack o f up-regulation with inhaled corticosteroid. This, of 
course, does not explain why prednisolone produced up-regulation o f apparently naive 
P2 -AR, as was the case in our previous study. It may be that higher doses o f 
fluticasone (ie > 2mg) up-regulate P2 -AR, although this would not be clinically 
relevant as the highest licensed dose is 2mg/day. Conversely, it would be interesting to 
know whether up-regulation occurs with lower doses o f prednisolone (eg. 22m ^ with 
equivalent adrenal suppression to fluticasone 2mg. Dose-ranging studies would be 
required to answer this important question.
We accept our study has its limitations as we used lymphocyte p 2-AR as a surrogate 
for airway P2-AR, although there is some evidence to suggest that this may be valid 
(Hayes, 1996). One would expect that fluticasone given by the inhaled route would 
produce higher local concentrations in the airway than in the systemic compartment. 
Nonetheless, inhaled fluticasone is well absorbed with 16% bioavailabüity (Thorsson, 
1997). Indeed, we showed evidence o f systemic absorption in terms o f adrenal 
suppression with an 11:1 milligram ratio versus oral prednisolone. Further studies are
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required to look at possible differential effects o f inhaled and oral corticosteroids on 
airway P2-AR function in asthmatic patients, in terms o f bronchoprotective or 
bronchodilator effects o f regular P2-agonist treatment.
Systemic corticosteroids, as well as having potent anti-inflammatory effects, have 
facilitatory effects on the P2 -AR (Davies, 1980). Corticosteroids regulate P2 -AR by 
increasing P2 -AR gene transcription (Mak, 1995a). Likewise, systemic corticosteroid 
demonstrate significant facilitatory effects on P2 -AR by reversing receptor down- 
regulation (Hui, 1982; Brodde, 1985; Brodde, 1988). However, our studies have 
demonstrated that inhaled high-dose corticosteroids do not appear to have facilitatory 
effects on the P2 -AR. In this respect, inhaled corticosteroid therefore would not be 
expected to protect against P2 -AR down-regulation and tachyphylaxis. This has been 
demonstrated in several studies involving formoterol (Newnham, 1994a; Newnham, 
1995; Chapter 3) and salmeterol (Grove, 1995), where P2 -AR down-regulation and 
bronchodilator subsensitivity developed despite m ost o f the patients receiving inhaled 
corticosteroid.
In summary, this study has shown that repeated dosing with high-dose inhaled 
fluticasone had no significant facilitatory effects on lymphocyte P2 -AR function in 
asthmatic patients, despite suppressing adrenal function with an estimated milligram 
equivalence ratio o f 1:11 compared with prednisolone.
CHAPTER 9
LOW DOSE PREDNISOLONE PROTECTS AGAINST
IN  VIVO 3 2 - a d r e n o c e p t o r  s u b s e n s i t i v i t y
INDUCED BY FORMOTEROL
(Chest 1998; 113: 34-41)
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9.1 INTRODUCTION
In Chapter 3, we had demonstrated that bronchodilator and systemic P2-adrenoceptor 
(P2-AR) subsensitivity occurs after regular inhaled formoterol in patients with asthma. 
This P2-AR subsensitivity was reversed with a bolus o f  high-dose systemic 
corticosteroid, demonstrating the facilitatory effects o f systemic corticosteroid on in- 
vitro and in-vivo P2-AR responses. In Chapters 7 and 8, we have shown that high-dose 
inhaled fluticasone propionate, in single and repeated doses, did not have significant 
facilitatory effects on lymphocyte P2 -AR function in contrast to a single dose 
prednisolone (50mg).
Intravenous corticosteroid infusion in rats protects against down-regulation o f 
pulmonary P2 -AR induced by isoproterenol in vivo (Mak, 1995). Mak et al 
demonstrated that this protective effect o f corticosteroid appears to be due to an 
increase in P2 -AR gene transcription which counteracts the decrease in transcription 
due to chronic P2 -agonist exposure. There have been no clinical studies investigating 
the protective effects o f corticosteroids on P2-AR down-regulation induced by P- 
agonists in man.
In this study, therefore, we were interested to investigate whether the concomitant 
administration o f systemic corticosteroid would protect against the development of 
P2 -AR subsensitivity and down-regulation induced by continuous exposure to inhaled 
formoterol in humans.
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9.2 METHODS 
Subjects
Eleven healthy male subjects, mean (SEM) age 28 (2) years were recruited to 
completion in this smdy. All gave written informed consent before being randomised 
into the double-blind, placebo controlled, cross-over study which was approved by the 
Tayside Committee on Medical Research Ethics. A full physical examination, 
biochemical and haematological parameters and 12-lead electrocardiogram were 
normal prior to inclusion. All subjects were supervised in the use o f a pressurised 
metered-dose inhaler using a Vitalograph aerosol inhalation m onitor (Vitalograph Ltd, 
Buckingham, UK).
Protocol
Subjects were randomised to receive one week treatm ent with either inhaled 
formoterol 24 pg twice daüy and placebo tablets or inhaled formoterol 24 pg twice 
daily and oral prednisolone 15 mg daily in double-blind, cross-over fashion. 
Formoterol was delivered by a pressurised metered-dose inhaler with 12 pg per 
actuation (Foradil®; Ciba-Geigy AG, Basel, Switzerland). Inhaled medication was 
taken twice daily at 08:00 AM and at 08:00 PM. Oral medication was taken once daily 
between 07:00 AM and 09:00 AM. Six subjects received placebo first and five subjects 
prednisolone first.
Subjects attended the laboratory at 08:00 AM prior to starting and one week after 
treatment, having withheld their study medication for the previous 24 hours on each 
occasion. At each visit, an intravenous cannula was inserted and kept patent by bolus 
injections o f heparinised saline. Cannula dead space o f 2 ml was withdrawn prior to 
blood sampling.
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After 15 minutes supine rest, 50 ml blood was withdrawn for serum cortisol and 
lymphocyte P2 -AR parameters. A dose-response curve (DRC) to inhaled salbutamol 
(Ventolin Diskhaler® 400 pg per actuation, Allen & Hanbury, Uxbridge, UK) was 
then constructed using doses o f 800 pg, 800 pg and 1600 pg (i.e. cumulative doses of 
800 pg, 1600 Pg and 3200 pg respectively) with doses separated by 25 minutes. 
Measurements o f serum potassium (K), heart rate (HR) and finger trem or (Tr) were 
undertaken over a 10 minute period at baseline and 15 minutes after each dose.
Measurements
Serum cortisol — see Chapter 2, Horm one Assays 
In vitro lymphocyte P 2 '^ ^  parameters -  see Chapter 2 
Heart rate - see Chapter 2 
Finger trem or - see Chapter 2 
Serum potassium - see Chapter 2
Statistical analysis
Data for finger tremor and were transformed using logarithm to base 10, as
both variables were not normally distributed. AU systemic variables were analysed as 
delta responses from baseline. Comparisons for the DRC were made as area-under- 
curve (AUC) and as maximum responses. For aU parameters, comparisons within and 
between treatments were made by multifactorial analysis o f variance (MANOVA) 
using subjects, treatments, periods and visits as factors for analysis. A probability value 
o f p<0.05 (two-tailed) was considered as being o f significance and 95% confidence 
intervals (95% Cl) for mean differences were calculated where significant.
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9.3 RESULTS
Early morning serum cortisol
There was no significant difference in 08:00 AM serum cortisol pre and post treatment 
with formoterol and placebo tablets (Table 9.1). As would be expected there was 
significant suppression o f early morning serum cortisol after treatm ent with 
formoterol and prednisolone (pre vs post) 338.0 vs 194.9 (95% Cl 50.0 to 236.2)
p<0.01.
In vivo systemic P2 -AR responses
Baseline values for systemic parameters were not significantly different for each 
treatment period prior to each DRC (Table 9.1).
After treatment with formoterol, there were significant (p<0.05) rightward shifts in 
the DRC (as AUC) for heart rate response (beats x 10^) (pre vs post), 0.76 vs 0.34 
(95% Cl 0.16 to 0.68), for tremor response (log units, h) 0.39 vs 0.18 (95% Cl 0.01 to 
0.41) and for potassium response (mmol.h/1) -0.34 vs 0.19 (95% Cl -0.04 to -0.28). 
(Figure 9.1 and 9.2). Peak systemic responses were likewise significantly (p<0.05) 
attenuated after treatm ent with formoterol (Table 2). Comparing pre vs post treatment 
values, for heart rate (beats/min) 28 vs 11 (95% Cl 7.7 to 25.8); for trem or (log units) 
0.72 vs 0.38 (95% Cl 0.01 to 0.67); and for potassium (mmol/1) -0.81 vs -0.49 (95% Cl 
-0.04 to -0.60). However, treatm ent with prednisolone protected against the 
development o f subsensitivity induced by formoterol, in terms o f AUC and peak 
response from the dose-response curves. Pre versus post values for AUC in presence 
o f steroid were not significantly different: for heart rate (beats x 10^), 0.74 vs 0.64; for 
tremor (log units, h), 0.35 vs 0.34 and for potassium (mmol.h/1), -0.30 vs -0.25. 
(Figure 9.1 and 9.2)
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Comparing values after formoterol treatment, the presence o f steroid significantly 
increased heart rate and trem or response compared to formoterol alone, as AUC and 
peak responses. For heart rate, this was (placebo vs PRED) 0.34 vs 0.64 (as AUC, 
beats X 10^) (95% Cl 0.07 to 0.50; p<0.05) and 11 vs 22 (as peak, beats/m in) (95% Cl 
1.6 to 18.6; p<0.05). For tremor, this was 0.18 vs 0.34 (as AUC, log units.h) (95% Cl 0 
to 0.32; p=0.05) and 0.38 vs 0.66 (as peak, log units) (95% Cl 0.02 to 0.55; p<0.05).
In vitro lymphocyte ^2"^^ parameters
Following treatm ent with formoterol, there was significant down-regulation in 
lymphocyte P2“^ ^  density (log Bj^^x’ Bnol/lO^^ cells) with placebo (pre vs post) 0.25 
vs 0.11 (95% Cl 0 to 0.22; p<0.05) and with prednisolone (pre vs post), 0.21 vs 0.10 
(95% Cl O.Ol to 0.27; p<0.05) (Figure 9.3). There was also a significant decrease in 
maximal cycUc AMP response to isoprenaline (Ej^^x» p îïio l/ i 0^ cells) after treatment 
with formoterol (pre vs post) 6.21 vs 2.29 (95% Cl 1.19 to 6.64; p<0.05). However, 
treatm ent with prednisolone attenuated this fall in Ej^ax induced by formoterol and 
there was no significant difference in pre versus post values: 4.60 vs 3.28. E ^ ^ ^  values 
prior to each treatm ent were not significantly different. Comparing values after 
formoterol treatment, there was a trend towards a higher Ejj^^x with formoterol and 
prednisolone than with formoterol alone: 3.28 vs 2.29 (p=0.06) (Figure 9.3). There 
was no significant effect on dissociation constant, K j  (pmol/1) with either treatment 
(Table 9.1).
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FM+PL FM+PL FM+PRED FM+PRED
Pre-treatment Post-treatment Pre-treatment Post-treatment
HR 69 . 69 71 70
(beats/min) (61 to 71) (66 to 72) (69 to 74) (68 to 73)
Tremor 2.29 2.37 2.36 2.24
(log units) (2.10 to 2.48) (2.18 to 2.56) (2.17 to 2.55) (2.05 to 2.42)
K 3.97 4.01 3.96 3.79
(mmol/1) (3.82 to 4.12) (3.86 to 4.16) (3.81 to 4.11) (3.64 to 3.94)
Cortisol 358.9 296.2 338.0 194.9* +
(nmol/1) (310.3 to 407.5) (247.6 to 344.8) (272.2 to 403.8) (129.1 to 260.7)
Kd 18.1 21.2 21.1 21.1
(pmol/1) (10.9 to 25.2) (13.4 to 29.1) (15.5 to 26.8) (15.5 to 26.7)
T ab le  9.1 Mean (95% CI) baseline values (prior to dose-response curve) for systemic 
P2 -AR parameters, early morning serum cortisol and lymphocyte ^ 2 " ^ ^  dissociation 
constant (K j) before and after each treatment period.
(* indicates p<0.05 for pre vs post treatment; + denotes p<0.05 for post-treatm ent 
comparison)
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FM+PL FM+PL FM+PRED FM+PRED
Pre-treatment Post-treatment Pre-treatment Post-treatment
HR 28 11* 29 22+
(beats/min) (22 to 35) (5 to 18) (23 to 36) (15 to 28)
Tremor 0.72 0.38* 0.71 0.66+
(log units) (0.48 to 0.95) (0.14 to 0.61) (0.51 to 0.91) (0.47 to 0.86)
K -0.81 -0.49* -0.74 -0.60+
(mmol/1) (-1.00 to -0.61) (-0.68 to -0.29) (-0.86 to -0.63) (-0.72 to -0.48)
Table 9.2 Peak mean (95% CI) systemic P2 -AR responses (as change from baseline) 
during the dose-response curve for salbutamol.
(* indicates p<0.05 for pre vs post treatment; + denotes p<0.05 for post-treatm ent 
comparison)
There were no differences between pre-treatm ent responses.
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Figure 9.1 Dose-response curves for systemic Pz-responses before and after regular 
treatment with formoterol and placebo (O  indicates pre-treatm ent and •  indicates 
post-treatment), and formoterol and prednisolone (D indicates pre-treatm ent and ■ 
indicates post-treatment). For peak response: * indicates p<0.05 for pre vs post 
treatment; + indicates p<0.05 for post-treatm ent comparison (ie. FM +PL versus 
FM +PRED).
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F igure  9.2 Dose-response curves for systemic Pz-responses represented as mean 
values for area-under-curve (AUC) before and after regular treatm ent with formoterol 
with and without prednisolone. * indicates p<0.05 for pre vs post treatment; + 
indicates p<0.05 for post-treatm ent comparison (ie. FM +PL versus FM +PRED).
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treatment.
152
9.4 DISCUSSION
We have demonstrated that regular treatment with inhaled formoterol produced in vivo 
systemic ^ 2 " ^ ^  subsensitivity associated with lymphocyte ^ 2 " ^ ^  down-regulation 
and desensitisation, consistent with previous studies (Newnham, 1994a; Newnham, 
1995). However, the co-administration o f low dose oral prednisolone protected 
against the development o f in vivo ^2“-^^  subsensitivity induced by formoterol. We 
believe that this is the first time the protective effect o f corticosteroid on P2"-^R 
desensitisation induced by long-acting has been demonstrated in humans.
The finding that low dose prednisolone exhibited dissociation in protection against 
systemic in vivo P2 -subsensitisation but not against ex vivo P2 -AR down-regulation is 
particularly interesting. In this present study, systemic in vivo P2 -AR subsensitivity 
induced by formoterol alone was followed by ex vivo lymphocyte P2 -AR down- 
regulation and desensitisation. The reduction in lymphocyte P2 -AR density induced by 
formoterol was not prevented by concomitant administration o f prednisolone. In 
contrast, the presence o f prednisolone attenuated the fall in caused by
formoterol. Thus, the presence o f corticosteroid attenuates the formoterol-induced 
desensitisation o f P2 -AR without altering the formoterol-induced down-regulation. 
Similar findings have been reported in a study in which healthy volunteers were given 
three days o f oral terbutahne, followed by in vitro incubation o f neutrophils with 
hydrocortisone (Samuelson, 1984). It was shown that hydrocortisone reversed 
terbutaline-induced desensitisation without affecting down-regulation.
There are several limitations to this study that we recognise. Firstly, we used healthy 
non-asthmatic subjects for evaluation. There were several reasons for this. We wanted 
to investigate the interaction between systemic corticosteroid and long-acting P2- 
agonist on P2-AR function in health first, and then to investigate this in patients with 
asthma to see if they behave differently. Also the administration o f systemic 
corticosteroid to asthmatic subjects would tend to improve pulmonary function
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making it difficult to compare bronchodilator dose-response curves due to 
confounding effect o f systemic steroid on baseline airway geometry. Secondly, we 
mvestigated the effects on systemic responses rather than airway ^2"-^^
responses. However, in previous studies with long-acting P2 "^g°^sts (Newnham, 
1994a; Newnham, 1995; Grove, 1995), airway P2 -AR subsensitivity was accompanied 
by a similar degree o f systemic P2 -AR subsensitivity, making it valid, therefore, to look 
at systemic P2 -AR responses as a surrogate for changes in airway P2 -AR. Indeed, in 
Chapter 3, we found that a 200mg bolus o f hydrocortisone produced rapid reversal of 
both airway and systemic P2 -AR subsensitivity induced by formoterol in asthmatic 
patients. From a clinical point, though, systemic P2 -AR tolerance may be seen as 
beneficial and augmented systemic P2 -AR responses would be less desirable. Likewise, 
we have evaluated lymphocyte P2 -AR parameters as a surrogate marker for airway P2 - 
AR. Controversy exists as to whether it is valid to extrapolate from changes seen in 
circulating lymphocytes in vitro to changes in pulmonary receptors (Hauck, 1990; 
Hayes, 1996).
Sub sensitivity o f P2 -AR caused by prolonged exposure to P2 -agonists is due to a 
num ber o f processes: reduction in receptor sites (due to internalisation and decreased 
production), desensitisation (fall in catecholamine-stimulated adenylate cyclase 
activity) and uncoupling (destabilisation o f  the high-affinity state o f the receptor) 
(Davies, 1984). Corticosteroids are known to reverse these processes, in that they 
increase receptor numbers by a process o f reversal o f internalisation (Davies, 1984) 
and by increased P2 -AR gene transcription (Collins, 1988; Mak, 1995a), and prom ote 
a high-affimty state o f the receptor (Davies, 1980). That we have shown systemic 
corticosteroid protects against ^ 2 "^ ^  subsensitivity is therefore, perhaps not 
surprising and in keeping with known acute facilitatory effects o f systemic 
corticosteroid (Hui, 1982; Brodde, 1985; Brodde, 1988). The mechanism for this 
protective effect appears to be due to maintained sensitivity o f  the ^ 2 " ^ ^  via agonist- 
stimulated adenylate cyclase activity, at least in terms o f effects on lymphocyte ^ 2 '^ ^
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parameters. It may also be due in part to enhanced coupling or prom otion o f the high- 
affinity state o f the receptor but this remains speculative as competition curves were 
not constructed to determine the ratio o f the high to low affinity states o f the 
receptor. This is in contrast to the findings o f Mak et al (1995b) in rats where the 
protective effect o f corticosteroid was due to increased receptor transcription such 
that there was no significant fall in receptor numbers after infusion with isoproterenol. 
This discrepancy may be due to cross-species comparison which may not be valid. In 
an in vitro study with hum an neutrophils (Davies, 1983), exposure to isoprenaline for 
3h resulted in diminished cAMP response to isoprenaline-stimulation, whilst exposure 
to both isoprenaline and hydrocortisone resulted in a significantly greater cAMP 
response compared to isoprenaline alone. It is interesting that, as in our study, ^ 2 "^ ^  
density in the isoprenaline and hydrocortisone group was not different from that o f 
the isoprenaline treatm ent group. The observed effect was due to an altered coupling 
state o f the receptor, where corticosteroid attenuated the decrease in stability o f the 
high-affinity state associated with desensitisation. In other words, it is possible for low 
dose systemic corticosteroid to protect against desensitisation by increased ^2-^^^ 
coupling without necessarily producing up-regulation. In this respect we have shown 
that a high doses o f prednisolone (50mg) appear to produce both up-regulation and 
increased cAMP response (Chapters 7 and 8).
The low dose o f oral prednisolone (15mg) used in this study is equivalent to high dose 
inhaled corticosteroid in terms o f systemic bioactivity. In Chapter 7 and 8, we have 
previously shown that inhaled fluticasone propionate had an estimated milligram 
equivalence of 1:10 as compared to prednisolone, in terms o f suppressing early 
morning serum cortisol. Hence, 15rng oral prednisolone would be equivalent to 1500 
Pg o f inhaled fluticasone. In previous studies, single or repeated doses o f up to 2000 
Pg inhaled fluticasone had no facilitatory effects on lymphocyte P2 -AR or
Emax ^  asthmatic patients in contrast to a 50mg dose o f prednisolone. The lack o f 
effect o f inhaled fluticasone may be because the subjects were using minimal amounts
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o f P2 -agonist and hence the receptors were not down-regulated. W hether doses 
greater than 15mg prednisolone in the present study would have protected against ex 
vivo lymphocyte P2 -AR down-regulation as well as in vivo P2 -AR desensitisation is 
unclear. The Tayside Committee for Medical Research ethics was not prepared to 
grant approval for higher doses o f systemic steroid to be used in this study in view of 
the potential side effects associated with higher doses o f systemic corticosteroid in 
normal volunteers. A proper dose-ranging study with prednisolone would therefore be 
needed to answer this question.
In conclusion, therefore, we have shown that low-dose oral prednisolone protects 
against formoterol-induced subsensitivity o f in vivo systemic P2 -AR as assessed by the 
response to inhaled salbutamol. This was associated with enhanced sensitivity but not 
density o f ex vivo lymphocyte P2 -AR. This has obvious implications for asthma 
treatment where glucocorticoids and long-acting P2 -agonists are usually given 
together. Studies in normal and asthmatic subjects to investigate whether high-dose 
inhaled corticosteroid would have similar protective effects as low-dose prednisolone 
on P2 -AR subsensitivity would therefore be required.
CHAPTER 10
LOSS OF NORMAL CYCLICAL 
P2 -ADRENOCEPTOR REGULATION 
AND INCREASED PREMENSTRUAL 
RESPONSIVENESS TO 
ADENOSINE MONOPHOSPHATE IN  
STABLE FEMALE ASTHMATIC PATIENTS
(Thorax 1997; 52: 608-611)
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10.1 INTRODUCTION
The role o f female sex-steroid hormones in asthma is still unclear, although there is 
much circumstantial evidence to suggest that they may be im portant as discussed in 
Chapter 1. Up to 40% o f female asthmatics report a premenstrual deterioration o f 
their condition (Hanley, 1981; Gibbs, 1984; Eliasson, 1986; Pauli, 1989). However, the 
pathophysiology o f this phenom enon remains unclear. Female sex-steroid hormones 
have a regulatory role on P2 '^(^G^oceptor (P2 -AR) function, and it has been 
postulated that abnormal P2 -AR regulation may be a possible mechanism for 
premenstrual asthma. It has previously been demonstrated that cyclical changes in 
lymphocyte P2 -AR function occur during the menstrual cycle in normal females with 
greater P2 -AR density and isoprenaline responsiveness in the luteal phase during the 
premenstrual period (Wheeldon, 1994). Further support o f this role is provided by in 
vitro studies which show that female sex-steroid hormones potentiate the 
bronchorelaxant effect o f catecholamines (Foster, 1983).
In this study, we have investigated P2 -AR regulation and airway responsiveness to 
AMP in female asthmatic subjects. AMP was used for two reasons. Firstly, previous 
work using direct-acting smooth muscle bronchoconstrictors such as histamine and 
methachoHne have failed to show changes during the menstrual cycle (Weinmann, 
1987; Pauli, 1989; Juniper, 1987). Secondly, it may be a better marker o f airway 
inflammation as it induces bronchoconstriction via mediator release from mast cells 
and stimulation o f sensory fibres (Polosa, 1991).
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10.2 METHODS 
Patients
15 stable well-controlled female asthmatics, mean age 25 years (range 18-39) and 
F E V | (SEM) 2.97L (0.11) (93.8% predicted), gave written informed consent to 
participate in this study which was approved by the Tayside Committee on Medical 
Research Ethics. AU had asthma according to the criteria o f  the American Thoracic 
Society (1987a) and aU were non-smokers. N one had had a recent exacerbation o f 
asthma in the preceding three m onths requiring the use o f oral corticosteroids or 
antibiotics. N one had any documented history o f subjective premenstrual 
deterioration in asthma control. Median consumption was 0.8 puffs/day
and ten subjects were receiving inhaled corticosteroid, median dose 800pg 
beclomethasone daily, (range 200-2000pg). Two subjects were on oral theophyUines 
(250mg and 600mg daily).
Protocol
Subjects were asked to keep a diary record o f morning and evening PEFR  using a 
Wright's peak flow m eter (Airmed, London, UK). The best o f three successive 
readings was recorded. Subjects attended the laboratory on two separate days, during 
the follicular (day 1-6) and luteal (day 21-24) phases o f the menstrual cycle. Day 1 
being the first day o f the menses. Before each visit, inhaled bronchodilators were 
withheld for eight hours, long-acting P2 ”^ goi^sts and oral theophyllines for 24 hours. 
Inhaled corticosteroids were continued unchanged. Both visits were made at the same 
time o f day at 0900 AM.
At each visit, an intravenous cannula was inserted into an antecubital vein, and after 
30 minutes rest, blood was removed for serum oestradiol and progesterone, serum 
eosinophil cationic protein (ECP) and lymphocyte ^ 2 '^ ^  parameters. Airway 
responsiveness to AMP was evaluated using a standard challenge protocol. After
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bronchial provocation, subjects were rested until FE V j returned to within ± 5% 
baseline F E V p A dose-response curve (DRC) to inhaled salbutamol via a spacing 
device (Ventolin® pressurised metered-dose inhaler and Volumatic®, AUen & 
Hanburys, Uxbridge, UK) was then constructed by giving cumulative doubling doses 
o f lOOfig, 200pg, 400pg, SOOpg and 1600pg. Measurements o f F E V |, FEF 2 5 _7 5 , 
plasma potassium and postural finger tremor were made at baseline and 20 minutes 
after each dose increment, with each dose increment given every 30 minutes.
Measurements
FEV I and FEF 2 5 _ 7 5  - see Chapter 2, Spirometry
Airway hyperresponsiveness to adenosine m onophosphate - see Chapter 2, Bronchial
provocation tests
Plasma potassium
Postural finger tremor
Lymphocyte (32-^(^Gnoceptor parameters
Serum oestradiol and progesterone
Serum eosinophil cationic protein (ECP)
Statistical analysis
PC 2 0 , Bmax and finger tremor were log-transformed for analysis as these are not 
normally distributed. Effects on salbutamol dose-response curves were analysed as 
peak responses and area under curve (AUC). Comparisons between the two phases 
were made by multifactorial analysis o f variance (MANOVA). A probability value o f p 
< 0.05 (two-tailed) was considered as significant.
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10.3 RESULTS
The results o f all parameters are summarised in Table 10.1. There were significant 
increases in both serum oestradiol (2.2-fold, p<0.001) and progesterone (7.2-fold, 
p<0.05) between the foUicular and luteal phases. Mean differences between the 
foUicular and luteal phases were 179.3pm ol/l for oestradiol (95% Cl: 112.4 to 246.1) 
and 11.8 nmol/1 for progesterone (95% Cl: 5.1 to 18.6). Baseline FEV^ (L) and 
FEF 2 5 _ 7 5  ( L / s )  were not significantly different: 2.77 vs 2.78 and 2.16 vs 2.34 
(foUicular vs luteal) respectively. There were significant changes in AMP 
responsiveness during the menstrual cycle, with geometric mean PC 2 0  19.0mg/ml 
during the follicular phase and 7.6m g/m l during the luteal phase (p<0.05): a 2.51 fold 
difference (95% Cl 1.19-5.30) amounting to 1.33 doubling doses. There was no 
significant correlation between the cyclical change in PC 2 0  AMP and the changes in 
oestradiol (r^=0.17) or progesterone (r^=0.08).
Lymphocyte |32-AR parameters and bronchodilator and systemic P2"^I^ responses to 
salbutamol (as peak or AUC) were not altered during the menstrual cycle. Serum ECP 
levels did not differ between the two phases o f the cycle. DormicUlary peak flow 
recordings did not show any changes during the menstrual cycle.
161
Follicular Luteal
a) Progesterone (nmol/1) 
Oestradiol (pmol/1)
1.9 (-2.9 to 6 .6 ) 
151.4 (104.1-198.6)
13.7 (8.9-18.5)* 
330.6 (283.3-377.9)**
b) PC 2 0  a m p  (mg/ml)"*" 19.0 (11.2-32.2) 7.6 (4.5-12.8)*
c) Bmax (fm ol/10^ ceUs)"*" 
Kd (pmol/1)
Emax (pm ol/10^ ceUs)
1.70 (1.4-2.0) 
12.92 (8.35-17.49) 
6.65 (4.30-9.00)
1.80 (1.5-2.1) 
13.79 (9.22-18.37) 
5.69 (3.18-8.21)
d) ECP (pg/1) 4.43 (2.87-6.00) 4.78 (3.21-6.34)
e) Peak delta FEV \ (L)
Peak delta FEF25_75 (L/S) 
Peak delta K  (mmol/1)
Peak delta tremor (log units)
0.48 (0.40-0.55) 
1.31 (1.12-1.51) 
-0.62 (-0.76 to -0.47) 
0.74 (0.50-0.98)
0.43 (0.36-0.51) 
1.10(0.91-1.30) 
-0.56 (-0.71 to -0.41) 
0.53 (0.28-0.79)
f) Morning PEFR (L/min) 
Evening PEFR (L/min) 
Diurnal variabiUty (L/min)
402 (388-416) 
424 (410-437) 
21 (15-27)
409 (395-423) 
426 (412-439) 
18 (12-24)
Table 10.1 Values are shown for sex hormones, AMP airway reactivity, lymphocyte^ 
2 “AR parameters, eosinophil cationic protein (ECP), peak responses for salbutamol 
DRC and peak flow readings, for foUicular versus luteal phases. Values are mean 
(95% CI).( indicate geometric mean values) * denotes p < 0,05 and ** denotes p < 
0 .001.
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10.4 DISCUSSION
O ur study showed a 2.5-fold increase in airway responsiveness to AMP in the luteal 
phase, during the premenstrual period. Previous studies have not shown any changes 
in airway responsiveness during the menstrual cycle. These have used methacholine 
(Juniper, 1987; Pauh, 1989) and histamine (Weinmann, 1987) which are agents that act 
direcdy on airway smooth muscle. AMP, on the other hand, induces 
bronchoconstriction indirectly by activating mast cells to release bronchoconstrictive 
mediators (Cushley, 1985). It may be that increased AMP responsiveness during the 
luteal period may be due to sensitisation o f adenosine receptors on mast cells by sex 
hormones, resulting in a lower threshold for mediator release in response to 
adenosine. Against this hypothesis is our finding o f no correlation between horm one 
levels and PC 2 Q- The influence o f female sex hormones is not only confined to airway 
responsiveness changes but is also evident in skin-prick test reactions to histamine and 
allergen, with greater weal-and-flare reactions during the early luteal phase 
(Kalogeromitros, 1995). Also, it has recently been reported that hormone-replacement 
therapy may increase the risk o f developing asthma in post-menopausal wom en and 
that seems to be related to the dose o f the oestrogen com ponent and duration o f use 
(Troisi, 1995).
O ur study has limitations which we recognise and accept. Firstly, we did not have a 
control group o f non-asthmatics for comparison. The reason for this was it would not 
be possible to compare PC 2 0  normal versus asthmatic airways because of 
confounding effects o f airway geometry, even when using airways conductance. 
Secondly, our patients were stable and did not exhibit premenstrual asthma. 
Nonetheless, we felt at the outset that it would be vahd to look at such patients as a 
way of investigating possible mechanisms for sex horm one modulation o f  airway and 
receptor function.
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Despite an appropriate rise in luteal phase sex-hormones in our group o f asthmatics, P 
2 ~AR parameters exhibited a loss o f normal cyclical regulation previously described in 
normal females (Wheeldon, 1994). It is unlikely that this was due to the effects of 
exposure to exogenous p 2 -agonists as their consumption was minimal. This raises the 
possibility that in asthmatic patients there may be subsensitivity to the post-ovulatory 
rise in endogenous progesterone. The lack o f difference in ECP probably reflects the 
low levels observed in this group o f stable patients with mild disease.
W hat is the clinical implication o f our findings? In stable asthma, it is im portant to 
appreciate that the intrinsic variability o f bronchial hyperresponsiveness is such that 
PC 2 0  values can vary by up to twofold ie one doubhng dose (Juniper, 1978). Our 
findings in this study are therefore hkely to have clinical relevance as it exceeds the 
limit o f biological variability. Hence, this change in airway responsiveness from the 
follicular to luteal phase may be a possible mechanism to explain worsening symptoms 
during the premenstrual period, although the latter was not experienced by our group 
o f rrtild asthmatics. It is conceivable that these changes may be more clinically 
significant in patients with m ore severe disease. W hether treatment for premenstrual 
asthma will involve drugs such as theophylline (Mann, 1985), sodium cromoglycate 
(Richards, 1988) or nedocromü sodium (Summers, 1990) which antagonise adenosine 
receptors would require further research.
CHAPTER 11
EFFECTS OF EXOGENOUS FEMALE 
SEX-STEROID HORMONES 
ON LYMPHOCYTE P2 -ADRENOCEPTORS 
IN NORMAL FEMALES
(British Journal of Clinical Pharmacology 1996; 41: 414-416)
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11.1 INTRODUCTION
Female sex-steroid hormones have a role in the regulation o f (32"^^ function. This 
has been demonstrated in a previous study where lymphocyte ^ 2 " ^ ^  density was 
significantly greater during the luteal phase as compared to the folHcular phase, in 
association with raised premenstrual levels o f  progesterone and oestradiol (Wheeldon, 
1994). However, in the previous chapter, we have shown that in female asthma 
patients, there is a loss o f this normal cycHcal regulation o f P2-AR by ovarian sex- 
steroid hormones. Indeed, it has been postulated that abnormal premenstrual ^ 2 "^ ^  
regulation may be a possible mechanism for this phenomenon.
The aim o f this present study was to determine which o f the female hormones, 
progesterone or oestradiol, is responsible for the previously observed change in 
lymphocyte ^ 2 ^ ^  density during the menstrual cycle. This was investigated by 
adrninistering exogenous high doses o f oestradiol and progesterone during the 
follicular phase when endogenous levels o f both hormones are low.
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11.2 METHODS 
Subjects
Eight healthy female volunteers participated in this study, mean (SEM) age was 25 (3) 
years. All subjects had a normal full blood count and biochemical profile prior to 
entry.
N one o f the subjects had any significant past medical history, nor were they taking any 
regular medication. All but 1 (para 3) were nuUiparous, with a normal menstrual 
history and regular cycles and none had recently (at least 3 months) taken oral 
contraceptives. All volunteers provided written informed consent prior to entry to the 
study which was approved by the Tayside Committee on Medical Research Ethics.
Protocol
Volunteers attended the laboratory during the follicular phase (day 1-6) on two 
successive menstrual cycles. Day 1 being the first day o f the menstrual cycle. Baseline 
levels o f serum progesterone and oestradiol were measured at each cycle. They were 
randomised to receive either progesterone (medroxyprogesterone lOmg, Upjohn Ltd) 
or oestrogen (ethinyloestradiol 50pg, Evans Medical Ltd) as single oral doses in cross­
over fashion for the two menstrual cycles. Forty ml o f peripheral blood was 
withdrawn, prior to the ingestion o f the tablet, at baseline (Tq), and then at 24 hours 
(T2 4 ) and 72 hours (Ty2 ) after ingestion, for lymphocyte ^ 2 " ^ ^  assay on each o f the 
two cycles.
Medroxyprogesterone was chosen as it is the least virihsing o f the progestérones. The 
tablets are the highest dose licensed which are recommended for normal clinical 
practice. Two of the subjects experienced nausea with oestrogen and one had nausea 
after progesterone, indicating that higher doses would have been poorly tolerated.
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Measurements
Lymphocyte P2-adrenoceptor parameters - see Chapter 2 
Serum oestradiol and progesterone
Statistical analysis
The power o f the study was 80% to detect a 25% difference in For and
K j, comparisons between treatments were made by multifactorial analysis o f variance 
(MANOVA) using subjects, treatments and time as within factors for the analysis. 
Duncan's multiple range test was then applied to ascertain at what times differences 
occurred within a given cycle for each treatment. For Bj^ax» which is not normally 
distributed, analysis was performed non-parametrically using Friedman's analysis of 
ranks. A probability value o f less than 0.05 (two-tailed) was considered significant. 
Data for Bj^^x shown as geometric means and non-parametric 95% Cl. All other 
data are shown as means and 95% Cl for within each treatm ent group.
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11.3 RESULTS
Female sex steroid hormones
Baseline levels o f oestradiol (pmol/1) and progesterone (nmol/1) were comparable for 
the two consecutive cycles (cycle 1 vs cycle 2) mean (95% Cl): Oes 326.5(129.2 - 
523.8) vs 252.1(54.8 - 449.4) and Prog 5.7(4.8-6.6) vs 6.1 (5.7 - 7.0).
Lymphocyte pz-adrenoceptor parameters
The changes in lymphocyte P2 -AR parameters following treatm ent with progesterone 
and oestradiol are summarised in Table 11.1. There were no significant differences in 
any parameter at T q when comparing the two treatments. There was a significant 
increase from  baseline (Tq) in receptor density (Bj^ax) T 2 4  following treatment 
with progesterone but not oestradiol (p<0.01 T 2 4  vs T q: 1.39-fold geometric mean 
difference, 95% Cl 0.97 - 2.00). By 72 hours, Bj^ax had fallen to approximately 
baseline (T q) levels. The increase in B ^ ^ ^  following progesterone is greater than 
oestradiol at T 2 4  (p<0.05, Oes vs Prog at T 2 4  1.28 fold geometric m ean difference 
95% Cl 0.95 - 1.73). There were no significant changes from baseline in K j  and 
Emax following either treatment. Likewise there was no significant difference between 
the two treatments at each time point; for K j ,  at T q (95% Cl -8.9 to 5.4), at T 2 4  (95% 
Cl -10.8 to 7.1) and at T 7 2  (95% Cl -8.0 to 9.7). For Ej^^x* ^0> (95% Cl -0.3 to 
2.4), at T 2 4  (95% Cl -1.3 to 2.3) and at T 7 2  (95% Cl -2 . 1  to 2 ).
Statistical analysis did not show any evidence for order effect.
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To T 2 4 T 7 2
®max
(fm ol/10^ cells)
Prog
1.40(1.16- 1.69) 
1.45(1.19- 1.77)
1.59(1.32 - 1.91) 
2.03(1.66-2 .47)* t
1.43(1.19- 1.72) 
1.56(1.28-1.90)
K d Oes 
(pmol/1)
Prog
10.85(4.22 -17.48) 
9.11(5.87 - 12.35)
13.54(6.91 -20.17) 
11.66(8.42 - 14.89)
10.65(4.02 -17.28)
11.50(8.26- 14.73)
^m ax
(pmol/1 O^cells)
Prog
5.53(4.55 - 6.51) 
6.60(5.26 - 7.93)
5.20(4.22 - 6.19) 
5.65(4.18-7.12)
5.68(4.70 - 6.67) 
5.61(4.28 - 6.95)
T A B L E  11.1 Mean (95% CI) values for Kd and following treatm ent with
Oestrogen (Oes) and progesterone (Prog) at baseline [Pg), 24 hours ÇJ2 À) 72 
hours (T7 2 ). Values for ^^e geometric means (non-parametric 95% Cl).
(* indicates p<0.01 for T 2 4  versus T q; indicates p<0.05 Oes versus Prog at T 2 4 )
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11.4 DISCUSSION
This study has demonstrated that an exogenous high dose o f  oral progesterone but 
not oestradiol, given during the follicular phase, significantly increased lymphocyte P2 " 
AR density. This would, therefore, suggest that endogenous progesterone is probably 
responsible for the previously observed increase in during the luteal phase of
the female menstrual cycle (Wheeldon, 1994). A degree o f caution is advisable in 
extrapolating our results with lymphocytes from normal subjects to changes in 
asthmatic airways. However, it has recently been shown with positron emission 
tomography that changes in lymphocyte P2 -AR density closely m irror those on lung P 
2 "AR, thus making comparisons between airway and lymphocyte P2 -AR parameters 
seem vahd (Hayes, 1996). The lack o f difference in Ej^ax with progesterone probably 
reflects the relatively small difference in B ^^^  at T 2 4  compared with T q. W hether a 
higher dose o f progesterone would have increased Ej^ax well as B ^ ^ ^  is unclear.
An alteration in normal cychcal regulation o f P2 -AR may be a possible mechanism for 
premenstrual asthma, as airway hyper-reactivity in response to both  methacholine 
(Juniper, 1987; Pauh, 1989) and histamine (Weinmann, 1987) is unchanged in 
asthmatic subjects during the menstrual cycle. In keeping with this hypothesis is the 
observation that in a small num ber o f patients with premenstrual asthma, 
intramuscular progesterone therapy prevented the falls in peak expiratory flow rates 
which occurred at this time, and allowed better control o f  these patients on smaller 
doses o f systemic steroids (Beynon, 1988). In the previous chapter, we found loss o f 
the normal cychcal P2 -AR regulation in asthmatic women associated with increased 
premenstrual airway hyperresponsiveness to AMP. It may be that hormonal regulation 
o f P2 "AR in asthmatic women is abnormal. The findings o f the present study showing 
that exogenous progesterone up-regulates P2 "AR may suggest a possible mechanism 
for this therapeutic effect, and provide future therapeutic strategies for modulation o f 
P2 -AR in premenstrual asthma.
CHAPTER 12
PARADOXICAL DOWN-REGULATION AND 
DESENSITISATION OF P2 -ADRENOCEPTORS 
BY EXOGENOUS PROGESTERONE 
IN FEMALE ASTHMATIC PATIENTS
(Chest 1997; 111: 847-851)
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12.1 INTRODUCTION
It has been shown that lymphocyte P2 -AR function in normal females is under the 
cyclical influence o f ovarian sex-steroids with greater p2"AR density and cyclic AMP 
response to isoprenaline during the luteal phase as compared to the folhcular phase, in 
association with raised post-ovulatory levels o f progesterone and oestradiol 
(Wheeldon, 1994). In contrast, in Chapter 10, we demonstrated that in female asthma 
patients this cyclical pattern o f p 2 "AR regulation is absent despite an appropriate post­
ovulatory horm one response. In Chapter 11, we have observed that the administration 
o f exogenous progesterone but not oestrogen in healthy females during the foUicular 
phase produced up-regulation o f lymphocyte P2 -AR density. W e postulate that there 
may be abnormal hormonal regulation o f P2 -AR in female asthmatics. The aim o f this 
present study was to investigate how exogenously administered sex-steroid hormones 
might alter P2 -AR regulation in female asthmatics.
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12.2 METHODS 
Subjects
Seven non-smoking female subjects with asthma, mean (SEM) age 26 (2) years 
participated in this study. Mean (SEM) FEV j was 3.03 (0.18) L, 94.7 (6.4)% o f 
predicted and FEF25-75 was 2 . 8 6  (0.30) L /s , 70.7 (7.4)% o f predicted. All gave 
written informed consent before being randomised into a double-blind, cross-over 
study which was approved by the Tayside Committee o f Medical Research Ethics. A 
full physical examination, biochemical and haematological parameters were normal 
prior to inclusion. AU had asthma according to the criteria o f the American Thoracic 
Society (1987a). Six subjects were receiving inhaled corticosteroid (beclomethasone or 
budesonide) in a median dose o f 400pg/day (range 200-800|lg/day). AU subjects were 
taking inhaled P2 -^gomsts on as required basis <200pg/day. One subject was 
receiving a sustained-release oral theophylline preparation.
P ro toco l
The protocol was identical to that in Chapter 1 1 . Subjects attended the laboratory 
during the foUicular phase (day 1-6) on two successive menstrual cycles, day 1 being 
the first day o f the menstrual cycle. Baseline levels o f serum progesterone and 
oestradiol were measured at each cycle. They were randomised to receive either 
progesterone (as medroxyprogesterone 10 mg, Upjohn Ltd) or oestrogen (as 
ethinyloestradiol 50 fig, Evans Medical Ltd) as single oral doses in double-blind, cross­
over fashion for the two menstrual cycles. Peripheral blood was withdrawn, prior to 
the ingestion of the tablet, at baseUne (Tq), and then at Ih  (T |), 24h (T2 4 ) and 72h 
(T7 2 ) after ingestion for serum sex hormones for each o f the two cycles. Lymphocyte 
P2 -AR parameters were measured at Tq, T 2 4  and T 7 2  for each o f the treatments.
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Medroxyprogesterone was chosen as it is the least virilising o f the progestérones. The 
tablets are the highest dose licensed which are recom mended for normal clinical 
practice.
Measurements
Lymphocyte P2-adrenoceptor parameters - see Chapter 2 
Serum sex-steroid hormones - see Chapter 2
Statistical analysis
In a previous study with n= 8 females, it was possible to show a 40% increase in Bmax 
with progesterone (Chapter 11). Data for Bmax were log-transformed prior to analysis 
as it is not normally distributed. For all parameters, comparison between treatments 
were made by multifactorial analysis o f variance (MANOVA) with subjects, 
treatments and visits as within factors for analysis. A probability value o f p<0.05 (two- 
tailed) was considered as being o f significance and Bonferroni multiple range testing 
was then applied to ascertain at what times differences occured within a given cycle 
for each treatment. 95% confidence intervals (95% Cl) for mean differences were 
calculated where significant.
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12.3 RESULTS 
Serum sex hormones
Baseline levels o f oestradiol (pmol/1) and progesterone (nmol/1) were comparable for 
the two consecutive cycles (Table 12.1). After treatm ent with medroxyprogesterone, 
serum progesterone decreased significantly by T j compared to Tq: mean difference 
0.77 nmol/1 (95% Cl: 0.03 to 1.52). Serum progesterone rose gradually to pre­
treatm ent levels by T 7 2  which was significandy greater than T p  mean difference 0.75 
nmol/1 (95% Cl: 0.01 to 1.49). There were no significant differences in serum 
progesterone between the two treatments at the respective time points. Serum 
progesterone was not altered significandy after treatment with ethinyloestradiol. After 
treatm ent with ethinyloestradiol, serum oestradiol decreased significandy by T 2 4  
compared to Tq: mean difference 70.91 pmol/1 (95% Cl: 3.24 to 138.57). Serum 
oestradiol levels increased by T 7 2  to baseline levels and significandy greater than T 2 4 : 
mean difference 103.38 pmol/1 (95% Cl: 35.71 to 171.04). Comparing between 
treatments, serum oestradiol was significandy lower at T j after treatment with 
ethinyloestradiol: mean difference 49.72 pmol/1 (95% Cl: 22.32 to 77.12); and at T 2 4 : 
mean difference 96.53 pmol/1 (95% Cl: 12.98 to 180.07). Serum oestradiol was not 
significandy altered after administration o f medroxyprogesterone.
Lymphocyte p2-adrenoceptor parameters
Receptor density, Bmaxj was not significandy different at Tq for both  treatments 
(Figure 12.1). After administration o f medroxyprogesterone, Bmax decreased 
significandy (p<0.05) by T 2 4  compared to Tq: amounting to a 1.34-fold geometric 
mean difference (95% Cl: 1.01 to 1.78). By T 7 2 , Bmax had increased to baseline 
levels. There was no significant change in Bmax following treatm ent with 
ethinyloestradiol. Comparing between treatments at T 2 4 , Bmax following 
medroxyprogesterone was significandy (p<0.05) lower than after ethinlyoestradiol: 
amounting to a 1.25-fold geometric mean difference (95% Cl: 1.00-1.56). Data for
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individual subjects are shown in Figure 12.2. Baseline values for maximal cyclic AMP 
response to isoprenaline (Emax) and dissociation constant (Kd) were no t significantly 
different before each treatm ent (Table 12.2). There was a trend toward a difference 
with Emax being lower after medroxyprogesterone at T 2 4  and increasing to baseline 
values by T 7 2  (p=0.06). Receptor dissociation constant (K j) was not significantly 
altered following either treatment.
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T rea tm en t T im e Serum  p rogeste rone Serum  oestrad io l
(nm ol/1) (pm ol/1)
Medroxyprogesterone To 2.08 (1.71-2.45) 139.57 (103.07-176.07)
Ti 1.31* (0.93-1.68) 138.15 (101.65-174.65)
T 24 1.91 (1.53-2.28) 138.44 (101.94-174.94)
T 72 2.05 (1.68-2.43) 117.02 (80.52-153.52)
Ethinyloestradiol To 1.79 (1.42-2.15) 112.82 (78.89-146.75)
Ti 1.29 (0.92-1.65) 88.43** (54.50-122.36)
T 24 1.59 (1.22-1.95) 41.91*+ (7.98-75.85)
T 72 1.66 (1.30-2.02) 145.29 (111.36-179.22)
T ab le  12.1 Serum progesterone and oestradiol levels at baseline (T q ), Ih  (Ti), 24h 
(T24) and 72h (T72) after administration of medroxyprogesterone 10 mg and 
ethinyloestradiol 50 pg. Values are mean (95% Cl).
(* p<0.05 vs Tq; + p<0.05 medroxyprogesterone vs ethinyloestradiol at T 24;
** p<0.05 medroxyprogesterone vs ethinyloestradiol at Ti)
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Treatment Time Emax (pmol/10^ cells) Kd (pmol/1)
Medroxyprogesterone To 5.20 (4.04-6.36) 13.79 (10.69-16.89)
T 24 3.67 (2.51-4.83) 10.34 (7.24-13.45)
T 72 5.58 (4.42-6.74) 15.44 (12.33-18.54)
Ethinyloestradiol To 4.29 (2.90-5.68) 17.42 (9.64-25.19)
T 24 4.33 (2.94-5.74) 15.94 (8.17-23.72)
T 72 4.90 (3.51-6.29) 14.72 (6.94-22.49)
T ab le  12.2 Maximal cyclic AMP response to isoprenaline (Emax) and receptor 
dissociation constant (IQ) at baseline (To), 24h (T24) and 72h (T72) after treatm ent with 
medroxyprogesterone and ethinyloestradiol. Values are mean (95% Cl).
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Figure 12.1 Bmax at To, T 24 and T 72 after the administration o f progesterone (as 
medroxyprogesterone, 10 mg) and oestrogen (as ethinyloestradiol, 50 pg). Values are 
mean log Bmax (SEM). * denotes p<0.05 for medroxyprogesterone versus 
ethinyloestradiol at T 24.
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Figure 12.2 Bmax for individual subjects at To, T 24 and T 72 after the administration of 
progesterone (as medroxyprogesterone, 10 mg^ and oestrogen (as ethinyloestradiol, 50 
Kg)-
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12.4 DISCUSSION
The results in this study show that the administration o f exogenous progesterone but 
no t oestrogen decreased lymphocyte P2 -AR density and responsiveness in asthmatic 
females during the follicular phase. This is in contrast to our previous study in healthy 
females where the administration o f progesterone (as medroxyprogesterone 10 mg) 
produced significant up-regulation o f P2 -AR density. Although we were not 
investigating airway P2 -AR directly, it has been shown that changes in lymphocyte P2 - 
AR density closely m irror those on lung P2 -AR (Hayes, 1996), thus making 
comparisons between airway and lymphocyte P2  AR parameters seem vahd. The 
change in Emax followed that o f Bmax although the trend was not statistically 
significant. This may be due to a relatively small difference in Bmax at T 2 4  compared 
to Tq. W hether a higher dose o f medroxyprogesterone would have produced a greater 
fall in Emax as well as Bmax is unclear. We also found that serum progesterone and 
oestradiol decreased significantly after the administration o f medroxyprogesterone and 
ethinyloestradiol respectively. This is most hkely due to the suppression of 
endogenous sex horm one production by the presence o f synthetic sex hormones.
W hat are the imphcations o f this study? Previous studies have not found any change 
in airway reactivity either to methacholine (Juniper, 1987; Pauh, 1989) or histamine 
(Weinmann, 1987) in female asthmatics during the menstrual cycle, and it has been 
postulated that abnormal hormonal regulation o f P2 -AR might be a possible 
mechanism for premenstrual asthma. This study has shown that instead o f having a 
facihtatory effect on P2"AR as occurs in healthy females (Chapter 11), exogenous 
progesterone significantly decreased receptor density in female asthmatics. This would 
be in keeping with our previous observation in female asthmatics that despite an 
appropriate post-ovulatory horm one response, there is a loss o f the normal cychcal 
pattern o f P2 -AR regulation (Chapter 10). It is therefore conceivable that during the 
prem enstrual/luteal phase o f the menstrual cycle when endogenous levels of
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progesterone are raised, airway P2 -AR may be attenuated and hence a loss o f efficacy 
to  endogenous catecholamines or exogenously administered P2-^go«^sts, precipitating 
worsening asthma. However, this is not in keeping with a case report (Beynon, 1988) 
which found that the administration o f intramuscular progesterone was beneficial in 
treating severe premenstrual asthma and therefore likely that other non-P2'A R 
mechanisms are implicated such as effects on sm ooth muscle (Fisher, 1978; Van Thiel, 
1976), prostaglandins (Koullapis, 1980; Hyman, 1978) and microvascular leakage 
(Beynon, 1988).
In conclusion, this study has shown that the administration o f exogenous 
progesterone but not oestrogen during the follicular phase decreased lymphocyte P2 - 
AR density and responsiveness, in contrast to the up-regulating effect seen in healthy 
females with identical doses. This ‘paradoxical’ effect may represent abnormal 
horm onal P2 -AR regulation in female asthmatics.
CHAPTER 13
MODULATION OF AIRWAY REACTIVITY 
AND PEAK FLOW VARIABILITY 
IN ASTHMATICS RECEIVING THE  
ORAL CONTRACEPTIVE PILL
(American Journal of Respiratory and Critical Care 
Medicine 1997; 155:1273-1277)
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13.1 INTRODUCTION
Female sex-steroid hormones may play an im portant role in asthma. Previous studies 
have not demonstrated any change in airway reactivity during the menstrual cycle 
using methacholine (Pauli, 1987; Juniper, 1989) or histamine (Weinmann, 1987) 
challenges, which are direct bronchoconstrictor agents. In Chapter 10, we have shown 
that in female asthma patients, there was a significant increase in airway reactivity to 
AMP during the luteal phase o f the menstrual cycle compared to the folhcular. This 
increase in airway reactivity during the luteal phase was associated with the normal 
increase in serum sex-steroid hormones.
W ith such compelling evidence for hormonal influence on airways, we have therefore 
chosen to evaluate a group o f female asthmatics with natural menstrual cycles and a 
group o f female asthmatics on the oral combined contraceptive pill. Again in this 
respect, we have chosen to investigate airway reactivity using AMP, an indirect 
bronchoconstrictor which acts by stimulating the release o f mediators from mast cells 
(Cushley, 1985).
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13.2 M E T H O D S  
P atien ts
18 female subjects with stable asthma were evaluated in this study. In group 1, there 
were 9 subjects, mean (SEM) age 24 (6) years, FE V j in litres and percentage predicted 
was 2.93 (0.46) L and 93 (10) percent predicted, with natural menstrual cycles. In 
group 2, there were 9 subjects, age and severity matched, who were taking the oral 
combined contraceptive pill, age 24 (6) years with FE V j 2.98 (0.38) L  and 93 (9) 
percent predicted. A fuU physical examination, biochemical and haematological 
parameters were normal prior to inclusion. AU gave written informed consent before 
being evaluated in this study which was approved by the Tayside Medical Ethics 
Committee. AU had asthma according to the criteria o f the American Thoracic Society 
(1987a), and aU were non-smokers. In the group with natural cycles, 7 subjects were 
receiving inhaled corticosteroid (either beclomethasone or budesonide), median dose 
600 pg/day  (range 200-2000 pg/day). One subject was taking inhaled salmeterol 50 p 
g bid and one was taking sustained-release theophylline. In the group on the OCP, 6 
subjects were receiving inhaled corticosteroid, median dose 400 pg/day  (range 200- 
1000 pg/day). One subject was also taking inhaled salmeterol 50 pg bid and one was 
taking sustained-release theophylline. AU had been inhaling short-acting P2"^gonists as 
required in doses o f <400 pg/day. AU medications were at stable dose for at least two 
m onths prior to the study and was taken at constant dosage throughout the study. 
N one had received oral corticosteroids for at least three m onths, and none had had a 
recent exacerbation o f asthma in the past month. AU had stable asthma with no 
subjective history o f premenstrual asthma.
In the group on the OCP, 6 subjects were taking m onophasic and 3 subjects were 
taking triphasic preparations. O f the monophasic preparations, 5 were on 
ethinyloestradiol 30 pg/day and one was on 35 pg/day o f ethinyloestradiol. There 
were different preparations and doses o f progestogens.
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Protocol
AU subjects were evaluated at two visits in the laboratory. Group 1 subjects were 
evaluated during the foUicular (visit 1) and luteal (visit 2) phases o f the menstrual 
cycle. The foUicular phase was defined as day 1-4 and luteal phase as day 21-24, with 
day 1 being the first day o f the menses. Group 2 subjects were evaluated during the 
week whUe off the OCP (visit 1, during the week o f menstruation) and at the end o f 
the 21-day course o f O CP (visit 2). A t each visit, subjects attended the laboratory at 
0900 AM, having withheld short-acting P2 "^g°«^sts for 8 hours, long acting ^2~ 
agonists for 48 hours and theophylline preparations for 48 hours. After a 15 minute 
period o f rest, 10ml o f blood was withdrawn from a peripheral vein for serum 
oestradiol and progesterone. Then, airway reactivity to adenosine 5'-monophosphate 
(AMP; Sigma, Poole, UK) was determined. This was expressed as PC 2 0 , the 
provocative concentration that causes a 20% faU in F E V \.
During the study, subjects were asked to keep a diary o f morning and evening peak 
expiratory flow readings using a Wright's peak flow meter (Airmed, London, UK) by 
recording the best o f three consecutive readings. They were also asked to give a daUy 
symptom score for wheeze (0-3) and for nocturnal symptoms (0-3), and the number 
o f rescue puffs o f P2 "^8 °nists needed.
Measurements
Female sex-steroid hormones - see Chapter 2, Horm one Assays
Airway reactivity to AMP - see Chapter 2, Adenosine m onophosphate challenge.
Statistical analysis
PC 2 0  was log-transformed for analysis, as it is not normally distributed. For aU 
variables, comparisons within groups for both visits were made by analysis o f variance
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(ANOVA) and where appropriate followed by Bonferroni multiple range testing. 
Comparisons between groups was by unpaired Student's t-test. A probability value of 
p<  0.05 (two-tailed) was considered as being o f significance and 95% confidence 
intervals (95% Cl) for mean differences were calculated where significant. The rescue 
requirements and symptom score were analysed non-parametrically using Kruskal- 
Wallis analysis o f ranks.
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13.3 RESULTS 
Baseline airway calibre
Baseline FEV j for both groups did not differ between the two visits. For group 1, 
(visit 1 vs 2) FEV j was 2.74 vs 2.73 (p=0.90), and for group 2, FE V j was 2.85 vs 2.87 
(p=0.77). Likewise, there was no significant difference between the groups at visit 1: 
2.74 vs 2.85 (p=0.67) and at visit 2: 2.73 vs 2.87 (p=0.53).
Female sex-steroid hormones
In group 1, who had natural cycles, there was a significant increase in sex hormones 
(Figure 13.1), at visit 2; for progesterone (mmol/1), visit 1 vs 2: 2.5 vs 13.5 (95% Cl 2.1 
to 19.9; p<0.02) and for oestradiol (pmol/1): 152.3 vs 358.1 (95% Cl 113.0 to 298.5; 
p<0.001). However, in group 2, who were on the OCP, there was no increase between 
visit 1 and visit 2 in female hormones; for progesterone (visit 1 vs 2), 0.9 vs 1.0 and 
for oestradiol 75.7 vs 21.8.
Airway reactivity to AMP
In group 1, there was a significant increase in airway reactivity during the luteal phase 
(visit 2) o f the menstrual cycle (Figure 13.2). The geometric mean PC 2 0  was 
18.8mg/ml at visit 1 and 4.7m g/m l at visit 2. This was a 4.0 fold difference (95% Cl 
1.25 to 13.03; p<0.03) which amounted to 2 doubling doses. One subject had shown a 
dramatic increase in airway reactivity from the follicular phase (log PC 20 1.398) to the 
luteal phase (log PC 20 -0.903). W hen this ‘outlier’ is removed (ie n=8), and analysis 
performed with the ‘trimmed’ geometric mean, there is still a significant difference 
between the foUicular (visit 1) and luteal (visit 2) phases o f the cycle: 18.2m g/m l at 
visit 1 and 7.4m g/m l at visit 2. This is a 2.5 fold difference (95% C l 1.68 to 3.64; 
p<0.001) amounting to 1.3 doubling doses. In contrast, there was no change in 
airway reactivity in group 2 between the two visits: 23.5m g/m l at visit 1 and 
21.4m g/m l at visit 2; a 1.06 fold difference (95% Cl 0.41 to 2.78; p=0.83). There was
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no difference in geometric mean PC 2 0  between the two groups at visit 1: 18.8 vs 23.5; 
a 1.25 fold difference (95% Cl 0.3 to 5.1; p=0.74). There was a trend toward a 
difference between the two groups at visit 2: 4.7 vs 21.4, a 4.57 fold difference (95% 
Cl 0.93 to 22.4; p=0.06).
Peak expiratory flow readings
In group 1, with natural cycles, there was a significant difference between morning 
and evening PEFR (L/min): at visit 1 (morning PEFR vs evening PEFR), 403 vs 430 
(95% Cl 5 to 50; p<0.001) and for visit 2, 415 vs 439 (95% Cl 1 to 46; p<0.001) 
(Figure 13.3). In group 2, on the OCP, there was no significant difference in morning 
and evening PEFR at both visits; at visit 1,411 vs 417 and at visit 2, 413 vs 427.
In both groups, there were no significant differences in symptom score and rescue 
requirements between visit 1 and 2.
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Figure 13.1 Female sex-steroid hormone levels at both visits in group 1 (with natural
cycles) and group 2 (on the OCP). * indicates p<0.05 for visit 1 versus 2.
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13.4 DISCUSSION
This study has demonstrated that airway reactivity to AMP shows cyclical change in 
female asthmatics during the menstrual cycle, with greater reactivity at the luteal 
phase, as shown previously in Chapter 10. This was accompanied by a significant and 
appropriate increase in female sex-steroid hormones at this phase o f the menstrual 
cycle. In contrast, endogenous female sex-steroid hormones were suppressed and 
showed no increase during visit 2 in the group o f asthmatics who were taking the oral 
contraceptive, as would be expected. Airway reactivity in this latter group did not 
show any variation during the cycle, in contrast to those with natural cycles. It is also 
interesting to note that this cyclical change in airway reactivity occured in the group o f 
asthmatics with natural cycles even though they were on a higher median dose o f 
inhaled corticosteroid. O ur patients had mild disease and so it may not be possible to 
extrapolate the present results to more severe asthmatics and particularly those with 
symptomatic premenstrual deterioration. It is interesting to note that in a recent study 
by Skobeloff et al (1996), almost half o f all female admissions for acute asthma 
occurred during the perimenstrual phase.
Previous studies using histamine or methachoHne, which act directly on airway 
sm ooth muscle have not shown any change in airway reactivity during the menstrual 
cycle. In the studies by Pauli et at (1989) (n = ll)  and W einmann et al (1987) (n=9), the 
subjects studied had natural cycles and none were receiving the oral contraceptive. 
Juniper et ai (1987) studied ten subjects with natural cycles and seven subjects 
receiving the oral contraceptive. The observation that ‘direct’ bronchoconstrictors like 
histamine and methachoHne show no cycHcal change together with the results in this 
present study would suggest that the mechanism of hormonal influence on airway 
reactivity is on mediator release. Since AMP mediates bronchoconstriction via 
mediator release from mast cells (Cushley, 1985), it is possible that the normal post­
ovulatory rise in sex-hormones may sensitise mast cells, and so, lower the threshold
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for mediator release. This in turn suggests that in the luteal phase during the 
premenstrual period, deterioration in asthma control may be due to augmented 
inflammatory mediator release. Thus, suppression o f endogenous horm one levels by 
the contraceptive piU may offer an explanation for the attenuation o f airway reactivity 
seen in this group o f subjects.
W hen evaluating changes in airway reactivity it is im portant to consider the intrinsic 
variability o f this measurement. This is such that PC2 0  values can vary by up to two 
fold ie ± one doubling dose - even in stable asthmatics (Juniper, 1978). In our study, 
we have shown that, in those with natural cycles, airway reactivity to AMP increased 
by four fold during the luteal phase, equivalent to 2 doubling doses o f AMP. Thus, as 
well as being statistically significant, this increase is also likely to have clinical 
significance as it exceeds the limit o f biological variability. It is also im portant to note 
that baseline airway calibre as assessed by F E V | was not significantly different 
between the two visits for the two groups. This is relevant to the evaluation o f PC2 0  
as airway geometry has an important influence on assessing airway responsiveness to a 
bronchoconstrictor agent (Chung, 1982).
The group receiving the contraceptive pill were also found to have attenuated diumal 
PEFR  variability compared with those with natural cycles. Clearly, it is im portant to 
know that the two groups were similarly matched for age and disease severity. In this 
respect, there were no significant differences in F E V | and PC 2 0  at visit 1. This makes 
it likely that the difference in PC 2 0  and PEFR variability between the two groups was 
due to the effect o f the contraceptive pül rather than any other confounding variables 
due to their asthma. Ideally, we would like to have evaluated the group o f asthmatics 
while on and off the oral contraceptive. However, this was not possible as the subjects 
concerned were reluctant to consent to this because o f the increased risk o f pregnancy 
while o ff the OCP. Likewise the Tayside Committee for Medical Research Ethics felt 
that this was ethically unacceptable.
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Cyclical menstrual changes are not confined to the airways but are also evident in skin- 
prick test reactions to histamine and allergen, with greater weal-and-flame reactions 
during the early luteal phase (Kalogeromitros, 1995). There are other possible 
mechanisms by which sex-steroids may influence the airways. In rabbit lung, 
oestrogen and progesterone have been shown to modify ^-adrenergic receptor density 
with oestrogen increasing and progesterone decreasing the num ber o f sites (Moawad, 
1982). Prostaglandins are known to be modulators o f airway tone (Hyman, 1978) and 
monthly cyclical variations in circulating PGF2ot metabolite have been reported 
(KouUapis, 1980). However, treatm ent with meclofenamate, a potent prostaglandin 
synthase inhibitor, did not prevent exacerbations o f premenstrual asthma (Eliasson, 
1987).
W hat then is the clinical relevance o f our findings? It is possible that exogenous 
female sex-steroid hormones may be used therapeutically in females with unstable 
asthma or those with premenstrual asthma, not controlled by conventional therapy, by 
smoothing out cyclical changes in airway reactivity. However, the effects o f exogenous 
female sex-steroid hormones are not entirely clear. In a recent questionnaire-based 
prospective cohort study QTroisi, 1995), there was an increased risk o f  developing 
adult-onset asthma in those women who had used hormone-replacement therapy or 
oral contraceptives, and this risk was related to duration o f use and dose o f oestrogen. 
Nevertheless, the modulatory effect o f exogenous female sex-steroids may be 
beneficial rather than deleterious in those with established asthma, by attenuating the 
cyclical changes in airway responsiveness. Clearly, further studies are needed to 
identify which hormone is responsible- for these airway changes, perhaps by 
administering the hormones individually by aerosol to the lung and assessing changes 
in airway responsiveness.
CHAPTER 14
CONCLUSIONS
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CONCLUSIONS
This series o f studies has examined the ways in which corticosteroids and P-agonists 
interact on the P2-AR and the role which abnormal horm one regulation o f p-AR plays 
in females with premenstrual asthma. The results, which we believe are novel and 
exciting, add to the existing body o f knowledge on these im portant subjects.
The initial study, (Chapter3), showed that asthmatic patients developed bronchodilator 
subsensitivity after regular use o f the long-acting P-agonist, formoterol. A bolus o f 
systemic corticosteroid rapidly (within Ih) restored bronchodilator responsiveness. 
Two recent studies have investigated the effect o f a bolus o f inhaled corticosteroid on 
the reversal o f loss o f functional antagonism o f P-agonists. Although the actual 
mechanism underlying the loss o f bronchoprotection in vivo is unknown, it probably 
relates to P2-AR down-regulation (Svedmyr, 1990). Yates et al (1998) treated 15 
steroid-naive asthmatic patients with terbutaline 500 pg four times daily for 12 days in 
a double-blind crossover study. Bronchoprotection o f terbutaline was evaluated with 
methachoHne and AMP challenges after a seven day run-in, at days 7 and 8 o f dosing 
and on days 11 and 12. O n day 10, they received either inhaled budesonide 800 pg or 
placebo 12h before challenge. The bronchial challenges were perform ed on separate 
days to avoid possible interaction. After regular terbutaHne treatment, there was 
significant loss o f bronchoprotection to AMP challenge (1.7 doubling dilutions), while 
there was no such tolerance to methachoHne (0.1 doubling dilutions). Although this 
was in keeping with the hypothesis that mast ceU P2-AR are m ore susceptible to 
tolerance than smooth muscle P2-AR, it is surprising that tolerance was not 
demonstrated against methachoHne chaUenge after terbutaHne (Chapter 1). Inhaled
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budesonide did not have any significant effect on methachoHne or AMP challenge 
compared with placebo. Aziz et al (1997, abstract) studied nine asthmatic subjects on 
inhaled steroid treatm ent in double-blind crossover fashion. Patients received inhaled 
formoterol 24 pg twice daily for two separate one week treatment periods with one 
week washout between periods. A single dose o f inhaled budesonide 1600pg or 
placebo was administered at the end o f each treatm ent period at the same time with 
the last dose o f formoterol having withheld usual inhaled corticosteroid treatm ent for 
24h. AMP challenge was performed 2h after the first dose o f formoterol and after one 
week o f dosing. Following formoterol treatment, there was significant loss of 
bronchoprotection against AMP, amounting to 5.55 fold difference between the first 
and last dose o f formoterol. However, after budesonide inhalation, there was 
significant reversal o f the loss o f bronchoprotection which amounted to a 5.66 fold 
difference compared with placebo, such that there was no difference from baseline. 
There are several possible explanations for the different results between the two 
studies. Firstly, the choice o f P-agonist might be important. Formoterol, being a long- 
acting and full agonist at the P2-AR, is a more potent inducer o f P2-AR tolerance and 
down-regulation. Corticosteroids are more likely to demonstrate an effect on P2-AR 
function in desensitised tissue. Chapter 3 describes how in vivo P2-AR responses 
(except for heart rate) were not augmented by a bolus o f systemic corticosteroid after 
placebo treatment, compared to the effect seen after dosing o f regular formoterol. In 
other words, the ‘up-regulating’ effects o f corticosteroid are heightened as tissue 
desensitisation increases. Secondly, there may be a dose-response effect o f inhaled 
corticosteroids in that the higher dose o f budesonide (1600pg) used by Aziz et al may 
have had a greater faciHtatory effect on p 2-AR. Finally, duration o f action may be 
significant. Aziz et al carried out AMP challenge 2h after inhaled budesonide, while
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Yates eî al performed the first challenge 12h after budesonide dosing, with the second 
challenge up to 36h afterwards. Corticosteroid effect may be more apparent at the 
peak, rather than at the end o f the dose. We similarly demonstrated in Chapter 3 that 
systemic corticosteroids had an effect on P2-AR function within Ih  o f dosing. The 
studies by Yates and Aziz question whether high-dose inhaled corticosteroids could be 
effective in acute asthma, given that repeated use o f P-agonists could lead to P2-AR 
tolerance in this situation. The avoidance o f oral steroids, where possible is attractive 
to both doctors and patients. In a general practice study o f  mild asthma exacerbations, 
Levy et al (1996) examined 413 patients randomised to receive two weeks o f either 
inhaled fluticasone propionate Im g twice daily or a reducing course o f prednisolone 
(starting at 40mg daily). N o significant difference was found between the two 
treatments, with the primary outcome measure being ‘treatm ent failure’ (peak flow < 
60% o f best/predicted, no improvement in symptom score or withdrawal from study). 
However, with a power o f only 57% in detecting a difference between treatments, 
there was increased likelihood o f a type 2 error in missing an actual difference. Despite 
this, these findings should prom pt further work on investigating high-dose inhaled 
corticosteroids in more severe asthma exacerbations and in children and adolescents 
who may be more susceptible to the effects o f systemic steroids. We have shown that 
systemic corticosteroids could reverse formoterol-induced bronchodilator 
subsensitivity (Chapter 3). It is not yet known whether this facditatory effect can be 
demonstrated with high dose inhaled corticosteroid.
In Chapters 5 and 6, we demonstrated the loss o f bronchoprotection against 
methacholine, a direct-acting stimulus, and against AMP, an indirect-acting stimulus 
with regular treatment with short and long-acting P-agonists. These findings in 
themselves are not novel. W hat is interesting is that in Chapter 5, the residual level of
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protection against methacholine was the same, irrespective o f differing formoterol 
dose and dosing regimen, and when compared with a short-acting P-agonist, 
terbutaline. In Chapter 6, once daily and twice daily formoterol produced a similar 
degree o f tolerance to the bronchoprotection against AMP. This could be explained 
by the prolonged receptor occupancy formoterol and bronchoprotective effect (up to 
24h) which formoterol has been shown to have against methacholine (Rabe, 1993). 
Tolerance to bronchoprotective effects o f P-agonists can be reversed by a single dose 
o f  inhaled corticosteroids (Aziz, 1997, abstract). The same group showed that this 
bronchoprotective subsensitivity cannot be overcome by a high dose o f P-agonist 
(Lipworth, 1998, abstract). This involved treatment o f ten asthmatic patients in cross­
over fashion with placebo, inhaled sakneterol 50fJ.g twice daily and formoterol 12pg 
twice daily for nine days each, with a one week washout between treatm ent periods. 
M ethacholine challenge was performed Ih  after the first dose and after seven days. 
After nine days’ treatment, a third methacholine challenge was performed Ih  after 
inhalation o f  a single 1600 pg dose o f salbutamol. After regular treatm ent with 
sahneterol and formoterol, there was loss o f bronchoprotection against methacholine 
o f 0.9 doubling doses and 0.5 doubling doses respectively. After nine days the 
bronchoprotective effect o f salbutamol after placebo was 2.7 fold greater than after 
sahneterol treatment and 3.6 fold greater than after form oterol treatment. This 
inability o f P-agonists to overcome prior subsensitisation to long-acting P-agonists has 
im portant implications. In acute asthma, patients may conceivably be desensitised due 
to repeated doses o f P-agonists, or the use a regular long-acting P-agonist. Following 
an encounter with a bronchoconstricting stimulus such as allergen or exercise, further 
administration o f P-agonists may therefore be o f limited protection. Asthmatic 
subjects in both these studies were receiving inhaled corticosteroid, again highlighting
201
the fact that these drugs do not protect against the development o f tolerance. This is 
further confirmed by their lack o f facilitating effect on P2-AR parameters on 
lymphocytes in asthmatic patients (Chapters 7 and 8). Single and repeated doses of 
high-dose fluticasone propionate (up to 2mg) failed to have any effect on P2-AR 
density and cAMP responsiveness. This is in contrast with a single dose o f oral 
prednisolone (50mg) which up-regulated P2-AR density and increased cAMP 
responsiveness to isoprenahne. However, high-dose fluticasone propionate may have 
demonstrated facihtatory action if P2-AR were initially down-regulated. To conclude 
the discussion on corticosteroids, low dose prednisolone was shown to protect against 
the development o f in vivo P2-AR desensitisation to formoterol (Chapter 9). 
Prednisolone 15 mg a day attenuated the fall o f in vitro cAMP response to isoprenaline, 
while receptor num ber down-regulation was not prevented, in keeping with data from 
Davies and Lefkowitz (1984). Further research on this subject would include a dose- 
ranging study o f oral prednisolone on the up-regulating effect on lymphocyte P2-AR. 
It would also be o f interest to discover whether high-dose inhaled corticosteroid 
protects against in vivo P2-AR desensitisation to P-agonists and whether high dose 
corticosteroids are able to reverse bronchodilator subsensitivity induced by long-acting 
P-agonists. Recent preliminary data from Rahman et al (1997), on the contrary, 
suggests that inhaled corticosteroid might exhibit differential protection against P2 -AR 
tachyphylaxis in normal and asthmatic subjects. They studied eight subjects (four 
asthmatic) who were treated with inhaled salbutamol and inhaled fluticasone 1500 pg 
twice daily for two weeks. There was no significant tachyphylaxis in airway and 
systemic P2 -AR responses, whilst pulmonary P2-AR density as assessed by positron 
emission tomography (PET) was unchanged in the asthmatic subjects. The normal
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subjects on the other hand, developed significant airway and systemic 
tachyphylaxis together with a 23% decrease in pulmonary P2 -AR.
In a num ber o f the studies, we have used lymphocyte P2-AR parameters as a surrogate 
for pulmonary P2-AR. Lung material for P2-AR can rarely be obtained while 
peripheral leukocytes are easily available and exclusively yield the P2-AR subtype 
(Brodde, 1981; Aarons, 1979; Davis, 1980). Therefore, peripheral leukocyte P2-AR 
have been claimed to be a reliable model for examining properties o f P2-AR in human 
lung o f healthy and asthmatic subjects. In several studies (Newnham, 1994a; 
Newnham, 1995; Grove, 1995), lymphocyte P2-AR down-regulation has occurred to a 
similar degree as bronchodilator subsensitivity, making it a useful surrogate for airway 
P2-AR. However, we recognise there is controversy as to whether it is valid to make 
this extrapolation. Tashkin et al (1982) demonstrated lymphocyte P2-AR down- 
regulation in asthmatic patients following treatment with oral terbutaline while 
bronchodilator responses to inhaled isoprenahne and subcutaneous terbutaline were 
maintained. Hauck et al (1990) examined the relationship between lymphocyte and 
pulmonary P2-AR directly. They evaluated 18 patients undergoing lung resection for 
bronchial carcinoma. Ten received subcutaneous terbutaline 0.5 mg twice daily for 24- 
72h preoperatively while eight received no treatment. Leukocyte P2-AR density was 
found to be reduced by 43% whilst there was no significant change in lung P2-AR 
density. While this may represent a constitutional difference in susceptibihty o f the 
two receptor populations to down-regulate, it is also possible that inadequate tissue 
penetration was achieved with the dose and the route o f administration used, or that 
the pulmonary P 2-AR were already down-regulated as a result o f  prior use o f P2- 
agonists (five of the treated group were already on regular P2-agonists). In a recent
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study, seven healthy subjects were treated with oral (up to 8 mg twice daily) and 
inhaled (up to 400 pg four times daily) salbutamol for two weeks. They found that the 
down-regulation in mononuclear leukocyte P2-AR density correlated closely with that 
o f in vivo pulmonary P2-AR changes as assessed by PE T  (Hayes, 1996). The authors 
conclude that it may be possible to predict changes in pulmonary P2-AR by measuring 
changes in peripheral blood m ononuclear leukocyte P2-AR. Thus, the validity o f this 
technique as an index o f pulmonary P2-AR function remains unclear.
We have performed some preliminary work on P2-AR polymorphism in asthma. As 
detailed in Chapter 4, homozygous Gly 16 asthmatic patients were m ore susceptible to 
bronchodilator desensitisation after regular formoterol than homozygous Arg 16 
patients. This is in keeping with in vitro studies with cultured hum an airway smooth 
muscle cells which have shown that the Gly 16 form o f the P2-AR predisposes to 
agonist-induced down-regulation and desensitisation to a greater degree than the Arg 
16 form (Green, 1995a). Recent preliminary data support the role o f P2 -AR
polymorphism in the development o f tolerance (Rahman, 1996). 12 male subjects (six 
with mild asthma not requiring treatment) were treated with inhaled salbutamol up to 
1.2 mg four times daily for two weeks. Eight subjects (homozygous Arg 16, Gly 16 
and heterozygous Arg 1 6 /Gly 16) developed significant bronchodilator and systemic 
P2 -AR tachyphylaxis associated with pulmonary down-regulation on PET. The
four subjects who were homozygous Glu 27 were resistant to P2 -AR desensitisation.
O ur study was a retrospective analysis o f three studies (Chapter 3; Newnham, 1994a; 
Newnham, 1995) and it would be im portant to confirm this finding by performing a 
prospective study. Subjects evaluated in Chapter 3 were genotyped for P2-AR
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polymorphism at codon 16 and 27. It would appear that reversal o f desensitisation to 
systemic steroids is not related to P2-AR polymorphism, although the small number 
did not allow statistical analysis. In vitro data suggest that P2-AR polymorphisms affect 
agonist-induced down-regulation by altering susceptibility to protein degradation of 
the receptor (Green, 1995b). As receptor synthesis is not influenced by P2-AR 
polymorphism, we may therefore not expect that corticosteroid reversal o f P2-AR 
down-regulation is also unaffected. P2-AR polymorphism does not appear to influence 
development o f tolerance to the bronchoprotective effect o f formoterol against AMP 
challenge (Chapter 6). Here, again, numbers were too small for formal analysis. 
Tolerance to the bronchoprotective effect o f P-agonists is readily demonstrable, in 
contrast to bronchodilator tolerance and thus P2-AR polymorphism is unlikely to be 
an im portant influence. However, this can only be confirmed by repeating the study 
using adequate patient numbers with known P2-AR polymorphisms. Future 
researchers wül be required to know the genotypes o f asthmatic patients, before 
examining both P2-AR function and the role o f P-agonists.
The development o f tolerance to the beneficial effects o f inhaled P-agonists has been 
suggested as one possible explanation for the deleterious effects o f frequent use of 
these agents in asthma. This has come about with the association o f increased P- 
agonist use and asthma mortality and morbidity (Pearce, 1990; Grainger, 1991; Spitzer, 
1992). With in vitro and now in vivo data showing that homozygous Gly 16 P2-AR 
polymorphism is predisposed to P2-AR down-regulation and tolerance, one would 
expect that this particular polymorphism would expose the affected individual to 
increased risk o f asthma-related death. Contrary to this hypothesis, recent abstracted 
data (Weir, 1997) showed a reduced prevalence o f the Gly 16 aUelle in patients with
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fatal or near fatal asthma compared with those with mild asthma. The Glu 27 allelle 
showed equal prevalence. Although there may be several explanations for these 
findings they illustrate that a single gene polymorphism is unlikely to account for the 
complex process o f asthma exacerbation. The regular use o f a short-acting P-agonist, 
fenoterol, in asthma patients, o f  whom  the majority were taking an inhaled 
corticosteroid, has been associated with increased exacerbations, decline in baseline 
lung function and an increase in airway hyperresponsiveness to methacholine (Sears, 
1990; Taylor, 1993). However, three studies with long-acting P-agonists produced 
different results (Greening, 1994; Woolcock, 1996; Pauwels,1997). Greening et al and 
W oolcock et al, in large multicentre studies, found that the addition o f sahneterol to 
inhaled corticosteroid was more effective than using a higher dose o f corticosteroid in 
those with persistent asthma symptoms, resulting in improved peak expiratory flow 
rates, symptom control and the use o f rescue bronchodilator over a period o f six 
months. There was no effect on exacerbation rates as these studies were not powered 
to detect this. More recently, Pauwels et al studied 852 patients with asthma in a 
parallel group design. They were assigned to one o f four treatments for one year: 
budesonide 100 pg twice daily plus placebo, budesonide 100 pg twice daily plus 
formoterol 12 pg twice daily, budesonide 400 pg twice daily plus placebo or 
budesonide 400 pg twice daily plus formoterol 12 pg twice daily. Exacerbation rates 
were significantly reduced when formoterol was added to budesonide. The higher 
dose o f budesonide alone was found to significandy reduce exacerbation rates. 
Likewise, peak expiratory flow rates and asthma symptoms were improved with the 
addition o f formoterol. We should be cautious, however, in extrapolating results from 
stable, mild asthmatic patients to those with severe asthma, in w hom  bronchodilator
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and antibronchoconstrictor tolerance may be significant, particularly in the face of 
worsening disease.
O ur studies with female sex steroid hormones indicate that there may be abnormal 
hormonal regulation o f  P2-AR in female asthma patients. In healthy women, 
lymphocyte P2-AR are normally influenced by ovarian sex steroid hormones, in that 
the post-ovulatory rise in progesterone and oestradiol is accompanied by an increase 
in receptor density and cAMP responsiveness to isoprenahne (Wheeldon, 1994). In 
Chapter 11, healthy women with natural menstrual cycles were given single doses o f 
ethinyloestradiol or medroxyprogesterone during the pre-ovulatory foUicular phase 
when endogenous levels o f sex hormones are low, to mimic luteal phase events when 
the hormone levels are elevated. Exogenous progesterone, but not oestradiol, resulted 
in a significant increase in lymphocyte P2-AR density, suggesting that the normal post­
ovulatory response is mediated by a rise in progesterone levels. However, as described 
in Chapter 12, the same study design produced paradoxical results in mild stable 
female asthmatic patients, when medroxyprogesterone produced a decrease in 
lymphocyte P2-AR numbers and cAMP responsiveness to isoprenaline. This suggests 
an abnormal regulation o f P2-AR in female asthmatics, and might be a possible 
mechanism for premenstrual asthma, as progesterone levels are high during the luteal 
phase. In Chapter 10, this hypothesis is supported by the finding that P2-AR 
regulation shows a loss o f the normal cyclical pattern in stable asthmatic women with 
natural cycles. This occurs despite an appropriate post-ovulatory rise in sex hormones 
during the luteal phase. In addition, there are cyclical changes in airway 
hyperresponsiveness to AMP, the latter being highest during the premenstrual period 
(Chapters 10 and 13). We had postulated that this may be due to regulation o f
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adenosine receptors on airway mast cells by circulating sex hormones. However, there 
was no correlation between horm one levels and changes in PC 20 AMP. Alterations in 
asthmatic inflammation within female airways during the menstrual cycle could 
account for this. AM P challenge may be a more discriminatory m ethod in detecting 
this airway inflammation than the direct smooth muscle stimuli methacholine or 
histamine, as adenosine acts indirectly on both airway mast cells and airway sensory 
nerves (Polosa, 1991). O ur findings, which may be the result o f increased 
inflammation could be confirmed by bronchoalveolar lavage and biopsies during 
different phases o f the menstrual cycle in female asthmatic patients. However, there 
are now several non-invasive ways to evaluate airway inflammation in asthma that may 
be applicable here. Exhaled nitric oxide is known to be elevated in asthma 
(Kharitonov, 1994b), and is thought to be a marker o f airway inflammation, as the 
abnormally elevated levels in symptomatic asthma are reduced by inhaled 
corticosteroid treatm ent (Kharitonov, 1996). A recent study showed that exhaled nitric 
oxide is elevated during the luteal phase o f the menstrual cycle in healthy women 
(Kharitonov, 1994a), and this could aid further understanding o f the possible changes 
in airway inflammation in premenstrual asthma. Exhaled nitric oxide measurements 
should therefore be performed in female asthmatic patients and in those with 
premenstrual exacerbations. Likewise, induced sputum has also been used to show 
changes in asthmatic airway inflammation, particularly in absolute eosinophil numbers 
and sputum ECP levels (Pizzichini, 1996). This technique could also be used to assess 
airway inflammation throughout both phases o f the menstrual cycle in female 
asthmatic patients. O ur results are further supported by recent preliminary results o f 
107 female asthma patients, which found that those with premenstrual asthma had an 
increase in airway responsiveness to methacholine o f almost 2 doubling doses during 
the late luteal phase compared to the foUicular phase (Dauletbaev, 1996 abstract).
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In Chapter 13, we found that these cyclical changes in airway responsiveness to AMP 
appear to be abolished in asthmatic women taking the combined oral contraceptive 
pUl, with suppression o f the normal post-ovulatory luteal phase rise in sex steroid 
hormones. However, it is no t possible to draw firm conclusions from our studies as all 
the patients had stable asthma with no premenstrual symptoms. Further research is 
therefore needed in patients with premenstrual asthma to evaluate whether altered P2- 
AR function and airway hyperresponsiveness to AMP provide an explanation for the 
underlying mechanisms in this condition. Studies are also required to investigate 
whether the combined oral contraceptive pill and adenosine antagonists such as 
theophylline and the cromones might benefit patients with premenstrual asthma, given 
the paucity o f data on treatm ent options. By studying pregnant and menopausal 
asthma patients, as well as those on horm one replacement therapy, more information 
could be obtained on the ways in which progesterone and oestradiol might influence 
P2-AR function and airway hyperresponsiveness. In a prospective, questionnaire-based 
study in a large num ber o f post-menopausal nurses over the course o f 10 years, the 
risk o f developing new-onset adult asthma was associated with the use o f exogenous 
oestrogen therapy (Troisi, 1995). The age-adjusted relative-tisk o f developing asthma 
for women who reported ever using postmenopausal hormones was 1.49 compared to 
women who reported never using these. This association was also related to the 
duration o f use and dose o f oestrogen. There was no difference in whether the 
horm one therapy contained progesterone or not.
Our studies have provided some insight into the facihtatory effects o f corticosteroids 
and female sex steroid hormones on P2-AR function and regulation in asthma. There
209
are still many unanswered questions and the studies we hope have opened up several 
possible avenues for further research in this area o f asthma.
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